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ABSTRACT 
 
Ulcerative colitis (UC) and Crohn’s disease (CD), collectively known as 
inflammatory bowel disease (IBD), are inflammatory diseases of the enteric mucosa 
whose etiology is currently undefined. While hypotheses for causation include 
genetic susceptibility, environmental risk factors, inappropriate and chronic immune 
responses to members of the intestinal microflora as well as failed immune 
regulatory mechanisms, many questions regarding IBD susceptibility, dysbiosis and 
immune dysfunction remain. Not surprisingly, current therapeutic targets are 
expensive, have questionable long term efficacy and are associated with risk of 
secondary bacterial and viral infections. As chronically ill patients substitute or 
supplement their treatments with alternative, nutraceutical remedies in ever greater 
numbers, more research is needed to ascertain the safety and efficacy of these 
products as therapeutics. 
Prunella vulgaris is a common ‘cure all’ which is popular in traditional Chinese 
medicine. P. vulgaris can be steeped in water and drank as a tea or ground into a 
salve, and is known for its anti-viral, anti-inflammatory and antioxidant benefits. P. 
vulgaris has never, until now, been studied in the context of colitic therapy and has 
yet to gain a foothold as a commonly utilized nutraceutical in western medicine. 
Hypericum gentianoides, akin to Hypericum perforatum/St. John’s Wort, is a 
unique and understudied species of Hypericum. H. gentianoides lacks the 
photoactive and cytotoxic compounds routinely found in other Hypericum species.  
While the bioactivity of this plant is not well characterized, it is known to have anti-
inflammatory, immunomodulatory and antibacterial potential. This potential and the 
lack of cytotoxic, photoactive compounds make H. gentianoides a good candidate 
for study in colitis models. 
Echinacea angustifolia is well studied, commonly utilized world-wide as a 
preventative or remedy for the common cold, and has great potential as a 
therapeutic agent in many disease modalities. The roots of this plant contain several 
types of compounds known to be bioactive. Like other nutraceutical, E. angustifolia 
 xi 
is documented anecdotally to cure or reduce symptoms related to countless 
maladies and diseases without sound scientific proof. E. angustifolia has never been 
studied as anti-colitic; however, pain suppressive and immunomodulatory 
capabilities of this plant lend credence to the potential for this type of study. 
In this study, the anti-colitic potential of P. vulgaris, H. gentianoides and E. 
angustifolia were determined in the mdr1a deficient (-/-) mouse model of 
spontaneous colitis or the chemically induced dextran sodium sulphate (DSS) 
mouse model of acute colitis. Extracts of E. angustifolia root or above-ground 
sections of P. vulgaris or H. gentianoides were extracted using the Soxhlet method 
in 95% ethanol and were solubilized in a final concentration of 5% ethanol for use in 
studies. P. vulgaris and H. gentianoides were tested at daily doses of 2.4 mg (~ 100 
mg/kg body weight) and 4.8 mg (~ 200 mg/kg body weight) respectively, while E. 
angustifolia was tested at daily doses of 100 mg/kg and 200 mg/kg body weight. 
In the DSS model of acute colitis, E. angustifolia was not found to be effective 
during the period of DSS treatment (in low dose 1.75% to high dose 2.5% DSS in 
male and female C57BL/6 mice), or during restitution. E. angustifolia was not found 
to be cytotoxic in vivo. Conversely, P. vulgaris was able to significantly (p < 0.05) 
decrease weight loss and improve macroscopic indicators of severe colitic wasting. 
The disparity between E. angustifolia and P. vulgaris efficacies in this acute model of 
colitis could be due to the difference in the constituent types found in these two 
extracts. E. angustifolia is composed mostly of phenolics and alkylamides, while P. 
vulgaris contains phenolics, flavonoids and triterpinoids. Certain types of phenols 
have been shown to have efficacy in low dose DSS colitis; however, flavonoids have 
efficacy in models of colitis as well, and in combination with phenols may be 
synergistic. Since flavonoids have recently proven very effective in ameliorating 
spontaneous colitis, P. vulgaris was also evaluated in the mdr1a-/- model of 
spontaneous colitis. 
In the mdr1a-/- mouse model of spontaneous colitis, P. vulgaris extract 
treatment was compared to mdr1a-/- mice treated with 5% ethanol vehicle, 
metronidazole (an antibiotic and anti-colitic control) and FVBWT mice. It was 
 xii 
discovered that P. vulgaris was able to delay onset of spontaneous colitis, 
significantly (p < 0.05) decrease macroscopic typhlocolitic and microscopic cecal 
disease scores, prevent cecal neutrophil influx, and downregulate nuclear factor-
kappaB (NF-κB) related cytokines/chemokines and gene targets. The 
downregulation of innate immune signals and function is hypothesized to contribute 
to the observed decrease in cecal tonsil CD4+ helper and CD8+ cytotoxic T cells as 
well as germinal center B cells. Adaptive immune function was also altered. Loss of 
immune tolerance to the microflora is a characteristic of chronic colitis. Unlike mdr1a-
/-
 vehicle treated mice, which displayed antibody production to microflora antigens, 
P. vulgaris treated mice displayed little to no Ab response to the same microflora 
antigens.  
H. gentianoides contains flavonoids, phenolics and a unique antimicrobial 
compound called uliginosin A. As the mdr1a-/- mouse model of spontaneous colitis is 
driven by the host immune response to the microflora and Hypericum species are 
known to be immunomodulatory, this extract was of interest as a therapeutic anti-
colitic in the mdr1a-/- model. Onset of spontaneous colitis was significantly delayed 
by H. gentianoides, but was not completely abolished. Macroscopic scores, 
microscopic scores, serum cytokine levels and myeloperoxidase production were all 
significantly (p < 0.05) reduced by H. gentianoides gavage. While H. gentianoides 
has immunosuppressant potential, a surprising increase in intestinal plasma cell 
infiltrate and an increase in serum IL-6 correlated with H. gentianoides gavage in 
mdr1a-/- mice. To date, anti-microbial functions have not been ruled out as a 
contributing factor in the efficacy of anti-colitic activity of this extract. 
Together, these novel experiments have identified new candidates for anti-
colitic therapy or therapeutic supplementation of current IBD treatment strategies. P. 
vulgaris, H. gentianoides and E. angustifolia merit further research as nutraceutical 
treatments of chronic inflammatory disorders, and these studies make it clear that 
synergy between phenolics, flavonoids and natural anti-bacterial compounds also 
warrant further research. 
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CHAPTER 1.  GENERAL INTRODUCTION 
 
General Introduction and Dissertation Organization 
 Inflammatory bowel disease (IBD) is a collection of idiopathic inflammatory 
enteric disorders which are growing in prevalence in adults and children every year 
(1, 2). With the growing cost of health care, increased instance of nosocomial 
infections in IBD patients, and the continued reliance on surgical intervention for 
patients suffering from Crohn’s disease and ulcerative colitis, the true impact of 
current IBD therapeutics are in question (1, 3, 4). New and safe therapeutic 
strategies are needed to combat the complex and multifactoral problem of IBD. 
Onset and chronicity of IBD is hypothesized to involve interactions among a 
compromised enteric mucosal epithelium, potential genetic susceptibilities, dysbiosis 
and aberrant and chronic immune reactivity (5). As the underlying interactions or 
causes of IBD are still poorly understood, physicians are forced to focus on 
symptomatic treatments for IBD. Successful IBD therapeutics will safely suppress 
chronic inflammation; encourage homeostatic immune reactivity and regulation; 
maintain a healthy microflora; and protect the patient from secondary infection 
through homeostatic maintenance or inherent antibacterial and antiviral activity. This 
list of activities might be unrealistic for pure compounds or individual biologic 
therapeutic modalities. Solutions to this problem turn patients and research to 
alternative nutraceutical remedies or supplements to current biologic therapies (6-9). 
The identification of nutraceutical plant extracts which harbor several bioactive 
compounds with synergistic efficacy in models of IBD will provide scientists, 
physicians and patients with new insights into the requirements for successful IBD 
therapeutics and supplemental treatments, not to mention new alternatives for safe 
treatment of IBD. This dissertation outlines the potential of Prunella vulgaris, 
Hypericum gentianoides, and Echinacea angustifolia as anti-colitic nutraceutical in 
multiple models of IBD, and uncovers potential mechanisms of anti-colitic and anti-
inflammatory activity. 
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 The dissertation is composed of 5 chapters. The current chapter, Chapter 1, 
encompasses the general introduction, organization of dissertation and literature 
review. Each of chapters 2, 3 and 4 consist of a journal paper. Chapter 2, entitled 
“Assessment of the in vivo anti-inflammatory activities of the ethanolic extracts of 
Echinacea angustifolia or Prunella vulgaris in the dextran sodium sulphate model of 
colitis”, is to be submitted for publication to the Journal of Gastroenterology. Chapter 
3, entitled “Prunella vulgaris prophylaxis attenuates spontaneous colitis in mdr1a 
deficient mice”, was prepared for submission to the American Journal of Physiology - 
Gastrointestinal and Liver Physiology. Chapter 4, entitled “Hypericum gentianoides 
extract prophylaxis delays onset and severity of spontaneous colitis in mdr1a 
deficient mice”, is to be submitted for publication in the Journal of Gastroenterology. 
Chapter 5 includes general conclusions, encompassing a summary of results, 
discussion of significant findings and implications for future research. Formats of 
references for each research paper follow the requirements put forth by the 
appropriate, specific journal to which the paper will be submitted. References cited 
for Chapter 1, general introduction and literature review, and Chapter 5, general 
conclusions, are formatted in the style of The Journal of Immunology. 
 
Literature Review 
 
Enteric mucosal homeostasis and defense 
 The intestinal milieu is constantly barraged by exogenous and endogenous 
antigens. Enteric mucosal homeostasis is a delicate balance maintained by pre-
epithelial, epithelial and post-epithelial defense and regulatory components 
described in the following section (10). 
 Enteric epithelium 
 The intestinal epithelium is a dynamic single cell layer responsible for 
maintaining energy dependant absorption and secretion in the gut and preventing 
passive transport of compounds from the lumen into the submucosa and underlying 
tissues (11). These functions are responsible for blocking transport of chemicals and 
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xenobiotics, preventing undue water loss to the lumen, and compartmentalizing 
luminal contents while still allowing for nutrient absorption and exchange. Epithelial 
cells regulate transcellular transport through specific transmembrane proteins (12). 
These protein transporters include:  the adenosine triphosphate (ATP)-dependant 
polyspecific efflux transporters of the ATP binding cassette (ABC) family; the 
polyspecific uptake transporter  ATP independent H+/oligopeptide co-transporter 
family SLC15; the polyspecific ATP independent organic anion transporter family; 
the ATP independent organic cation/anion/zwitterion transporter family SLC22; and 
the ATP independent multidrug and toxin extrusion (MATE) H+/drug antiporters (13-
17). The epithelium prevents passive paracellular transport through maintenance of 
tight junction or apical junction complexes (18). The paracellular pathway directs 
flow based on solute size, charge and hydrophobicity through two checkpoints, the 
apical junctional complex and subjunctional space (19).  
 The tight junction complex is built to guard passage of substances through 
the paracellular pathway, and at the same time create and sustain epithelial polarity 
by compartmentalizing the varied protein composition, lipid characters and 
physiologic roles of the apical and basolateral domains (20). Tight junction 
complexes (TJ) are divided into three vertical domains at the apical surface of the 
cell (21). Closest to the luminal surface of the cell, but below the brush border at the 
apical cell surface is the tight junction, below that is the adherens junction, and 
closest to the basolateral plasma membrane are the spot desmosomes. The tight 
junction domain is composed of the intramembrane proteins occludin, one of the 19 
members of the claudins, and a junctional adhesion molecule (JAM). Studies have 
shown that occludens cannot confer tight junction functionality; only claudins can 
ensure efficient tight junction formation and function (22). Zonula occludens (ZO) are 
scaffolding cytoplasmic proteins that interact with occluden, claudins and JAM in the 
tight junction domain.  ZO-1 interacts specifically with occluden, claudins and JAM, 
while ZO-2 and ZO-3 interact with ZO-1. ZO-1 has been molecularly associated with 
the cytoskeleton and could participate in tight junction function (23). Actin filaments, 
which extend from the inside of each microvillus in the brush border into the apical 
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cytosol, are bound with the peripheral actin-myosin ring/sphincter. This ring is bound 
to the adherens junction, in which E-cadheren associates with the ring and cytosolic 
signaling residues to control tight junction function (24). It is hypothesized that tight 
junction and adherens junction associations with the cytoskeleton and signaling 
molecules are two mechanisms by which TJ permeability is altered, and studies 
show that myosin light chain kinase (MLCK) is a key regulator of TJ permeability 
(25-27). Aside from apical TJ, the epithelium has luminal protections as well.   
 Compounds are further excluded from the epithelium and submucosa by pre-
epithelial defenses. Goblet cells produce a thick mucus layer composed of mucins, 
trefoil peptides, glycoprotiens, phospholipids and a glycocalyx (28-30). Trefoil 
peptides assist in the intracellular bundling of mucins and function to increase the 
viscosity of the mucus complex (31). Into the mucin layer a bicarbonate fluid and 
Immunoglobulin (Ig)A are secreted. The bicarbonate fluid maintains an almost 
neutral pH at the epithelium. IgA, known for its abundance relative to other isotypes, 
is secreted on the apical intestinal epithelial surface as a dimer bound to the 
polymeric Ig receptor (pIgR) (32). IgA assists antigen sampling by M cells and 
facilitates clearance of microbial antigens utilizing the Fc alpha receptor I (FcαRI) 
(33, 34).  
If the epithelium is damaged, the cells have several mechanisms by which to 
heal and prevent excess water loss to the lumen. The epithelium naturally 
proliferates at a rapid rate. The lower third of crypts in the large intestine are 
comprised of proliferative stem cells, and as cells differentiate and mature they are 
pushed upward by the cells proliferating behind them at the base of the crypt (35-
37). Thus, the most mature and differentiated cells are found at the surface 
epithelium at the shoulders of crypt and proliferation is balanced by cell shedding at 
the crypt shoulders. As crypt progenitors divide every 12 to 16 hours, the epithelium 
is completely replenished every 3 to 5 days. The process and speed of crypt 
proliferation can be observed by identifying crypt progenitors using tritium-thymidine 
injection or 5-bromo-2-deoxyuridine injection, which incorporates into the genetic 
material of the cell and is passed to daughter cells during mitosis (38, 39). 
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Proliferation is not, however, the first step in epithelial wound healing. Minutes to 
hours after superficial wounding, restitution begins with epithelial cells adjacent to 
the wound relocating into the wounded area by cytoskeleton rearrangement, and the 
formation of psuedopod-like processes called lamellae (40). Proliferation and 
differentiation of epithelial cells then replaces the diminished cell numbers. Extensive 
wounding activates a more complex healing process involving inflammation, 
extracellular matrix components and regulatory peptides. Acutely following deep 
colonic wounding, endothelin-1 binds endothelin A and B receptors, causing strong 
myofibroblast constriction and colonic shortening (41). This is a first line of barrier 
integrity defense. Transforming growth factor (TGF) β stimulates acute epithelial 
restitution while TGFα encourages proliferation, migration, and differentiation of 
epithelial cells; while also upregulating the production of enzymes which aid in 
electrolyte and nutrient transport to the affected area (42). Fibroblast growth factors 
and insulin-like growth factors stimulate angiogenesis, epithelial restitution and 
matrix formation; and downregulate apoptosis while promoting chemotaxis of 
endothelial cells, respectively (43). Trefoil factors (TFF) protect the mucosa and 
discourage apoptosis, while colony stimulating factors (CSF) recruit inflammatory 
cells to clean up cell debris (44). The wound healing process underscores the need 
for epithelial interactions with nourishing enteric microbes and other cell types. 
 Epithelial-neutrophil interactions 
 Neutrophils are extravascular acute inflammatory cells which are 
chemotactically drawn into the tissues upon damage and distress (45). Neutrophil 
presence in the intestinal epithelium and submucosa is an indicator of active 
inflammation (46). Epithelial damage or recognition of pathogens through pattern 
recognition receptors (PRR) receptors or Toll-like receptors (TLR) on/in epithelial 
cells initiate a signaling cascade to attract neutrophils to the tissues. Activation of 
map kinase (MAPK) and nuclear factor-kappa B (NF-κB) signaling cascades through 
TLR ligation have been implicated in the upregulation of epithelial basolateral 
expression of interleukin (IL)-8 and KC; the human and mouse chemotactic factors 
for neutrophils, respectively (47, 48). IL-8 directs neutrophil migration across the 
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endothelium utilizing β2 integrins cluster of differentiation (CD) 11b/CD18, and 
through the lamina propria to the subepithelium, where the apical chemoattractant, 
pathogen-elicited chemoattractant (PEEC) mediates migration across the epithelium 
and into the lumen (49, 50). Recent studies have shown that basolateral epithelial 
contact of neutrophil produced serine proteases results in activation of epithelial 
protease-activated receptors (PARs) which increase epithelial permeability to allow 
neutrophil transmigration (51). Matrix metalloproteases (MMP) also participate in this 
process.  
Upon arrival in the tissues, neutrophils stimulate chloride secretion which 
hydrates the mucosal surfaces and aids in washing away accumulated debris or 
microbes (52). Neutrophils also phagocytose debris or invading microbes, and 
degranulate to give off myeloperoxidase, lysozyme, elastase, cathepsins, and 
lactoferrin (53). 
Under normal conditions, wound healing mechanisms, mentioned previously, 
restore transcellular integrity. Following complete transmigration of neutrophils, TJ 
reseal as a function of the aforementioned wound healing process. As wounds are 
closed by epithelial restitution, F-actin-myosin bands encircle the wound and restore 
TJ function by sphincter-like contraction (54). Anti-inflammatory epithelial trefoil 
factors and eicosanoids, such as lipoxin A4 (LXA4), downregulate inflammatory NF-
κB signaling and IL-8 production (55). This aspect of epithelial-innate immune cell 
interactions overlaps with microbial clearance of pathogens, however, the 
commensal microflora are bacterial species that are vital to epithelial maintenance 
and function. 
 Epithelial-microflora interactions 
 It is currently estimated that anywhere from 500 to 1000 species of bacteria 
are found in the gut (56). In fact, approximations place bacterial cell numbers within 
the human body 10-fold higher than human somatic and germ line cells (57). While 
the microflora benefit from host ingested nutrients and an intestinal niche, the host 
gains much from the presence of the microflora as well. The enteric microflora 
nourishes the intestinal epithelium by aiding in metabolism of plant polysaccharides 
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and producing short-chain fatty acids (SCFA) like butyrate (58). Butyrate is the 
primary nutrient source for colonocytes (59). Metabolized nutrients provided to the 
epithelium by the microflora play a vital role in wound healing and TJ function as well 
(60).  
 Much of what is now known regarding epithelial-microflora symbiosis comes 
from studies utilizing germ-free mice and rats. Mice lacking microflora are more 
susceptible to infection, exhibit reduced potential for angiogenesis, are deficient for 
digestive enzyme activity, display thickened muscularis tissues, are less capable of 
cytokine and immunoglobulin production, have underdeveloped peyer’s patches and 
fewer intraepithelial lymphocytes (57). Germ-free mice require an increased caloric 
intake to thrive comparably to conventionally colonized mice; emphasizing the 
importance of the microbial role in nutrient availability, uptake and storage (61). In 
2003 it was shown that mono-association of germ-free mice with Bacteroides 
thetaiotaomicron restores angiogenic potential through paneth cell signaling, and 
similarly upregulates production of paneth cell proteins which are antibacterial for 
gram-positive gut pathogens like Listeria (62, 63). These experiments illustrate that 
even simple monoassociation of the gut is enough to restore more homeostatic 
epithelial function. It is also of importance that components of the microflora, such as 
LPS, play a role in homeostatic immune function and oral tolerance, which will be 
further described later in this review (64). 
Epithelial-immune cell interactions 
 The epithelium is more than just a discrete barrier in the intestine. Epithelial 
cells possess antigen presentation capabilities which lead to the activation of 
adaptive immune responses through T cell interactions. Intestinal epithelial cells are 
a unique antigen presentation cell (APC) subset as they display classical type I 
presentation molecules and are the only non-professional APC to constitutively 
express MHC II molecules (65, 66). Intestinal epithelial cells are no different than 
any other nucleated cell in the body in that they express MHC I molecules that allow 
for presentation of antigen to CD8+ cytotoxic T cells. The class I presentation 
pathway involves antigens from infected or malignant cells whose proteins are 
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ubiquitinated and targeted to the proteasome complex. Proteasomal enzymatic 
processing of these proteins results in their transportation to the endoplasmic 
reticulum (ER) by the transporter associated with antigen processing (TAP), where 
they are loaded into freshly synthesized MHC I molecules and shipped from the 
golgi to the cell surface (67). Thus far, it has only been shown that intestinal 
epithelial cells fail to insight cytotoxic T cell responses (68, 69).  
Functionally, T cell interactions with epithelial MHC II molecules are polarized 
in similar fashion to the epithelium itself; apical antigens can only trigger a 
basolateral response (70). In 2005, Beers et al. showed that the lysosomal cysteine 
protease cathepsin S (Cat S) is responsible for invariant chain degradation and MHC 
class II maturation in intestinal epithelial cells (71). Moreover, this study illustrated 
for the first time that intestinal epithelial class II bound endogenous peptides are 
presented to naïve CD4+ T cells in vivo. Professional APCs secrete exosome-like 
membrane blebs containing classical restriction elements which can interact with T 
cells (72). Similarly, it has been shown that membrane blebs from intestinal epithelial 
cells also contain MHC II and could potentially cross into the lamina propria to 
interact with CD4+ T cells (73). Karlsson et al. went on to demonstrate that these 
epithelial membrane blebs could be isolated from peripheral blood and used to 
induce antigen-specific tolerance in vivo. 
Intestinal epithelial cells have also been shown to express several non-
classical class I-like molecules which are capable of interacting with many immune 
cell types (74). MHC class 1 chain-related protein A and B (MICA/B) are functionally 
indistinguishable molecules expressed on intestinal epithelial cells. These proteins 
interact with natural killer (NK) receptor NKG2D, which is expressed on NK cells, NK 
T cells, cytotoxic CD8+ T cells, γδ T cells, and macrophage (75). MICA/B activates 
NK cells and co-stimulates T cells (76). Tieng et al. described that upon E. coli 
adhesin to its cell receptor, MICA expression was upregulated on intestinal epithelial 
cells, implying that MICA expression and its functions are modulated by enteric 
microbes (77). UL16-binding proteins (ULBPs) on intestinal epithelial cells are 
genetically distinct from MICA/B, but functionally similar in that they are human 
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ligands for NK cell NKG2D receptors that activate cytokine secretion from NK cells 
(78). Human leukocyte antigen (HLA)-E (humans) and Qa-1 (mice) on intestinal 
epithelial cells can present peptides in similar fashion to MHC I (79). These 
molecules bind NKG2A, NKG2B and NKG2C on NK cells and cytotoxic CD8+ T 
cells; their expression can be IFNγ regulated (80). HLA-E and Qa-1 have been 
documented to stimulate CD8+ regulatory T cell subset expansion as well (81). The 
neonatal Fc receptor (FcRn) is a misnomer as it is expressed in adult intestinal 
epithelial cells as well as in neonates (82). FcRn does not present antigen, but binds 
the constant (Fc) region of IgG for the purpose of apical to basolateral transport and 
basolateral to apical transport (82). FcRn-IgG binding is optimal at acidic pH and bi-
directional shuttling is regulated by sorting signals in the cytoplasmic tail of FcRn 
(83-85). Blumberg et al. were able to prove that antibodies capturing antigen in the 
lumen could be transported into the lamina propria by FcRn and delivered to CD11c+ 
dendritic cells (DC) cells which in turn activated antigen specific CD4+ T cell 
responses in vivo (86). These results solidify the role of intestinal epithelial cells as a 
signaling link between luminal antigens and immune cells in the lamina propria. 
Human CD1d, and murine homologs are expressed by professional APCs as well as 
intestinal epithelial cells and they present glycolipid and glycoprotein antigens to 
several T cell subsets (87, 88). CD1d is most associated in the literature with 
activation of NK T cells expressing the NK1.1 marker, which produce IL-4 and IFNγ 
upon activation (89). Interestingly, a regulatory subset of CD8+ T cells is restricted 
by CD1d expressed on intestinal epithelial cells and displays strong contact-
dependant regulatory activity (90). CD1d expression is upregulated by IFNγ, cecal 
bacterial antigen exposure and in a positive feedback loop by regulatory T cells (91). 
While crosslinking of CD1d has been shown to upregulate IL-10 production, 
intestinal tolerance is not CD1d-restricted (74). Murine MHC T locus (TL) antigens, 
expressed on thymocytes and intestinal epithelial cells, do not present antigen, but 
bind CD8 and activate cytotoxic γδ and αβ T cells in a professional APC restricted 
manner (92-94).  Together these observations clearly highlight the importance of 
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intestinal epithelial cell APC functions to immune cell activation and cytotoxic 
responses in the enteric mucosa. 
Co-stimulation is a required aspect of specific T cell activation in addition to T 
cell receptor (TcR) engagement. Anergy is the consequence of TcR engagement in 
the absence of co-stimulation. Early on in this area of research it was found that 
intestinal epithelial cells do not express the typical CD80 or CD86 T cell co-
stimulatory molecules; this observation raised questions about the APC functions of 
intestinal epithelial cells and causation of anergy (95). Since that time, expression of 
non-traditional co-stimulatory molecules has been characterized on intestinal 
epithelial cells. In vitro and ex vivo experiments identified the expression of B7h, 
positive signal ligand for inducible co-stimulator (ICOS) on T cells; and B7-H1, 
inhibitory ligand of PD-1 on T cells (96). These studies concluded that B7h and B7-
H1 are only expressed on intestinal epithelial cells isolated from inflamed tissues. 
Additionally, only anti-B7h monoclonal antibody (mAb) inhibited proliferation of 
intestinal epithelial cell stimulated T cells, suggesting that B7h, but not B7-H1, is 
important for T cell activity in diseased intestinal tissues. Human intestinal epithelial 
cells also express basolateral CD58 (97). Studies by Framson et al. utilized anti-
CD58 mAb to illustrate that blocking of CD58 co-stimulation could abolish intestinal 
epithelial-T cell HLA class II mediated antigen presentation (97). Intestinal epithelial 
cells hold potential as co-stimulatory mediators for T cell stimulation via B7h and 
CD58 molecules. Together, this evidence highlights the multiple niches the intestinal 
epithelial cell participates in with regard to T cell activity and regulation in 
homeostasis and disease states. 
 Cytokines, chemokines and inflammatory mediators 
 Cytokine, chemokines and other inflammatory mediators produced by multiple 
cell types in the gut, homeostatically and during inflammation or infection, are 
essential for intestinal protection and maintenance. Intestinal epithelial cells produce 
many neutrophil chemotactic molecules meant to basolaterally attract these cells for 
defense. CXCL chemokines 1, 2, 3, 5 and 8/IL-8 are all produced by intestinal 
epithelial cells for the purpose of attracting neutrophils upon infection or 
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inflammatory cytokine signals (98, 99). CXCL8/IL-8 is quickly released in large 
amounts by distressed intestinal epithelial cells and is short lived for expedient and 
substantial neutrophil chemotaxis (100). On the other hand, CXCL5 production in 
these cells is delayed, weakly potent and long lived for a mild but sustained 
chemotactic neutrophil response (101). Granulocyte colony stimulating factor (G-
CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) are cytokine 
signals which are not chemotactic for neutrophils, but are responsible for local 
maintenance and survival of neutrophils once they have reached the intestinal 
tissues (102). These cytokines act to increase neutrophil proliferation and survival. 
CCL2/monocyte chemotactic protein (MCP)-1 and RANTES are produced as 
chemotactic factors for monocytes and macrophage (103). Intestinal signals for 
innate immune cells are not constitutively expressed, unlike chemotactic signals for 
T cells. 
 CXCL9/monokine induced by gamma interferon (MIG), CXCL10/interferon 
inducible protein 10 (IP-10) and CXCL11/interferon-inducible T cell α-
chemoattractant (I-TAC) are all IFN inducible chemotactic factors for CXCR3 
expressing CD4+ T cells (104). These chemokines are constitutively expressed in 
healthy intestinal tissues and can upregulate IFN production in CXCR3 expressing 
cells, including mononuclear cells and intraepithelial lymphocytes (104). These 
chemokines are usually associated with T helper 1 (Th1) type CD4+ lymphocytes, 
which are most common in the gut (105). Constitutive expression of 
CCL22/macrophage-derived chemokines (MDC) is chemotactic for T helper 2 type 
CD4+ T cells (106). Expression of this chemokine is upregulated by infection or 
increased production of TNF and IFN, but is downregulated by IL-4 and IL-13. This 
chemokines is one of many examples of NF-κB responsive chemical signals 
expressed in the enteric mucosa. 
 Dendritic cells (DC) are a critical linker of innate and adaptive immunity, 
serving as a professional antigen presenting cell to intraepithelial and more distal 
lymphocytes. CCL20 is produced by intestinal epithelial cells and most lymphocytes 
and is chemotactic for CCR6 expressing immature DC (107). Immature DC are 
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highly phagocytic, but upon antigen uptake will downregulate their phagocytic 
function and migrate to present the antigen they have collected and processed to T 
cells (108). Not surprisingly, CCL20 production is upregulated by epithelial infection, 
TNF production and IL-1 production. It is hypothesized that CCR6 expressing DCs 
that chemotax to the intestine participate in uptake of antigen across the epithelium 
(109). DCs have characteristic long dendrites which can form temporary TJ with 
intestinal epithelial cells as they insert their dendrites between epithelial cells to 
sample antigens in the lumen (110). After sampling, the dendrites retract and the 
dendrite-epithelial TJ are replaced immediately by epithelial-epithelial TJ. 
 Additional cytokine signals are upregulated in the intestine upon infection by 
pathogens. TNF and IL-1α serve as warning signals to initiate inflammatory 
cascades in the enteric mucosa. IL-1α is interesting in that it does not require 
cleavage, like IL-1β, for activity. IL-1α activity is abolished by IL-1 receptor agonist 
(IL-1Ra), which also downregulates IL-1 induced IL-8 production (111). It should be 
noted that mRNA expression of IFNγ, IL-2, IL-3, IL-4, IL-5 and IL-12p40 is not 
present in intestinal epithelial cells (112). This observation underscores the notion 
that while intestinal epithelial cells play an acute and vital part in the initiation of 
inflammation in the gut, these cells are not meant to sustain antigen specific immune 
responses.  
One of the most important mediators of inflammation is the transcription factor 
NF-κB. In the absence of signaling leading to NF-κB activation, NF-κB dimers are 
sequestered in the cytoplasm by IκB inhibitors which mask the transcription factor’s 
nuclear localization domains (113). Host cell detection of microbes or TNF or IL-1 
production cause IκB phosphorylation, polyubiquitonation, and proteasomal 
degradation, freeing NF-κB to translocate into the nucleus (114). Catalytic IKKβ 
mediated IκB degradation leads to activation of many innate defense mechanisms. 
Such mechanisms include CXCL1, CXCL8, CCL2, CCL20, CCL22, intercellular 
adhesion molecule 1 (I-CAM), TNF, nitric oxide synthase 2 (NOS-2) and 
cyclooxigenase 2 (COX-2) (115). The partnership of intestinal epithelial cells and 
local lymphocyte and monocyte populations in cooperatively initiating protective 
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mechanisms in the gut is a complex and highly regulated relationship in which 
homeostasis is balanced by inflammation and tolerance. 
 Oral tolerance 
 Oral tolerance could be described as the body’s way of extending self-
tolerance to annexed host microflora and constant food antigen exposure. The 
traditional definition of oral tolerance relates the specific suppression of immune 
responses (cellular and/or humoral) to antigens previously dosed by the oral route. 
This tolerance functions to avert hypersensitivity to food antigens, immunologic 
depletion of the microflora, and the subsequent tissue damage that would result from 
these immune responses. This is a necessary immune mechanism as 130 to 190 g 
of food derived proteins are absorbed every day by the average intestine, and 
human stool contains 1012 bacteria/gram (60, 116). Additionally, the gut has a 
greater concentration of Ig-secreting cells than that found in all other lymphoid 
organs combined (117, 118). Indeed, dietary and microflora antigens usually induce 
tolerance without detrimental local or systemic immune reactivity. Experimentally, 
the role of food proteins in immune system development is valuable for normal 
maturation of gut-associated lymphoid tissues (GALT), IgA and IgG maintenance, 
normal lymphoid organ morphology and function, as well as balanced Th1/Th2 
profiles and homeostatic IL-10, IL-4 and IFNγ ratios (119).  
 The two primary effector mechanisms of oral tolerance are in induced, in part, 
by antigen dose. One arm of oral tolerance is induced by clonal anergy or clonal 
deletion in response to high doses of oral antigen (120). T cell anergy was 
pinpointed as a tolerogenic mechanism when it was discovered that tolerance could 
be abolished by exogenous IL-2 (121). Now clonal anergy is defined as IL-2 
responsiveness to high doses of oral antigen in the absence of transferable 
suppression (120, 122, 123). Anergic regulatory cells have also been hypothesized 
to function by producing IL-4 and IL-10 (122). Clonal deletion has also been 
observed in mice fed high antigen doses followed by systemic challenge with 
adjuvanted antigen (124). Additionally, long-term ovalbumin (OVA) feeding to T cell 
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receptor (TCR) transgenic mice increases caspase activity in Ag specific CD4+ T 
cells (125).  
The second limb of oral tolerance is active suppression, induced by low doses 
of oral antigen (126). It has been documented in mice that autoimmune gastritis and 
ovarian/testicular inflammation associated with neonatal thymectomy is abrogated 
by the restoration of a CD4+CD25+ subset of T cells (127, 128). Anergic TNF 
receptor and FoxP3 transcription factor expressing T regulatory cells (Treg) mediate 
regulation through contact, while T helper 3 (Th3) and T regulatory cell type 1 (Tr1) 
Tregs regulate immune responses through the production of TGFβ and IL-10 
respectively (129-132). CD8+ TGFβ secreting Treg cells have been identified in the 
maintenance of oral tolerance in several autoimmune models (133, 134). 
Specifically, IL-4 and IL-10 producing CD8+ regulatory cells are induced by feeding 
antigen, even after CD8+ T cell tolerization (135).  It has also been shown that if an 
orally tolerized T cell and a naïve T cell of different specificities interact with the 
same DC, The tolerized T cell can influence the DC to induce differentiation of the 
naïve T cell to a regulatory phenotype (136). While it has been illustrated that CD8+ 
Tregs are not necessary for induction of systemic tolerance, it seems that these cells 
are able to fill certain regulatory niches in the mucosa (137). Ke et al. have also 
reported that γδT cells are vital to oral tolerance and enteric mucosal protection 
(138). In this study δTCR-deficient mice, which lack γδT cells, were incapable of 
eliciting tolerogenic responses to low doses of oral antigen. Conflicting reports exist 
regarding the role of NK T cells in oral tolerance. Several reports characterize the 
oral tolerance induced by NK T cells in the liver, however, other studies illustrate an 
intact oral tolerogenic response in mice lacking NK T cells (139-141). Perhaps this 
data implies that while not required for complete oral tolerance, NK T cells can serve 
as additional tolerogenic effectors in the liver and other organs. Most recently a 
subset of invariant FoxP3+ NK T cells has been described (142). This population 
was observed to arise in a transforming growth factor beta (TGFβ) dependant 
fashion in the cervical lymphnodes of mice with experimental autoimmune 
encephalitis as well as in the gut. Like FoxP3+ Tregs, these cells suppress in a 
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contact-mediated fashion, and like NK T cells, they preferentially migrate to the liver 
upon adoptive transfer into mice. 
The suppressive or regulatory activities of these cell types are supported by 
cytokine signals. While suppression of interferon gamma (IFNγ) is a commonly 
recognized phenomenon in oral tolerance challenge experiments, it is also known 
that primed antigen-specific T cells produce large amounts of IFNγ during the 
inductive phase of tolerance (143). Preserved IFNγ production been linked to models 
of T cell anergy, while depletion or absence of this cytokine has also been shown to 
abrogate existing tolerance or prevent induction of tolerance (144-147). Confounding 
this issue are studies which report a lack of tolerance interference by in vivo IFNγ 
depletion or lack of the IFNγ receptor in vivo (148-150). Clearly, more research 
regarding the role of IFNγ in the development and maintenance of oral tolerance is 
needed. Perhaps the key cytokine modulator of adaptive suppression is TGFβ. 
TGFβ is a pleuripotent cytokine whose latent form relies on degradation of the 
coupled latency associated peptide (LAP) after αvβ integrin recognition for activity 
(151). This cytokine can be secreted in bioactive or latent forms. Miller et al. first 
suggested the link between TGFβ and oral tolerance by reporting the dependence of 
CD8+ T cell mediated suppression of experimental autoimmune encephalitis in mice 
orally tolerized to myelin basic protein on TGFβ (152). Since that time it has been 
found that TGFβ secreting cells can be isolated from peyer’s patches and 
mesenteric lymphnodes of orally tolerized mice, as well as from the blood of humans 
orally tolerized to myelin basic protein (153, 154). In addition to enhancing leukocyte 
recruitment and IgA secretion, TGFβ is known to aid in the differentiation of 
CD4+CD25- T cells into CD4+CD25+ Tregs (155-157). T cell clones from tolerized 
mice exhibit a CD4+CD25+ TGFβ producing Treg phenotype (153, 158). These cells 
have been found to express cytotoxic T-lymphocyte antigen 4 (CTLA4); an inhibitory 
molecule which binds B7 molecules on T cells; or FoxP3 and exhibit functional 
suppressive capabilities in vitro and in adoptive transfer models where tolerance is 
transferred by these cells to naïve cells of the recipient (159-161). TGFβ is also 
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released by apoptotic T cells in which mitochondrial membrane potential has been 
compromised and existing cytokine is released to the cytosol (162). Uptake of 
apoptotic cells by macrophage and dendritic cells induces TGFβ production and a 
decrease in pro-inflammatory cytokine production (163-165). In addition to secreted 
TGFβ, a membrane bound form of TGFβ has been characterized (166, 167). A 2010 
study has shown that latent TGFβ is incorporated into the extracellular matrix by a 
complex, including latent TGFβ-binding protein 1, which is functionally dependant on 
pericellular assembly of fibrillin microfibrils (168), while a 2009 report related the 
importance of the leucine-rich repeat molecule GARP to tethering the complex to the 
cell membrane (169). The activity of TGFβ, and the subsequent generation of Tregs 
and tolerance is greatly influenced by the presence or production of the cytokines IL-
10, IL-4 and IL-2. While IL-2 has been shown to support TGFβ induced Treg 
differentiation and expansion, IL-4 can also fill this role with respect to Th3 type 
Tregs from tolerized mice (153, 158). TGFβ induced Tregs are capable of producing 
IL-4 in combination with IL-10 or of producing IL-10 alone. In 2009, Zheng  et al. 
observed the requirement for IL-4 in the production of highly suppressive CD8+ 
Tregs (170). IL-10 is produced by many cell types but is recognized as the key 
product of the Tr1 CD4+ Tregs (171). Studies involving IL-10 deficient mice illustrate 
the importance of IL-10 to immune tolerance, as these mice spontaneously develop 
severe colitis related to lack of sufficient immune regulation and subsequent chronic 
immune reactivity to antigens of the enteric microflora (172). Housing these mice in 
germ-free conditions prevents colitic onset (173). IL-10 is thought to act upon APCs 
by inhibiting MHC class II and co-stimulatory molecule expression in these cells 
(174). With regard to modulation of T cell effector functions, IL-10 serves to inhibit 
effector cells in a feedback control capacity (175). IL-10 therapy has been shown to 
restore enteric mucosal tolerance in mice with IBD (132). 
In summary, the enteric mucosa relies on a complex and tightly regulated 
community of innate and adaptive immune cells, as well as cross talk with the 
resident microflora, to maintain homeostasis and immune tolerance. Antigen 
excluding epithelial barriers are maintained by tight junctions, nourished by microbial 
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metabolites and supported by innate immune surveillance. While effector T cells are 
readily called to action by APCs in the event of pathogen immune escape, regulatory 
cytokines and T cells are constantly acting to suppress inappropriate and chronic 
immune activation. The early induction of tolerogenic mechanisms by anergy, clonal 
deletion and active suppression are vital to enteric homeostasis. While the cellular 
interactions protecting the intestines on a daily basis are very thorough and not 
without several fail-safes, this system is not perfect and is subject to malfunction. 
The next section of this review will discuss the mechanisms and consequences of 
homeostatic breakdown in the enteric mucosa in the context of inflammatory bowel 
disease. 
 
Inflammatory Bowel Disease (IBD) 
 Inflammatory bowel disease primarily encompasses the etiologically 
undefined and multifactorial disorders of Crohn’s disease and ulcerative colitis. 
These conditions involve an array of complications including, but not limited to, 
epithelial barrier dysfunction, microflora dysbiosis, chronic immune activation and 
ineffective immune regulation. The following section will discuss IBD from clinical 
and basic science perspectives, as well as current therapeutic strategies. 
 Clinical and epidemiological perspectives 
 Ulcerative colitis (UC) is a chronic inflammatory disorder which manifests in 
the lower intestine. Characteristically, lesions in UC patients are found in the rectum 
and progress proximally up the colon. The ileum is generally unaffected in UC 
unless ‘ileal backwash’ has occurred (176). UC can be broken into clinical categories 
based on the placement of colonic involvement:  ulcerative proctitis is localized to 
the rectum, proctosigmoiditis refers to sigmoid colonic involvement, left-sided colitis 
encompasses the entirety of the descending colon to the intersection of the 
transverse colon and pancolitis describes UC lesions found beyond the splenic 
flexure and possibly into the cecum (177, 178). Physical examinations of patients 
suffering from mild to moderate UC are usually normal and common clinical signs of 
UC include increased frequency of bowel movement, blood in the stool, uncontrolled 
elimination, diarrhea, fecal incontinence, constipation, passage of hard stools, 
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abdominal pain, nausea, vomiting and weight loss (179). In severe cases 
malnourishment and abdominal distention can become externally apparent (180). 
There is as yet no standard UC disease activity index, although a combination of 
approaches including classical scoring developed by Truelove and Witts, Mayo 
index and Baron endoscopic scores are utilized in many clinical settings (181-183). 
The Truelove Witts index breaks disease phenotypes in to mild, moderate or severe 
based on bowel movement frequency, presence of blood in stool, heart rate, 
hemoglobin level and erythrocyte sedimentation rate (183). This index has been 
validated by reviews of retrospective data which found a correlation between 
Truelove Witts index score and severity of UC outcome (184, 185). Five primary 
outcomes are defined in UC patients:  chronic relapsing disease, chronic unremitting 
disease, single episode without recurrence, colectomy and death (186). These 
outcomes are greatly affected by preceding disease activity and systemic symptoms 
associated with diagnosis. Flares can be aggravated by non-steroidal anti-
inflammatory drugs, cessation of smoking, and mucosal infections (187). Endoscopic 
observations and scores, like that of the Baron endoscopic score, also tend to 
correlate well with clinical activity of UC and can lend insight to practitioners in 
outcome prediction (188). Several endoscopic features noted in UC affected 
intestines are common to other inflammatory disorders of the gut and include 
edema, loss of normal vascular pattern, mucosal friability and mucosal granularity 
(189). A somewhat unique endoscopic finding in UC patients is a continuous 
inflammatory distribution with severity peaking in the rectum and decreasing toward 
the transverse colon without healthy tissue between lesions. While patchy lesions 
and rectal sparing can occur in UC patients, most studies find that these are rare 
events and usually emerge in pediatric patients (189). Histologic lesions in UC 
patients are marked by depleted goblet cell numbers, common crypt abscesses and 
architecture distortion, uniformly heavy lymphocytic infiltrate, lack of granulomas, 
thickened muscularis mucosa, and scant submucosal inflammation (190). 
Endoscopic and histologic findings in UC patients are often indicators of the potential 
for UC patients to develop additional non-neoplastic or neoplastic intestinal 
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complications (191). In pancolitic and left-sided colitic UC patients, systemic toxicity 
accompanied by dilation of the colon more than 6 centimeters (cm) in the absence of 
obstruction is occasionally noted and termed toxic megacolon (192). This 
complication can be marked by the presence of Clostridium difficile, Campylobacter, 
Shigella, Salmonella, amebic infections or cytomegalovirus and is a risk factor for 
perforation. Other intestinal complicating factors for pancolitic UC patients, though 
rare, are hemorrhage and benign or malignant stricture. Patients suffering from 
pancolitis or left-sided UC also have a greatly increased risk of developing rectal 
cancer, colon cancer, or cholangiocarcinoma, with risk increasing even more in 
patients experiencing greater chronicity of UC or concurrent bouts with primary 
sclerosing cholangitis (193, 194). Studies show that in addition to intestinal 
complications of UC, patients will manifest at least one extraintestinal complication. 
Some recorded non-intestinal complications include osteoporosis, abnormal 
pulmonary functions, pyoderma gangrenosum, iritis, uveitis, venous thrombosis, 
arthralgias, and arthritis (195). It should be noted, however, that most extraintestinal 
complications are not uniquely linked to UC and are therefore not a distinguishing or 
diagnostic factor for practitioners attempting to differentiate between UC, CD or 
intermediate colitis. With advancing interest and funding for medical research and 
technology the life expectancy of UC patients is no different than that of the average 
member of the population (196). Mortality is slightly increased within the first few 
years of diagnosis, and chronicity and severity of UC is not surprisingly linked to 
higher mortality.  
 Crohn’s disease (CD) is a chronic, enteric inflammatory disorder which 
manifests as a patchy lesion anywhere from mouth to rectum (197). While CD 
lesions can be quite spread out, it seems that 90% of newly diagnosed patients 
present with gross small intestinal, colon restricted, or combined small and large 
intestinal lesions in a patchy pattern. Clinical categories or presentations for CD can 
be divided into terminal ileum, colonic, ileocolonic or upper gastrointestinal 
manifestations. The terminal ileum is by far the most consistently affected area of 
the intestine in CD patients. Lesions isolated to the mouth, esophagus, and stomach 
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are rare in the absence of primary intestinal lesions. It has been noted in several 
population-based retrospective studies that it is possible for the primary 
concentration of lesions or the location of CD involvement to change overtime in 
patients, but that is not the majority case (198). Common symptoms of CD include 
abdominal pain, diarrhea, weight loss, and occasional fever and bloody stools. 
Interestingly, there is a correlation between instance of abdominal pain and ileal 
lesion localization (199). There also seems to be a correlation between diarrhea, 
bloody bowel movements and colonic CD. Again, due to the variable and 
unpredictable nature of CD, no standard disease activity index exists for CD, 
however the Crohn’s Disease Activity Index (CDAI), Harvey-Bradshaw Index (HBI), 
Van Hees Index (VHI), Perianal Disease Activity Index (PDAI) and Pediatric Crohn’s 
Disease Activity Index (PCDAI) are all used in practice regularly, depending on the 
category of CD involvement, the patient type and some other CD-related 
complications (199-202). The CDAI is by far the most commonly utilized index (199). 
The CDAI takes into account 8 parameters over a seven day time period:  instances 
of diarrhea, severity of abdominal pain, quality of life, extraintestinal complications, 
requirement of anti-diarrheal drugs for control, presence of abdominal masses, 
hematocrit and body weight. The HBI is a simplified version of the CDAI, while the 
VHI ignores subjective CDAI parameters (199, 200). It has been shown that CD 
patients suffering from perianal disease score deceptively low on the CDAI and 
subsequently require use of the PDAI (202). The past decade has been marked by a 
steady increase in severe CD development in pediatric patients, in whom the PCDAI 
is most appropriate (201). The two most common disease outcomes in CD patients 
are chronic intermittent disease and chronic continuous disease (203). Mild 
intermittent disease also occurs, but chronic intermittent CD is the most common 
outcome. External factors which affect CD outcome are smoking and use of the oral 
contraceptive pill; both of which encourage focal thrombosis and intensity of CD 
activity (204). Endoscopic scores, such as the Crohn’s Disease Endoscopic Index of 
Severity (CDEIS) or the Simple Endoscopic Score for Crohn’s Disease (SES-CD) in 
combination with various imaging methods are crucial for disease assessment due 
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to the highly variable and patchy manifestation of CD lesions (205). Again, several 
common endoscopic characteristics seen in CD patients are not limited to CD. 
Typical CD lesions are patchy with normal mucosa between lesions. Asymmetry and 
heterogeneity of lesions is also common. The presence of lesions interrupted by 
normal mucosa and more common rectal sparing are typical of CD. Small ileocecal 
valve or terminal ileal ulcerations are pathognomonic for CD. Histologically, CD 
patients exhibit thickened gut tissues interspersed with fistulas which can create a 
‘cobblestone’ appearance, increased adipose wrapping around the gut tissue, 
normal goblet cell distribution, occasional to rare crypt abscesses, intact glandular 
architecture, patchy lymphocytic infiltrate ranging from mild to severe, granulomas, 
normal muscularis mucosa, and excessive submucosal inflammation (206). Related 
to these occurrences are the three main intestinal complications associated with CD:  
intestinal inflammation, stricture and penetration. Lesions in CD patients are 
transmural in nature and can involve fibrosis of the bowel wall leading to stricture. 
Bowel penetration and fistulae adjoining nearby organs and skin are not uncommon 
in CD. The development of these disease manifestations is not usually absolute. 
Most severe patients present with inflammation that leads to stricture and then 
penetration. The course of CD can be cyclical with any one or multiples of these 
manifestations occurring at any given time. Chronic inflammation can lead to 
penetration or fistula formation between the diseased colonic section and the urinary 
bladder, vagina or neighboring bowel segment (207). Like UC patients, those 
suffering with CD have an increased risk of colorectal cancer, however, as many of 
the most inflamed and severe cases of CD involve extensive or complete bowel 
resections, this lowers the risk of colonic adenocarcinoma in the most severely 
affected patients (208). In addition to intestinal complications of CD, extraintestinal 
CD complications can occur simultaneously with and be associated with a flare of 
disease or can occur in a fashion independent of intestinal CD activity (209). Joint 
inflammation is the most common extraintestinal disturbance associated with CD. 
Joint inflammation presents as acute peripheral arthritis involvement of the large 
joints associated with the duration of a CD flare or as acute peripheral arthritis 
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involvement of the small joints independent of a CD flare. Several inflammatory 
disorders of the skin develop in CD patients. While CD imparts a slightly increased 
risk for Sweet’s syndrome and pyoderma gangrenosum, erythema nodosum is the 
most frequently reported cutaneous disorder associated with CD. Erythema 
nodosum is characterized by painful red lumps on the skin caused by a 
hypersensitivity reaction in the panniculitis, or subcutaneous fat layer. This 
inflammatory reaction is self limiting and usually resolves within 3 to 6 weeks of 
onset. Cases of CD associated neutrophilic cutaneous disorders, such as Sweet’s 
syndrome are infrequent. Non-specific eczema and psoriasis seem to be genetically 
linked to CD. Although ocular inflammation and liver disease, such as iridocyclitis, 
episcleritis and primary sclerosing cholangitis respectively, are reported in CD 
patients, these are more commonly associated with UC. Osteoporosis and deep 
venous thrombosis are also reportedly linked to CD. Increased mortality in CD 
patients correlates with disease duration, with later stage cases at a greater risk. 
 Epidemiologic data collected and assessed in the context of IBD is 
complicated by many factors. Time to diagnosis, accuracy of diagnosis, patient 
access to medical care, and efficiency of patient tracking are only a few of the 
complicating factors to consider when reviewing epidemiologic data, however, much 
valuable epidemiologic data has been collected which sheds light on potential 
etiologic mechanisms in IBD. Recent estimates figure that 1.4 million Americans and 
2.2 million Europeans suffer from CD or UC (210). While the worldwide instance, or 
relative number of newly diagnosed cases over a period of time, of UC has been 
stable for some years now, the instance of CD has only relatively recently plateaued 
since its more recent discovery in 1932. The more recent increase in instance of CD 
is likely attributed to its relative infancy compared to UC. There is a documented 
north-south gradient associated with risk of IBD (211). One hypothesis for this 
gradient is the ‘hygiene hypothesis’ (212). This hypothesis asserts that people living 
in southern geographic regions are more apt to spend time outdoors, come in 
contact with more beneficial microorganisms, acquire greater antigenic or immune 
stimulation from a less sterilized indoor environment, or come into contact with more 
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environmental pollutants or transmissible organisms. Theoretically, the hygiene 
hypothesis characterizes the environments in which IBD is most prevalent to have 
been made too sanitary. Thusly, people in those areas do not receive the right 
amount of immune stimulation. Supportive of the hygiene hypothesis is the 
observation that people with higher socioeconomic standing are more likely to 
develop IBD. Similarly, it has been shown that women whose occupation involves 
cleaning or maintenance and men whose occupations require them to work outdoors 
were less likely to develop IBD than those working indoors in office buildings or in 
jobs were they are not regularly exposed to greater levels of environmental antigen. 
Interestingly, instance of IBD has stabilized in geographic areas of high IBD 
frequency, but has recently begun to increase sharply in areas of lower IBD 
frequency. More specifically, cohorts in the United States and Northern Europe have 
seen a relatively steady instance of IBD over the past decade, while instances in 
eastern and southeastern Asia have increased greatly during that time. This 
increase in IBD instance specifically points to a rise in UC cases over CD. Some feel 
that this shift is due in part to “westernization” and cultural shifts in countries like 
Japan (213). Prevalence, or the number of recorded cases at a given time, is not a 
great epidemiologic measure of IBD (214). Prevalence is equivalent to incidence of 
disease multiplied by time. While prevalence should equal incidence for acute 
diseases, IBD is chronic in nature and manifests variably in terms of general and 
individual patient contexts such as cultural, geographical and microbial 
considerations. The patient to patient, region to region and culture to culture 
differences noted in IBD make prevalence a less accurate measure of chronic 
disease. Accordingly, most epidemiologic studies of IBD prevalence have resulted in 
variable numbers with little consensus within and among studies. While pediatric IBD 
totals have recently been estimated to encompass 33% of IBD cases in the United 
States, the average age of IBD onset is between late adolescence and early 
adulthood worldwide (215). In North America, the observed age of CD diagnosis is 
generally between 33 and 45 years of age, while UC diagnosis tends to occur 5 to 
10 years later in life (210). Many epidemiologic studies have found a bimodal age 
 24 
distribution in UC cohorts world wide, in which a primary peak age of onset of UC 
occurs between the third and fourth decades of life; while a second peak age of 
onset occurs later in life beyond the fourth decade (216). This same bimodal 
observation is also noted in CD epidemiology, but not as reliably or extensively as 
that recorded for UC cohorts (216). While it is generally accepted that there is no 
significant sex bias in either CD or UC, many epidemiologic studies note that there is 
a slight skew toward increased female instance of CD while a similar skew shows an 
increased bias toward males with regard to UC instance (217). With regard to race 
and ethnicity, most studies conclude that both CD and UC are most prevalent in 
Caucasians but not that far from numbers in Black cohorts (218). Jewish populations 
are highly affected and this trend is most notable for CD (219). In the United States, 
the most infrequently represented groups are Hispanics and Asians, but as 
mentioned previously, these formerly low instance groups have seen increased 
instance of IBD in recent years in North American cohorts as well as in the native 
countries of Japan and Mexico (220). Diet is closely tied to health and culture around 
the world and epidemiologists have collected much data on the effect of certain 
items in the human diet on IBD. Several studies have asserted a link between sugar 
and carbohydrate intake and increased instance of IBD (221). More than a few IBD 
cohort studies have documented antibodies to wheat and corn in IBD patients (222, 
223). Studies of Japanese cohorts explained that the increases in IBD instance seen 
in that country are significantly linked to an increase in sugar and fast food intake 
(224, 225). Another study also noted a lower intake of fruit and vegetable fiber and 
an increased intake of refined sugars by IBD patients (226). While studies such as 
these are not without some interest or validity, several opposing views have also 
been proposed. One such study concluded that sugar intake was not linked to 
increased instance of IBD (227). With regard to fruit and vegetable fiber intake by 
IBD patients it should be pointed out that those fibers are some of the most difficult 
to digest and might make these foods uncomfortable or unappealing for those with 
IBD to eat. Similarly, while some studies postulate a tie between milk protein 
sensitivity in childhood and adult onset of IBD, Sonnenberg has found that dairy 
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products and derivatives like margarine have no causative tie to IBD instance (228). 
It is also unclear if fat intake has any effect on IBD susceptibility. Some studies have 
suggested a lower instance of IBD in cohorts were large quantities of fish containing 
omega-3 fatty acids are regularly consumed, such as Asian cohorts (229). In 
general, it seems that data regarding the effects of foods and food additives on IBD 
risk is inconsistent. It remains unclear if food intake differences in IBD cohorts are 
causative or consequential factors of IBD. It cannot however be denied that dietary 
compounds have a great effect on individual host microbiota and it is well accepted 
that the microbiota play a key role in homeostatic and IBD related gut functions as 
will be discussed in later sections of this review. Likewise, genetic factors, which 
vary from population to population and with different cultural mating habits, have an 
effect on hormone production, immune function and homeostatic regulation in the 
human body (189). IBD epidemiology hints at the multiple complications involved in 
human susceptibility to UC and CD, and is a useful tool for pinpointing potential 
etiologic factors of IBD.   
 Etiopathogenesis of IBD 
 While many etiologic hypotheses exist for IBD, the causative nature of IBD 
remains undefined. Current theories of IBD etiology focus on four general instigating 
parameters:  environmental interactions, genetic susceptibility, immune response, 
and luminal microbes (5, 230). In recent years it has become increasingly apparent 
that no single parameter listed above is likely to be individually causative (231). 
Multiple murine models of IBD, which will be discussed in more detail in following 
sections, have shown that while severe alteration of a single parameter is capable of 
inducing IBD, most models repeatedly highlight causes linked to multiple milder 
disturbances in homeostatic states. When considering the complexity of the gut 
environment, perhaps this finding is not surprising. Interactions between gut 
microbiota, microbial metabolites, epithelial cells, immune cells, and ingested 
compounds are a few of the exchanges which take place on a constant basis and 
greatly influence IBD (173, 230). When considering the four parameters mentioned 
previously, it is difficult to conceptualize them as autonomous. Most factors 
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hypothesized to contribute to IBD causality highlight the overlap between these four 
parameters. For example, much work has been done to characterize the contribution 
of persistent pathogenic infections to IBD onset and susceptibility.  
Routes and mechanisms of  persistent pathogenic infection could be 
considered environmental, persistent infection or ineffective clearance involve 
immune function and genetic susceptibility, while interactions between host and 
pathogen or host commensal and pathogen can alter the microflora balance in the 
gut as well as intestinal health and function (230). One of the first theories to link IBD 
etiology to bacterial pathogens was formed upon the observation of similarities 
between the granulomatous nature of Mycobacterium paratuberculosis infection and 
human idiopathic granulomatous enterocolitis (108). The similarities between CD 
and Johne’s disease extend beyond granulomatous lesions as several studies 
document the isolation of M. paratuberculosis DNA from CD tissue biopsies (232). 
Investigators such as Greenstein argue that M. paratuberculosis is the causative 
agent of CD; largely based on the satisfaction of Koch’s postulates and 
granulomatous lesions (233). Those in opposition point out that the success of anti-
TNF therapy in CD management is contrary to the observation that anti-TNF seems 
to reactivate latent M. paratuberculosis infections (234). Similarities also exist 
between E. coli infections and IBD pathogenesis. Symptomatically, adherent-
invasive E. coli (AIEC) infected macrophage release high levels of TNFα. The levels 
of TNFα released by these cells is above and beyond that released by 
lippopolysaccharide (LPS) exposed cells, and TNFα is known to be produced in 
large quantities and play a major role in CD (235). It is well documented that AIEC 
can be recovered from CD patient biopsies/samples of the ileum, ulcers, fistulae and 
lamina propria macrophages (236-238). E. coli is universally present in Boxer dog 
granulomatous tissues and initiates pathnomonic granulomas in the intestinal 
mucosa (239). Non-pylori species of Helicobacter, such as H. hepaticus and H. bilis, 
can contribute to initiation of colitic symptoms in animal models of IBD (240-243).  
These studies highlight the propensity of Helicobacter colonization to parallel 
dysbiosis. Several Helicobacter species have also been detected in colitic patients 
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and cotton-top tamarins (244, 245). In addition to the potential role of persistent 
pathogenic infections in IBD pathogenesis, defective pathogen clearance has also 
been suggested to contribute to IBD maintenance. 
Defective pathogen clearance links genetic and immune response 
dysfunction to the pathogenesis of IBD. Caspase recruitment domain 15 
(CARD15/NOD2) genetic mutations are well documented to predispose patients to 
CD (246). It has been shown that mutations in these pattern recognition receptors 
decrease NF-κB activity related to TLR ligands and consequently increase the 
severity of dextran sodium sulphate (DSS) induced colitis (247, 248). The specific 
truncation mutation addressed in this work causes defective bacterial killing. 
Likewise, some CD patients exhibit low copy numbers of human beta defensin 2 and 
reduced production of alpha defensin by paneth cells (249, 250). Defective bacterial 
clearance related to neutrophil dysfunction is thought to contribute to lesions in CD 
patients (251-253). CD patients present with abnormal neutrophil migration, lack of 
superoxide generation, decreased phagocytosis and lack of bacterial killing. All of 
these symptoms can arise from neutrophil abnormalities. Another related potential 
contributor to the pathogenesis of IBD is bacterial dysbiosis. 
The gastrointestinal commensal microflora is usually quite stable. Alterations 
in the composition or functions of the host microflora can initiate and maintain 
chronic intestinal inflammation (254). Studies of germ-free mice and spontaneous 
colitic models support the importance of the microflora in the development of IBD as 
spontaneous colitic onset in these models is microflora dependant (255, 256). 
Dysbiosis has a major impact on gut homeostasis due to the critical involvement of 
the commensal microflora in maintaining a healthy gut environment, metabolism and 
immune homeostasis (257). It is difficult to effectively study the role of dysbiosis in 
IBD as primary and secondary effects are currently not clear (258). Adding to this 
difficulty are issues of microflora cultability and lack of fecal sample correlation 
relative to mucosal associated commensals. IBD is characterized by an increase in 
mucosally associated organisms and an increase in bacterial concentrations coupled 
with a decrease in diversity favoring gram-negative anaerobes and 
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Enterobacteriacea while curtailing Firmicutes (235, 238, 259, 260). The gut mucosal 
environment which supports the microflora can be altered by antibiotics, stress and 
diet, all of which can be linked as contributors to the predisposition for IBD (213, 
261, 262). It has been hypothesized that hydrogen sulfide produced by anaerobic 
bacteria, the concentration of which is increased in CD patients, blocks beneficial 
short-chain fatty acid (SCFA) metabolism by colonic epithelial cells (263). The 
affects of this metabolic block are epithelial starvation and one less regulatory 
mechanism to dampen NF-κB activation. Furthermore, it has been shown that IL-1 
production, common in inflammatory diseases like IBD, enhances proliferation of 
virulent E. coli (264). As previously mentioned, populations of mucosally associated 
bacteria are increased in IBD patients. This observation is linked to another potential 
contributor to IBD pathogenesis, mucosal barrier dysfunction. 
It seems that intestinal barrier dysfunction is another prospective contributor 
which could play a primary or secondary role in onset and maintenance of IBD (265, 
266). Lack of homeostatic epithelial integrity can come about genetically or through 
environmental disturbance. Deficiencies in the mucosal barrier can also be 
considered in the context of damage or impaired healing. Acquired permeability can 
be the result of corticosteroids, TNF secreted by lamina proprial cells, or zinc 
deficiency (267-269). Some postulate that barrier defects are a genetic 
predisposition due to the abundance of relatives of IBD patients who manifest leaky 
mucosa in the absence of colitic disease and the observation that IBD patients have 
mucosal dysfunction between flares (265). The environment plays a role in this 
deficit, as animal models of colitis develop severe intestinal inflammation mediated 
by host microflora following acute non-steroidal anti-inflammatory (NSAID) exposure 
(270, 271). The mucus layer enhances barrier function as proven by the 50-fold 
increased uptake of Formyl-Methionyl-Leucyl-Phenylalanine (FMLP), a product of 
protein degradation related to injury, in the absence of the mucus layer (272). The 
severity of spontaneous colitis observed in mouse models of IBD caused by genetic 
susceptibilities to barrier dysfunction, such as the mdr1a deficient mouse model, 
underscore the role of barrier integrity in IBD (273-276). Deficiencies in genes 
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related to epithelial healing or mucosal restitution have been shown to delay the 
healing process following colitic insult and enhance mortality (277). Overlapping the 
issue of barrier dysfunction is the instance of immune dysregulation and loss of 
tolerance to the microflora.   
Human and experimental IBD is typified by an exaggerated immune response 
to the host microflora (278, 279). While the host immune system usually does not 
react adversely to the microflora, this tolerance is lost in the setting of IBD (135, 
280). A Th1/Th17 cytokine profile has been observed in CD patients while those 
diagnosed with UC exhibit a mixed Th1/Th2 profile (281). Specifically, it has been 
shown that lamina proprial mononuclear cells produce elevated levels of IL-12, IL-17 
and IFNγ, while UC patients produce more IL-5 and IL-13. Dendritic cells from IBD 
patients have been found to be hyperactive when stimulated with LPS (278). This is 
significant given the role of DC in pro-inflammatory cytokine production and 
promotion of effector T cell differentiation (109). Abnormalities in TLR and NOD 
receptor function are thought to contribute to the inappropriate activation of DC in 
the context of IBD (108). This DC hyperactivity leads to aberrant T cell activity and 
an imbalance between T effector and T regulatory cell populations (282, 283). This 
observation pairs with the fact that T effector apoptosis is greatly diminished in the 
context of IBD. Chronic intestinal inflammation in IBD is also typified by increased B 
cell activity in which plasma cells produce antibodies specific to the host microflora 
(223, 240, 241, 279). This observation underscores the loss of immunologic 
tolerance to the resident microflora in the setting of IBD and the role of immune 
dysregulation in the chronicity of disease. 
  In summary, current research has made an effective argument for the 
multifocal nature of IBD onset relating to genetic predisposition, environmental 
contributions, immune dysfunction and microfloral antigens. Several etiopathogenic 
hypotheses emphasize the overlap in these factors. Persistent infections, defective 
pathogen clearance, defective barrier function and restitution, dysbiosis and loss of 
immune tolerance to the microflora have all been implicated in the onset and 
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chronicity of IBD. The relevance of these implications are eloquently illustrated in the 
many animal models of experimental IBD. 
Animal models of IBD 
 Research would be decades behind without the advent of animal models of 
gastrointestinal inflammation to uncover aspects of pathogenesis related to the 
idiopathic collection of disorders encompassing IBD. With respect to IBD, this area 
of research and model development began with the 1960s ovalbumin/formalin rabbit 
model of colonic hypersensitivity developed by Kraft and Kirsner. Since that time, 
mouse and rat models of colitis have become the most widely utilized tool in IBD 
research with regard to mechanistic, pathogenic, therapeutic and surgical 
investigations. Due to the multifocal and highly variable presentation among patients 
suffering from UC or CD, it is important to note that no “perfect” model of UC or CD 
exists. Most models highlight one or several aspects of a symptomatic/pathogenic 
mix of UC and CD. Table 1 below is adapted from Kirsner’s Inflammatory Bowel 
Diseases, sixth edition, chapter 9 (284). This table is meant to summarize the vast 
number and mechanistic depth of the most utilized and characterized models of IBD 
in use currently. 
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Table 1. Summary of popular animal models of IBD 
Method of 
Induction 
Animal Model 
Designation/Title 
Immune 
Mediation of 
Inflammation  
Pathogenesis 
Acetic acid Innate Arachidonic acid pathway activation 
DSS Innate (acute) Th1/Th2 (chronic) Epithelial toxin 
Indomethacin Innate Epithelial toxin 
TNBS/alcohol Innate (acute) Th1 (chronic) Overly aggressive effector cell response 
PG-PS Th1 Pattern recognition receptors 
Chemically 
Induced 
Oxazalone Th2 IL-4 or IL-13 producing NK T cells 
Cotton-top tamarin Mixed Mucin and T cell abnormalities 
C3H/HeJ Bir Th1 Overly aggressive effector cell response Spontaneous 
Samp- I/Yit Th1 Overly aggressive effector cell response 
A20-/- Th1 Overly aggressive effector cell response 
CD40 L TG Th1 Overly aggressive effector cell response 
HLA-B27/β2µ TG Rat Th1 Defective regulation/ Regulatory cell activity 
IL-2-/- Th1 Defective regulation/ Regulatory cell activity 
IL-2R-/- Th1 Defective regulation/ Regulatory cell activity 
IL-10-/- Th1 Defective regulation/ Regulatory cell activity 
IL-10R-/- Th1 Defective regulation/ Regulatory cell activity 
Giα2-/- Th1 Overly aggressive effector cell response 
Mdr1a-/- Th1 Epithelial barrier dysfunction 
N-cadherin DN uncharacterized Epithelial barrier dysfunction 
STAT-3-/- Th1 Defective regulation/ Regulatory cell activity 
STAT-4 TG Th1 Overly aggressive effector cell response 
TCRα-/- Th2 Overly aggressive effector cell response 
TGFβ RII DN TG Th1 Defective regulation/ Regulatory cell activity 
TGFβI-/- Th1 Defective regulation/ Regulatory cell activity 
Genetically 
Engineered 
TNF ∆ ARE Th1 Overly aggressive effector cell response 
CD45RBhi  SCID Th1 Defective regulation/ Regulatory cell activity T cell 
Transfer BM  CD3ε TG Th1 Defective regulation/ Regulatory cell activity 
 
-/- = deficient or knockout, DN = dominant negative, TG = transgenic, BM = bone marrow 
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 Dextran sodium sulphate induced model of colitis 
 This section will describe the DSS mouse model of colitis in some detail as it 
is relevant to later chapters of this dissertation. Dextran sodium sulphate is 
extremely chemically stable and used to induce colitic symptoms by dosing in 
drinking water . Generally used in rodent modalities, 2.5% to 10% dosed 
consecutively for 5 to 7 days results in pancolitis (285). Continuous dosing for 7 days 
is typical of a progressively severe DSS colitic model. A controlled lesion is achieved 
by dosing an initial high DSS dose for 2 days followed by a mild dose for up to 5 
days (286). Repeated cycles of DSS dosing and DSS free restitution periods has 
been used to simulate chronic colitis (287). DSS susceptibility varies based on 
murine background, with Balb/c mice being very resistant and C57BL/6 mice being 
more susceptible. 
Severity of DSS colitis and related inflammation is tunable in a dose response 
manner based on concentration and duration of dosing (285, 288). DSS colitis is 
variably characterized by weight loss, mild to severe intestinal ulceration, colonic 
shortening, lymphoid aggregation, as well as mononuclear and neutrophil infiltrate. 
Chronically, DSS colitis can lead to epithelial dysplasia and adenocarcinoma. 
DSS is generally thought to be an epithelial toxin, but recent data allude to 
other mechanisms of pathogenesis as treatment of DSS exposed mice with 
muramyl-dipeptide (a NOD2 ligand) has been shown to ameliorate DSS induced 
colitis (289, 290). Blockade of IL-18 also abolishes DSS induced disease (291). DSS 
is concentrated in phagolysosomes of lamina proprial macrophage and has been 
shown to increase IL-1 production by macrophage in vitro (292). Data implicating 
bacterial involvement in the pathogenesis of acute DSS colitis is mixed. DSS insult 
causes an increase in Bacteroides species in the gut, can be attenuated by 
antibiotics in some instances and is variably effective in different germ-free mouse 
models (256, 293, 294). Pathogenesis of acute DSS colitis does not exhibit a T cell 
component but does result in typical Th1 cytokine production (288). Acute 
pathogenesis in this model is thought to involve epithelial injury and related 
activation of neutrophils and innate cytokine and chemokine cascades (288, 295-
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297). Chronic DSS colitis does include T cell activity and is typified by a Th1 and 
Th2 cytokine profile mixture (298). Some hypothesize that repeated epithelial injury, 
and not T cell activity is the only true requirement for even chronic DSS colitis (299). 
The DSS model of colitis is cost-effective, easily adjustable with regard to severity, 
and convenient for simple screens of drug efficacy in acute colitis.  
Mdr1a deficient mouse model of spontaneous colitis 
 This section will describe the mdr1a mouse model of colitis in some detail as 
it is relevant to later chapters of this dissertation. The genetic basis of this model 
involves the gene for one member, mdr1a, of the ATP binding cassette transporter 
family(300). This is the multiple drug resistance gene for P-glycoprotein 170. This 
transporter is expressed in many tissues including luminal intestinal epithelial cells, 
with a heavy concentration in colonic epithelial cells. The function of mdr1a pump is 
to transport xenobiotics and amphipathic cations across membranes in an ATP 
dependent manner. The mdr1a transporter has been identified in mouse and human 
tissues and is a vital means of drug efflux (301). As mdr1a is expressed in blood-
brain capillaries, this knockout mouse model was originally developed to enhance 
the permeability of the blood-brain barrier for the purpose of studying compound 
uptake and efficacy in the brain in the absence of p-glycoprotein drug efflux (300). 
The surprise observation was noted that these mdr1a deficient (mdr1a-/-) mice 
developed colitis between 8 and 30 weeks of age (274). As previously mentioned, 
mdr1a is heavily expressed on intestinal epithelial cells. It is therefore not surprising 
that deficiency of mdr1a predisposes these mice to intestinal epithelial barrier 
dysfunction (302). Despite this obvious contribution to colitic onset, the mechanism 
of colitic onset and maintenance is not fully understood for this model for several 
reasons. The mdr1a transporter is expressed on several immune cells, including 
CD4+ and CD8+ T cells, DCs, NK cells and PBMCs (276). While the functions of 
these cells seem intact in mdr1a-/- mice, the implications of mdr1a deficiency for the 
individual functions of these cells have yet to be fully investigated. P-glycoproteins 
and transporters like them have been implicated in cholesterol metabolism and 
regulation of cell differentiation, proliferation and survival (276). This data would 
 34 
indicate that mdr1a deficiency could have effects reaching beyond that of epithelial 
barrier integrity which could contribute to IBD pathogenesis. Additionally, the precise 
development and mechanism of barrier dysfunction in mdr1a-/- mice is unclear. It has 
been hypothesized that lack of the mdr1a transport function leads to a build-up of 
bacterial byproducts within epithelial cells, leading to increased antigen presentation 
of bacterial products and a subsequent loss of tolerance due to a robust T cell 
response to those products (276). Early, pre-colitic cytokine changes have been 
discovered in mdr1a-/- mice, which would support this hypothesis (302). 
 The average age of colitic onset in mdr1a-/- mice occurs at 20 weeks of age 
(274). This colitis is non-transmissible and has been shown to be preventable by 
antibiotic therapy. Metronidazole dosed in the drinking water has specifically been 
shown to ameliorate colitis in this model (275). This evidence and the observation 
that mdr1a-/- mice housed in germ free conditions do not develop colitis speaks to 
the vital contribution of the microflora to colitic onset in this model. Colitic lesions in 
mdr1a-/- mice are transmural and generally continuous throughout the colon (303). 
Mucosal edema, thickening and lamina proprial inflammatory cell infiltrate are 
common to these lesions.  
 Colitic susceptibility of mdr1a-/- mice is increased by DSS administration, but 
not by TNBS (275). No one bacterial species has been implicated as responsible for 
colitic susceptibility in mdr1a-/- mice, but it has been shown that H. bilis accelerates 
colitic onset and severity in these mice while H. hepaticus delays onset of colitis in 
mdr1a-/- mice (304).  
 This model is also relevant to human IBD. Enhanced expression of IFNγ, IL-6, 
IL-1β, TNFα, MCP-1, MIP-1α, RANTES and Eotaxin mRNA, along with increased 
expression of the chemokine receptors CCR2 and CCR5 is comparable to changes 
seen in patients with UC and CD (273). Furthermore, mdr1a has been directly 
implicated in human UC and CD (276, 300, 305).  
 The totality of this data indicates that the mdr1a-/- mouse model of colitis is a 
relatively well characterized and relevant model for the study of human and animal 
IBD. 
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Therapeutic and surgical perspectives on IBD 
 This section will review relevant therapies commonly used for the treatment of 
IBD as well as the use of surgical interventions for UC and CD patients. 
Aminosalicylates, immunomodulators, biologic therapies and CAM use will be 
reviewed in the context of IBD therapeutic benefits, drawbacks to therapy, and 
patient and physician concerns associated with treatment. 
 Implications for surgery differ between patients suffering from CD and UC, 
and these implications also vary depending upon the severity and symptomatic 
manifestations and persistence of these forms of IBD (306-308). Current estimates 
emphasize that up to 75% of CD patients will require discussion with their physicians 
regarding surgical intervention (309). Absolute indications for surgical intervention in 
CD include perforation, severe hemorrhage, therapeutically non-responsive 
complete bowel obstruction, or high-grade dysplasia (203). Early laproscopic 
intervention is generally acceptable and feasible given the patchy nature of CD 
(309). It is still controversial as to whether early surgical intervention should 
immediately follow therapeutic non-responsiveness or if development of more 
severe symptoms should be allowed to manifest first (310). Bowel resection is 
unfortunately not rare in patients with CD, but is considered a last resort to 
therapeutic failure and minimally invasive procedures (311). Due to the continuous 
and concentrated colonic nature of UC, this form of IBD is viewed as a surgically 
‘curable’ condition (312-314). This observation is leads to strong biases in opinions 
regarding medical practices of therapeutic vs. surgical intervention strategies (306). 
While it is true that immunomodulatory therapies are a newer arm of UC treatment, 
the idea of therapeutic first-line treatment is only now becoming more accepted in 
the treatment of UC. Absolute indications for surgical intervention in UC include 
perforation, colonic obstruction caused by stricture, high-grade dysplasia or 
uncontrolled hemorrhage (179, 312, 315, 316). Advances in therapeutic strategies 
have made surgical intervention less likely for patients with secondary toxic 
megacolon or fulminant colitis (317, 318). If colectomy is indicated, it usually occurs 
as two operations and up to 10% of patients must undergo further procedures to 
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repair ileal pouch failure (316). It is also estimated that 30 to 60% of patients will 
experience post-operative pouchitis. This information strengthens the need for 
development of new therapeutic strategies for UC and CD as well as continued 
optimization of current therapeutic modalities.     
Aminosalicylates, or 5-amino salicylic acids (5-ASA)/mesalazine, are 
commonly used to prevent recurrent flares associated with mild to moderate UC but 
are not generally recommended for the treatment of CD as most clinical trial data in 
the context of mesalazine CD therapy is mixed (319, 320). One clinical trial noted a 
90% positive response rate in UC patients receiving 5-ASA therapy who were non-
responsive to prior treatments (321). 5-ASAs are generally not used as first line 
treatments but as maintenance therapies for UC (322). Mesalazine is generally safe 
and well tolerated. The mechanisms of 5-ASA efficacy are not well defined but 
mesalazine has been found to be inactive in 5-aminosalicylic acid is ineffective in 
peroxisome proliferator-activated receptor-gamma+/- mice (PPARγ+/-) (323). It is 
known that 5-ASA activity is related to topical, not absorptive effects (324, 325). Due 
to this observation, 5-ASA vehicles were being formulated to increase contact time 
with the mucosa and delay dissolution of the drug, but these have been found to be 
more toxic (323). 5-ASAs are most effective when dosed rectally when compared to 
oral 5-ASA efficacy or rectal corticosteroid treatment (326). Patient compliance 
related to 5-ASA dosing is very poor (327, 328). New oral dosing strategies and 
titration recommendations are being proposed to improve patient compliance (329). 
Side effects include headache, nausea, dyspepsia, and diarrhea. Less common are 
the side effects of pleuritis, pericarditis, myocarditis, pancreatitis, chlestatic hepatitis, 
nephritis, renal dysfunction and increased colitic symptoms related to osmotic 5-ASA 
effects (326, 330). The use of 5-ASA can also be very expensive, especially given 
the newly suggested daily oral treatment regimen. 
Another common therapeutic modality for IBD is a group of 
immunomodulatory drugs. Thiopurines (azathioprine and 6-mercaptopurine), 
corticosteroids (budesonide, dexamethasone, hydrocortisone, methylprednisolone, 
prednisolone and prednisone) and methotrexate are indicated for maintenance of 
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remission in those diagnosed with mild CD or chronically active/relapsing UC which 
is refractory to 5-ASA drugs (331). Dosing these immunomodulators involves a slow, 
three month titration process for safety (331). Delicate titration underscores the 
toxicity caused by these modalities, which are also plagued with variable metabolism 
between individual patients (331-336). The greatest drawback to this treatment 
strategy is the broad-immunosuppression caused by these drugs. Secondary 
treatments, such as antibiotics, are often required to substitute for the lack of 
homeostatic immune function inhibited by these drugs. To address these issues, 
pharmaceutical companies are developing new formulations, dosing strategies, and 
delivery methods for immunomodulators. This is especially true for thiopurines and 
corticosteroids, which seem to have the most wide-spread side-effects (334, 337, 
338). These therapies are generally more affordable to patients than several other 
therapeutic modalities (331). 
Antibiotics have been investigated as therapies for the treatment and 
remission maintenance of UC and CD, but will not be discussed at length here as 
they are not commonly reliable for primary IBD treatment. Metronidazole, 
ciprofloxacin and other antibiotics are more commonly utilized to treat secondary 
complications of IBD (i.e. toxic megacolon, abscess, secondary infection, sepsis) 
and are not successfully utilized long term (339). 
Perhaps the newest therapeutic options for IBD patients are biologic 
therapies, the most utilized and well studied being anti-TNFα antibodies. Other 
biologic therapies such as monoclonal antibodies to IL-12/23p40,(ustekiumab), IL-6 
(tocilizumab), CD-25 (basiliximab), and chemokine/adhesion blockers (natalizumab) 
are also studied for efficacy in IBD therapy but will not be discussed at length in this 
review (340). As anti-TNF antibody therapies, infliximab, adalimumab and 
certolizumab are specifically targeted in their immunologic suppression (340). It is 
generally accepted that anti-TNF infusions extend remission, shorten hospital stays 
and improve the quality of life of those IBD patients who do not respond to the more 
conventional therapies previously discussed in this section (341, 342). Biologic 
therapies intensify debates regarding ‘step-up’ vs. ‘top-down’ treatment strategies 
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and the combination of biologic and conventional therapies (343, 344). While 
antibody therapies exhibit great efficacy in the maintenance of remission of UC and 
CD, their use is not without drawbacks. TNFα is not simply a contributor to the 
detrimental inflammation associated with IBD, but is also necessary for homeostatic 
immune functions and host protection against illness and infection (338, 340). The 
most dangerous potential side effects of anti-TNF therapies are secondary infections 
or development of malignancy (345-348). Several studies have shown a correlation 
between the use of anti-TNF therapies and the increased instance of tuberculosis 
infections (349). An increased instance of T cell lymphomas also has been shown to 
correlate with biologic suppressive therapies (350). Furthermore, due to the 
relatively new use of this type of therapy, long term efficacy and safety studies are 
not complete (350). Patients can become refractory to anti-TNF therapies and these 
patients have been shown to respond poorly, or not at all, to alternate biologic 
therapies (351). IBD patient compliance is difficult to maintain with biologic therapies 
despite their efficacy, due to very high cost worldwide and general inaccessibility to 
these drugs in developing countries where the instance of IBD is on the rise (344). In 
summary, anti-TNF antibodies are the newest therapeutic option for IBD and have 
great therapeutic efficacy, but lack long term study and their use is not without safety 
concerns. 
This section will conclude with a short discussion of probiotic and 
prebiotic/herbal CAM as primary and adjunct therapies for IBD, as the focus of the 
data in this dissertation relates to the use of herbal extracts as therapeutic and 
prophylactic modalities in models of IBD. In addition to the three forms of CAM listed 
above, exercise, meditation, chiropractic and osteopathy are also utilized but are not 
relevant to the work presented in this dissertation and will not be discussed at 
length. Using a very broad definition of CAM, Burgmann et al published that up to 
60% of Canadian IBD patients surveyed used CAM as primary or supplementary 
treatments for CD or UC (352). As opposed to physician recommendation, CAM is 
usually sought out by patients for the purpose of direct or indirect disease related 
benefits (7). Probiotics are a relatively new CAM and are defined by the content of 
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viable microorganisms which at least transiently colonize the intestine. Examples if 
common probiotic organisms include lactic acid bacilli, Lactobacillus, 
Bifidobacterium, E. coli Nissle 1917, Saccharomyces boulardii, Clostridium 
butyricum, Streptococcus salivarius thermophiles and bacteria genetically 
engineered to secrete IL-10 (257). Broad probiotic bioactivity can encompass anti-
pathogenic suppression of growth or suppression of binding and invasion, improved 
epithelial barrier function, and immunoregulatory activities (259). The greatest 
efficacy of probiotics is seen in studies involving pouchitis and UC therapy. One 
clinical study showed that daily dosing of VSL-3 (a combination of 4 Lactobacillus 
species, 3 Bifidobacterium species and an S. salivarium) prevented chronic pouchitis 
relapse for the 9 month trial following antibiotic induction of remission (353). With 
regard to UC therapy, E. coli Nissle 1917 has been shown to be equally effective as 
low dose 5-ASA in maintenance of remission (354, 355). Prebiotic therapies for IBD 
can include dietary components that stimulate the growth or metabolism of the 
enteric host microflora or influence immune function (356-358). Nutraceuticals are 
considered by most to fall into this category. Examples of prebiotics documented in 
the literature include lactosucrose, fructo-oligosaccharides, inulin, bran, germinated 
barley and psyllium (359). These prebiotics/nutraceuticals can encourage the growth 
of Lactobacillus and Bifidobacterium species which produce the short chain fatty 
acid butyrate (360). Increases in butyrate production effectively nourish the intestinal 
epithelium. Prebiotics can also stimulate the growth of protective lactic acid bacilli to 
stave off pathogenic bacteria (361). Several prebiotics have also been implicated in 
immunomodulation and anti-inflammatory bioactivities (362-364). Antioxidant effects 
of berries have been shown to contribute to the amelioration of experimental colitis 
(365). Herbal therapies are underrepresented in the literature of most diseases, but 
surprisingly, are often documented as the most commonly utilized CAM by IBD 
patients (366-368). The following section will address the specific 
nutraceutical/herbal extracts investigated in the experimental chapters of this 
dissertation. 
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Prunella vulgaris 
 This section will briefly review the origins of medicinal use of P. vulgaris. 
Additionally, relevant chemical compounds identified in P. vulgaris related to 
potential bioactivity in vitro and in vivo will be described.  
 Origin and preparation for medicinal use 
 Termed ‘Self-heal’ or ‘Heal-all’, P. vulgaris (PV) is a perennial flowering plant 
found throughout Europe, Asia and North America. PV is well documented as a 
traditional medicinal Chinese herb (369). Traditional medicinal indications for PV 
include wound healing, indigestion, burns and anti-inflammatory therapy (370). In 
Asia, PV is generally steeped in hot or boiling water as a tea or occasionally ground 
into a save (369). Similar to traditional preparations, the experiments utilizing PV in 
later chapters of this dissertation present  use of the extract of the above-ground 
portions of PV prepared by steeping and boiling in the soxhlet extraction method.    
 Constituents 
 P. vulgaris contains several bioactive phenolics, triterpenoids, and flavonoids 
(371). Dietary phenolics like rosmarinic acid, ursolic acid and caffeic acid, which are 
all found in P. vulgaris, have been shown to have antioxidant, anti-inflammatory and 
anti-cancer activities (372-377). Caffeic acid has also been shown to effectively 
attenuate chemically induced experimental colitis through upregulation of cychrome 
P450 (CYP4B1) (378). Flavonoids, like those found in P. vulgaris, have been 
implicated as potential therapeutics for IBD as well. The flavonoid luteolin was found 
to attenuate spontaneous colitis by downregulating NF-κB. Recently rosmarinic acid, 
the most plentiful phenolic compound found in P. vulgaris, was found to protect 
against sepsis by downregulating inflammatory genes in the NF-κB pathway and the 
related inflammatory cytokines TNFα and IL-6 (379). 
 Bioavailability 
 Bioavailability varies from compound to compound and can be considered in 
the context of a tissue/cell type or in the context of metabolic interactions with host 
microflora. Qiang et al recently described the permeability of rosmarinic acid and 
ursolic acid, two major components found in PV, across human intestinal epithelial 
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Caco-2 cell monolayers (380). As detected by HPLC, it was found that rosmarinic 
acid and ursolic acid contained in whole extracts of PV were able to permeabilize 
intestinal epithelial monolayers with equal efficiency as purified rosemarinic acid or 
ursolic acid. Additionally, UA is not subject to intestinal glucuronidation/sulfation 
which would potentially increase the bioavailability of this compound. It should be 
noted that this dissertation focuses on intestinal bioavailability, which can be 
uniquely altered by microflora metabolism and the condition of the intestinal, luminal 
epithelial barrier in the context of health and homeostasis as well as during onset 
and maintenance of colitis (381). The epithelial barrier changes which occur in the 
intestine in the context of colitis could dramatically alter the cell types and tissues to 
which target compounds could be exposed and bioavailable to (302). The diversity 
and quality of the microflora is also altered in the colitic intestinal milieu which could 
additionally alter bioavailability of these plant compounds (257).  
 Aim of the use of Prunella vulgaris in this dissertation 
 To date, PV has not been studied as a primary or adjunct therapy for IBD. 
The aim of use of ethanolic PV extracts in original studies described in the following 
chapters of this dissertation is to uncover potential efficacy of PV as a therapeutic or 
prophylactic modality for the treatment of experimental colitis relevant to human and 
animal medicine. Additional studies seek to address the mechanism of such 
potential efficacy in anti-colitic bioactivity. 
Echinacea angustifolia 
 This section will briefly review the origins of medicinal use of E. angustifolia. 
Additionally, relevant chemical compounds identified in E. angustifolia related to 
potential bioactivity in vitro and in vivo will be described. 
 Origin and preparation for medicinal use 
 Termed ‘coneflower’ or ‘Kansas snakeroot’, E. angustifolia (EA) is a perennial 
flowering plant found throughout North America (382). Numerous traditional 
medicinal uses of EA are documented and most involve fresh or dried preparations 
of the roots. Past and present medicinal indications for EA include its use as an 
antibiotic, antiviral, antiseptic and anti-toxin for snake bites (382). EA is most 
 42 
commonly considered as therapeutic for infections of the sinuses, respiratory tract, 
urinary tract, and skin, but also has been documented to speed wound 
healing/restitution (383). EA can be found in pill, capsule, powder, liquid and save 
form (384). The experiments utilizing EA in later chapters of this dissertation 
describe use of the root extracts of EA prepared by steeping and boiling in the 
soxhlet extraction method. 
 Constituents 
 Barnes et al. have hypothesized that no single compound in EA is responsible 
for its medicinal or bioactive efficacy (383). This hypothesis is supported by the idea 
of synergistic relationships between chemical constituents in whole or partially 
fractionated plant preparations or extracts, in which the mixture fosters chemical 
stability and biologic activity (385). Compounds in EA which are thought to contribute 
to bioactivity of EA include ketones, alkamides and caffeic acid derivatives (386-
389). These constituents have been implicated in the anti-infective and anti-
inflammatory activities of EA. Recent work has shown that EA extracts can cause 
reductions in prostaglandin E2 (PGE2) production and cyclooxygenase 2 (COX2) 
activity (387).  
 Bioavailability 
 Matthias et al has characterized the ability of caffeic acid derivatives and 
alkamides from EA to cross monolayers of human intestinal epithelial Caco-2 cells 
(388). The caffeic acid conjugates caftaric acid, echinacoside and cichoric acid 
exhibited poor epithelial permeability, while cinnamic acid readily diffused across the 
monolayer. Alkamides readily permeated the intestinal monolayer. The authors 
concluded that alkamides and cinnamic acid, but not other caffeic acid conjugates, 
would be readily bioavailable in vivo. Permeability of these compounds was not 
altered by the presence of other chemicals in the whole extract as permeability was 
compared to, and not found to differ from, that of purified compounds. As mentioned 
previously, for the purpose of use in original studies described in the following 
chapters of this dissertation, this bioavailability data must be also be considered in 
the context of a compromised, colitic milieu. 
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 Market availability and reliability 
 EA is commonly found as a nutraceutical supplement in commercial markets 
worldwide (384). Nutraceuticals and dietary supplements are not regulated by the 
Food and Drug Administration (FDA), in the United States, to a level greater than 
that of food safety. Several investigators have chemically analyzed commercial EA 
products sold to the public for content of EA constituents and quality. A 2003 study 
of 25 commercially available Echinacea extracts found that only 56% of the extracts 
tested where of claimed quality (390). Many of the 25 products did not state the type 
of Echinacea they contained or specify estimated Echinacea content at all. One of 
the 25 products was contaminated with 3 times the allowable concentration of 
microbes as defined by World Health Organization (WHO) guidelines. Another study 
found that only 10% of 59 commercially available Echinacea products contained any 
detectable constituents of Echinacea (384). Echinacea extracts and products 
containing Echinacea are readily available but rarely of dependable quality and are 
not FDA regulated for quality of claims.  
 Aim of the use of Echinacea angustifolia in this dissertation 
 To date, EA has not been studied as a primary or adjunct therapy for IBD. 
The aim of use of ethanolic EA extracts in original studies described in the following 
chapters of this dissertation is to uncover potential efficacy of EA as a prophylactic 
modality for the treatment of experimental colitis relevant to human and animal 
medicine. 
Hypericum gentianoides 
 This section will briefly review the origins of medicinal use of H. gentianoides. 
Additionally, relevant chemical compounds identified in H. gentianoides  related to 
potential bioactivity in vitro and in vivo will be described. 
 Origin and preparation for medicinal use 
 Very little reliable scientific data is available regarding H. gentianoides (HG). 
A current Pub med search yields only one reference. HG, also commonly called 
‘orangegrass’ is dispersed throughout the eastern United States. HG was used 
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medicinally by Native Americans to reduce gastrointestinal upset, fever and speed 
wound healing (391). 
 Constituents 
 This species of Hypericum is unique in that it contains the anti-bacterial 
compounds uliginosin A and B but lacks hypericin, pseudohypericin and 
hyperforin.(392, 393) This could indicate that HG could retain some anti-bacterial 
activity and have fewer potential toxic side effects when compared to other 
Hypericum species. Recently it was shown that HG reduces inflammatory 
prostaglandin E2 (PGE2) production in RAW 264.7 macrophage cells with no 
significant cytotoxicity.(393) 
 Bioavailability 
 Bioavailability of compounds in the context of HG extracts have not been 
evaluated scientifically. 
 Aim of the use of Hypericum gentianoides in this dissertation 
 To date, HG has never been studied in vivo or as a primary or adjunct therapy 
for IBD. The aim of use of ethanolic HG extracts in original studies described in the 
following chapters of this dissertation is to uncover potential efficacy of HG as a 
prophylactic modality for the treatment of experimental colitis relevant to human and 
animal medicine. Additional studies seek to address the mechanism of such 
potential efficacy in anti-colitic bioactivity. 
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Abstract 
Background. Due to known side-effects associated with IBD therapies, 
complementary or alternative medicine (CAM) is being recognized as an adjunct 
therapeutic approach to treat or ameliorate chronic inflammatory diseases. In this 
context, and in light of the low toxicity and numerous bioactive compounds in these 
herbs, nutraceutical extracts derived from Echinacea angustifolia (EA) and Prunella 
vulgaris (PV) were investigated for their in vivo anti-inflammatory therapeutic 
potential in the dextran sodium sulphate (DSS) model of colitis. Methods. Vehicle 
(5% ethanol), EA (100 or 200 mg/kg) or PV (100 mg/kg) were orally administered 
daily to C57BL/6 mice (6-7 weeks old) prior to DSS treatment and during DSS insult. 
EA was also studied to evaluate its ability to enhance the restitution of epithelial 
lesions induced by DSS. Macroscopic disease assessment included measurement 
of daily weight, colon length and combined colonic/cecal score. Results. EA 
prophylaxis did not significantly attenuate the severity of weight loss, macroscopic 
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disease/inflammatory scores, or colon lengths directly following DSS treatment. 
Likewise, there was no observed benefit to lesion resolution for mice treated with 
EA. Mice receiving PV prophylactically had significantly (P < 0.05) less weight loss, 
lower macroscopic disease/inflammatory scores, and more normal colon lengths 
following exposure to DSS. In contrast, the use of PV as a therapeutic treatment did 
not attenuate the severity of colitis. Conclusions. The ethanolic extract of PV 
ameliorated the severity of DSS-induced colitis and warrants further examination as 
a therapeutic and immunomodulatory agent for the treatment of gastrointestinal 
inflammatory diseases. 
Key Words:  Echinacea angustifolia, Prunella vulgaris, colitis, IBD, DSS 
 
Introduction 
The addition of herbal forms of CAM to dietary and therapeutic regimens is 
growing in popularity worldwide. Low toxicity, high patient interest, improved 
compliance, low cost, and increased availability have resulted in acceptance of the 
general public, physicians and researchers as to the potential of botanically-derived 
materials to improve human and animal health. As therapeutic or prophylactic 
modalities, CAM is underrepresented in high-impact studies, clinical trials, and 
educational programs.1 Contrary to this point, over half of the pharmaceuticals 
developed in the last two decades are derived from naturally occurring compounds.2 
Unlike purified compounds, whole herbal extracts in particular have the advantages 
of containing combinations of anti-inflammatory, anti-bacterial, anti-viral, and 
antioxidant compounds while inducing fewer toxic side effects due to synergy of the 
multiple components.3, 4 Two examples of herbal CAM which are used as dietary 
supplements or secondary therapeutic regimens are EA and PV.  
  Most thoroughly characterized for its use in the prevention or treatment of the 
common cold and other infections, EA is also gaining repute for anti-inflammatory 
and immunomodulatory activities.5 EA has been shown to reduce production of 
prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX2) activity. 6 Recent studies 
point to the bioactivity of alkylamides, caffeic acid derivatives, and ketones as key 
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components in the anti-infective and anti-inflammatory activities of EA.6, 7 Due to its 
ease of cultivation and previous reputation as a cold remedy, it is readily available in 
the United States and worldwide.8 
 As a medicinal plant, PV is infrequently utilized in the United States but has 
long been used in traditional Chinese medicine, primarily for the purpose of wound 
healing.9 The presence of polyphenols, triterpenes and flavonoids are well 
documented in PV extracts and these compounds have been implicated in anti-viral, 
anti-bacterial, anti-inflammatory, and immunomodulatory bioactivities.10-16 The 
variety of potentially bioactive compounds and growing amount of literature 
regarding this plant will certainly influence its medicinal use. 
 These nutraceuticals are prime candidates for therapeutic research involving 
idiopathic inflammatory diseases for several reasons. Many of these diseases are 
etiologically poorly understood. Problems with current therapeutic strategies arise 
with respect to the high cost, low specificity, symptomatic rather than causative 
treatment, poor patient compliance, and lack of reproducibility and predictable effect 
across patient populations. In this context, inflammatory bowel diseases (IBD) are no 
exception. The primary IBD presentations, Crohn’s disease (CD) and ulcerative 
colitis (UC) are highly complex and symptomatically variable among patients.17 
Typical IBD manifestations include relapsing gut mucosal lesions of variable 
placement and severity throughout the digestive tract.18 With recent adult CD and 
UC instance in the USA estimated at 238/100,000 and 201/100,000 and pediatric 
instance estimated at 43/100,000 and 28/100,000, respectively, IBD is a growing 
medical and economic concern.19 Perhaps even more troubling is the knowledge 
that the most effective current biologic therapies, such as anti-TNF monoclonal 
antibody infusions, are as costly as to be scarce in countries where IBD instance is 
increasing at the greatest rate.20, 21 To compound this issue, 20 to 30 percent of 
patients with CD and 30 to 40 percent of patients with UC eventually become 
refractory to the continued use of anti-TNF therapy and fail to respond to a switch in 
anti-TNF agent.22-26 The difficulties in titration, toxicity, low tolerance, low patient 
compliance, and delayed activity related to use of the traditional corticosteroids, 
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mesalazines, and other immunosupressants underscore the need for additional 
medications to combat side effects and secondary infections.27 
Because of the current drawbacks associated with IBD therapy to date, CAM 
is being recognized specifically in the context of IBD therapeutic regimens. An 
estimated 50 percent of IBD patients in North America utilize some form of CAM.28, 29 
IBD patients specifically utilizing herbal supplementation represent a large portion of 
CAM-related use worldwide.29 While the use of CAM is increasing worldwide, neither 
EA nor PV has been evaluated for biologic activity in acute colitis. In this study, we 
evaluated the efficacy of the ethanolic extracts of EA or PV to prevent or attenuate 
acute colitis induced by DSS. The results of these studies will increase the breadth 
of our understanding regarding the capabilities of these plants to be used as 
therapeutic modalities to combat the inflammatory complications associated with 
colitis. 
 
Materials and Methods 
Reagents.  EA and PV dried plant materials were kindly provided by Dr. Mark 
Wiederlichner at the USDA-ARS North Central Regional Plant Introduction Station 
(NCRPIS, Ames, IA). DSS (MW 36,000–50,000) was purchased from ICN 
Biomedicals (Aurora, OH) and 95% ethanol was purchased from Sigma (St. Louis, 
MO). 
Echinacea angustifolia or Prunella vulgaris extract preparation. 
Information about the specific provenance of EA or PV accessions (PI 636395 or 
Ames 27748, respectively) obtained from the NCRPIS, is available on the 
Germplasm Resources Information Network database at http://www.ars-
grin.gov/npgs/acc/acc_queries.html. Roots of EA (PI 636395) or arboreal portions of 
plants from PV (Ames 27748), harvested in 2008, were prepared for storage by 
drying for 8 days at 38°C in a forced-air dryer with constant humidity. The dried 
material was ground with a 40-mesh screen and stored at -20 °C until extraction. 
Extractions were made in 95% ethanol (EtOH) solvent by the Soxhlet method (6 
hours).30 Upon complete drying of the extract by evaporation, the weight of the 
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extracted material was recorded; the residue was lyophilized and stored at -20 °C. 
Prior to administration to mice, the extract was solubilized in 5% EtOH (the lowest 
concentration of EtOH that would allow solubilization) at a final plant extract 
concentration of 100 or 200 mg/kg for an average 20 gram mouse (2.4 or 4.8 mg/mL 
respectively). The working solutions of each extract were divided into 2 mL aliquots 
and stored at -20°C until use. The ethanolic extracts were screened for endotoxin by 
using the Limulus Amebocyte Lysate Test (BioWhittaker, Inc., Walkersville, MD) 
according to manufacturers’ specifications for a microplate assay, and there was no 
detectable endotoxin present in either extract (data not shown 
Animals. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) at Iowa State University before any experiments 
were performed. Six to eight week old male and female C57BL/6 (B6) mice were 
obtained from Jackson Laboratories (Bar Harbor, ME). Animals were housed and 
maintained in the Laboratory Animal Resource facility at the College of Veterinary 
Medicine, Iowa State University. Established specific pathogen-free husbandry 
practices were followed and 12 hour light/dark cycles were applied. Upon arrival, 
mice were fed a defined Harlan Teklad AIN93 (M) rodent chow (Madison, WI) to 
control the amount of phytochemicals in their diet. 
Experimental Design. This work describes two experimental designs used to 
assess 1) the ability of the extracts to prevent or attenuate colitis and 2) the impact 
of the extracts on mucosal restitution (i.e., mucosal healing) after the cessation of 
DSS treatment (Table 1). 
For EA studies not evaluating lesion restitution, the following treatment 
groups were used and were comprised of both male and female B6 mice:  1) oral 
daily gavage with 100 mg/kg EA extract in a 200 µl volume (prepared as described 
above) in the absence of 2.5% DSS; 2) oral daily gavage with 100 mg/kg/day EA 
extract in a 200 µl volume in the presence of 2.5% DSS; 3) oral daily gavage with 
200 mg/kg/day EA extract in a 200 µl volume in the absence of 2.5% DSS; 4) oral 
daily gavage with 200 mg/kg/day EA extract in a 200 µl volume in the presence of 
2.5% DSS; 5) oral daily gavages with 200 µl 5% EtOH vehicle in the absence of 
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2.5% DSS; or 6) oral daily gavages with 200 µl 5% EtOH vehicle in the presence of 
2.5% DSS. Gavages with the ethanolic extracts began on day -6 and continued 
through the day of necropsy (day 7), while the appropriate groups were given 2.5 % 
DSS in their drinking water beginning on day 0 and ending on the day of necropsy 
(Table 1).  
Additionally, the effect of EA on mucosal healing or restitution was observed.  
For all EA restitution studies the following treatment groups were included:  1) oral 
daily gavage with 200 mg/kg EA extract in the absence of DSS; 2) oral daily gavage 
with 200 mg/kg EA extract in the presence of low dose 1.75% DSS; 3) oral daily 
gavage with 200 mg/kg EA extract in the presence of high dose 2.5% DSS; 4) oral 
daily gavage with 5% EtOH vehicle in the presence of 1.75% DSS; 5) oral daily 
gavage with l 5% EtOH vehicle in the presence of 2.5% DSS; or 6) oral daily 
gavages with 5% EtOH vehicle in absence of 2.5% DSS. All treatments were 
administered in a 200 µL volume and gavages began on day -6 and continued 
through the day of necropsy (day 14). The appropriate groups were given DSS in 
drinking water at 1.75% or 2.5% beginning on day 0 and ending on day 7. During the 
restitution period (day 8 to 14), the mice were provided drinking water free of DSS, 
but continued to receive the EA extract through day 14 (Table 1).  
For all prophylactic PV studies, both male and female B6 mice were included 
in each treatment group.  Separate groups of mice were treated as follows: 1) oral 
daily gavage with 100 mg/kg PV extract; or 2) oral daily gavage with 5% EtOH 
vehicle. The oral administrations (200 µL volumes) began on day -6 and continued 
daily through the end of the experiment (day 7). On day 0, half of the mice in each 
group continued to receive normal drinking water and the other half received 
drinking water containing 2.5 % DSS. For the DSS treated mice, the concentration of 
DSS in the drinking water was adjusted to 1.5% DSS beginning on day 2 and 
continued through day 7 (Table 1).31 To evaluate the therapeutic potential of the PV 
extract, the treatment groups were the same as those mentioned above for the 
prophylactic studies. However, the treatment of the mice with the PV extract did not 
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begin until day 0 in conjunction with the DSS exposure (Table 1). The number of 
mice used for each experimental design is noted in the appropriate figure legend.  
Macroscopic typhlocolitis assessment. All mice were euthanized at 
necropsy by CO2 asphyxiation. Following euthanization, the colon and cecum were 
excised, photographed, measured and scored for severity of macroscopic lesions. 
Gross typhlocolitic lesions were scored using a nine point additive scale; a score of 
zero being assigned to a healthy colon and a score of nine being a maximally 
diseased colon. Score parameters evaluated included: 1) cecal atrophy, 2) enlarged 
cecal tonsil or other enlarged lymphoid aggregates, 3) cecal emptying, 4) abnormally 
watery or mucoid intraluminal cecal and/or colonic contents, 5) luminal blood in the 
cecum, 6) luminal blood in the colon, 7) visible thickening and rigidity of the cecum, 
8) visible thickening and rigidity of the colon, and 9) absence of formed fecal pellets 
in the colon. 
Statistical analysis. Statistical significance of parametric data was evaluated 
by student’s t-test. Non-parametric data (e.g., scores) were evaluated by the Mann-
Whitney test. A P-value of ≤ 0.05 was considered statistically significant. Prism 5 
software was used for all statistical calculations. 
 
Results 
The ethanolic extract of EA has no significant macroscopic efficacy or 
toxicity in a DSS induced model of murine colitis. To determine the prophylactic 
ability of the ethanolic EA extract to prevent or attenuate to DSS-induced colitis, 
separate groups of mice were gavaged daily with vehicle (5% EtOH) or 100 mg/kg or 
200 mg/kg EA extract. EA treatment began 7 days prior to DSS treatment and 
continued for an additional 7 days while mice were dosed with 2.5% DSS in drinking 
water. As depicted in Figure 1a, all mice treated with DSS alone began to lose 
weight by day four of DSS treatment. Treatment of mice with either dose of EA failed 
to prevent the weight loss induced by exposure to 2.5 % DSS. Regardless of the 
dose of EA administered, there was no attenuation of the severity of typhlocolitis 
(Fig. 1b) or in the degree of colon shortening (Fig. 1c and Suppl. Fig. 1) observed. 
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Photographs of ceca and colons (Supp. Fig 1) show the extent of macroscopic 
lesions induced by 2.5% DSS. These observations held equally true for both male 
and female mice (data not shown).   
EA has no significant impact on restitution or healing following DSS 
induced colitis.  Recently, Zhai et al, demonstrated that the ethanolic extract of E. 
pallida had a positive effect on the healing of skin lesions in stressed mice.30 In this 
regard, we sought to evaluate the potential for the EA extract to accelerate mucosal 
healing following the exposure to DSS. As described above, EA treatment began 7 
days prior to DSS treatment and continued daily for a total of 21 days including 7 
days after the cessation of the DSS treatment. Two doses of DSS (1.75 and 2.5 %) 
were evaluated to discern the efficacy of EA in restitution following different levels of 
colitic severity. As described above, all DSS only recipients, regardless of the dose, 
lost an average of 10% of their baseline bodyweight (Fig. 2a). EA treatment did not 
significantly lessen weight loss during the DSS treatment period or accelerate weight 
recovery during restitution (Fig. 2a). Only one low DSS dose mouse presented with 
a score of 4 or greater at necropsy following restitution compared to 67% of high 
dose DSS recipients. DSS recipients that received EA treatment showed no 
significant improvement in macroscopic scores following restitution when compared 
to the corresponding DSS dose controls (Fig. 2b). Colon lengths were also not 
improved in either DSS dose treatment with the addition of 200 mg/kg EA (Fig. 2c 
and Supp. Fig). These observations were consistent in male and female mice (data 
not shown). The ethanolic extract of PV has significant prophylactic, 
macroscopic efficacy in a DSS induced model of murine colitis. To determine 
the efficacy of PV extract in the treatment of DSS-induced colitis, mice were 
gavaged daily with vehicle (5% EtOH) or 100 mg/kg PV extract beginning seven 
days prior to treatment with DSS. To induce and maintain a consistent colitic lesion 
severity, DSS was dosed at 2.5% for two days and continued at 1.5% for another 5 
days.31 This model was typified by weight loss in DSS treated mice (Fig. 3a). 
Prophylactic treatment with the PV extract significantly (*P < 0.01,) reduced weight 
loss during the last 3 days of DSS administration (Fig. 3a). Significant improvements 
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in macroscopic scores (Fig. 3b) and colon lengths (Fig. 3c) were also observed in 
mice treated with PV extract when compared to DSS only control mice (Fig. 3b and 
c, Supp. Fig. 5). There was no sex bias linked to these observations (data not 
shown) and administration of 100 mg/kg PV extract alone to mice for 14 consecutive 
days induced no clinical signs of disease or distress in the mice (Supp. Fig. 6). In 
contrast to the apparent prophylactic health benefits, the PV extract was not 
therapeutically efficacious when treatment began on the first day of exposure to DSS 
(Supp. Fig. 7). 
 
Discussion 
Botanical extracts are not a new line of research with regard to experimental 
colitis. A study by Araki et al, found that barley was able to reduce DSS-induced 
weight loss and mucosal damage in rats by preserving homeostatic balances among 
resident microfloral and increasing short-chain fatty acid production.32 Several 
studies have characterized the importance of certain chemical compounds or groups 
of constituents present in botanical extracts for bioactivity in DSS-induced colitic 
models. A recent study showed that a coca extract particularly rich in polyphenolic 
content was responsible for reduction of clinical signs  induced by DSS due to 
modulation of STAT1 and STAT3 phosphorylation.33 Antioxidant potential is a major 
area of interest in nutraceutical research. Recently, the antioxidant activity of 
compounds in black raspberry powder were found to preserve mucosal health 
despite the colitic insult induced by DSS.34 In spite of a resurgence of interest, the 
potential of numerous botanicals with regard to anti-inflammatory and 
immunomodulatory bioactivity are still in question.   
The present studies examined the in vivo efficacy of Echinacea angustifolia or 
Prunella vulgaris extracts to prevent or ameliorate the lesions induced by exposure 
to DSS. Because the DSS model offers the ability to tune severity of colitis by dosing 
more or less of the chemical in drinking water,35 The anti-inflammatory efficacy of EA 
or PV extracts was assessed in the development of moderate to severe and mild 
colitis and in the context of prophylaxis or onset therapy. Hypothetically, pre-
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treatment/prophylaxis with an anti-inflammatory extract would allow for accumulation 
of bioactive compounds in the body which would have a greater chance to effectively 
influence the onset of inflammation caused by the exposure to DSS. As adsorption 
of some compounds into the deeper layers of the lamina propria or submucosa 
could be poor, there is a better chance that the mechanism of action for these 
bioactive compounds is to directly modulate the mucosal epithelium to exert 
beneficial effects.36  Because the colonic epithelium turns over or replenishes every 
4 to 7 days,37, 38 treatment with a medicinal extract for at least 7 days prior to the 
exposure to DSS would ensure that all intestinal epithelial cells would have matured 
in the presence of the anti-inflammatory compounds. 
 Previously, EA has been shown to inhibit inflammatory prostaglandin E2 
(PGE2) production and modulate COX-2 signaling in cell culture experiments.6 
Based on these in vitro observations, the anti-inflammatory bioactivity of EA as an 
anti-colitic preventative was evaluated. Exposure of mice to 2.5% DSS caused 
moderate to severe lesions based on the extent of macroscopic damage. Based on 
the progression of weight loss, macroscopic disease scores and observed colon 
lengths, prophylactic treatment of the mice with EA, regardless of dose, did not 
effect the severity of colitis induced by 2.5% DSS. If EA were toxic, it could 
potentially have caused exacerbated weight loss or additional adverse effects in 
mice treated with DSS; however this was not observed. 
 While EA had no macroscopic anti-colitic benefit during the epithelial injury 
phase of the study, the ability of the EA extract to accelerate epithelial healing or 
restitution was evaluated. The EA extract was tested in a DSS model that included 
the continuation of the treatment period for 7 days after the cessation of the 
exposure to DSS. Separate groups of mice were treated with either 1.75 % or 2.5 % 
DSS and the results demonstrated that treatment with EA was ineffective in 
attenuating the magnitude of inflammation. nor did the EA extract accelerate tissue 
restitution. 
 Previous studies have shown that PV is anti-inflammatory when tested in 
several models and contains several bioactive phenolics, triterpenoids, and 
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flavonoids.10, 11, 14-16 Because colitis leads to greater mucosal permeability, even 
poorly bioavailable components have an increased chance of exerting beneficial 
effects in colitic models. Prophylactic use of the ethanolic extract of PV was 
examined in the context of DSS-induced colitis. Analysis of the daily weight 
changes, macroscopic lesion scores, and colon lengths all indicated that PV 
significantly reduces the severity of colitis in DSS treated mice. It was also observed 
that PV was not efficacious if treatment began consequent to the exposure to DSS 
(Supp. Fig. 7). This would indicate that exposure of gut tissues to the PV extract is 
required prior to inflammatory insult. Again, this model also does not address 
inflammation related to dysbiosis or genetic polymorphisms that could also 
contribute to colitic development and maintenance. 
 In summary, the bioactivity of EA and PV in the DSS model of colitis is quite 
different. This could be explained in a number of ways. Previous studies highlight the 
importance of alkylamides and ketones in EA, while PV harbors many bioactive 
polyphenols and flavonoids making the totality of their chemical compositions are 
very different.6, 10, 11 Studies are ongoing to address the metabolic byproducts 
associated with these extracts, transport of extract components and their 
bioavailability in healthy, homeostatic gut tissues compared to leaky colitic tissues. 
This work indicates the need for further study of the PV extract, extract components, 
mechanism(s) of action, and ways to alter the extract to improve efficacy for 
therapeutic use in other models of inflammatory disease.  
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Figures and Tables 
 
 
Table 1.  Experimental treatment groups. 
Ethanolic 
Extract 
Efficacy 
Query 
Treatment 
Groups 
Extract 
Dose 
Timeline 
DSS 
Dose 
and 
Timeline 
Restitution 
Timeline 
Prophylactic 
prevention of 
DSS colitis 
1) 100 mg/kg EA  
2) 200 mg/kg EA 
3) 100 mg/kg EA + 
DSS 
4) 200 mg/kg EA + 
DSS 
5) 5% EtOH vehicle 
6) 5% EtOH vehicle 
+ DSS 
Day -6 
through 
day7 
2.5% 
DSS 
 
Day 0 
through 
day 7 
None 
Echinacea 
angustifolia 
Benefit to 
mucosal 
healing/ 
restitution 
1) 200 mg/kg EA  
2) 200 mg/kg EA + 
DSS 
3) 200 mg/kg EA + 
DSS 
4) 5% EtOH vehicle 
+ DSS 
5) 5% EtOH vehicle 
+ DSS 
6) 5% EtOH vehicle  
Day -6 
through 
day7 
1.75% or 
2.5% 
DSS 
 
Day 0 
through 
day 7 
Day 8 
through    
Day 14 
Prophylactic 
prevention of 
DSS colitis 
1) 100 mg/kg PV  
2) 5% EtOH vehicle 
3) 100 mg/kg PV + 
DSS 
4) 5% EtOH vehicle 
+ DSS 
Day -6 
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day7 
2.5% 
DSS Day 
0 through 
day 2 
 
1.5% 
DSS Day 
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day 7 
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Prunella 
vulgaris 
Therapeutic 
prevention of 
DSS colitis 
1) 100 mg/kg PV  
2) 5% EtOH vehicle 
3) 100 mg/kg PV + 
DSS 
4) 5% EtOH vehicle 
+ DSS 
Day 0 
through 
day7 
2.5% 
DSS Day 
0 through 
day 2 
 
1.5% 
DSS Day 
3 through 
day 7 
None 
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Figure 1. Efficacy of 200 or 100 mg/kg Echinacea angustifolia extract in a DSS 
chemically induced model of colitis. 
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Figure 2. Effect of 200 mg/kg Echinacea angustifolia extract on restitution following 
low or high dose DSS induced colitis. 
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Figure 3. Efficacy of 100 mg/kg Prunella vulgaris  extract in a DSS chemically 
induced model of colitis. 
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Supplementary Figure 1. Photographs of colons and ceca from 2.5% DSS induced 
colitic or non-colitic mice treated with 5% EtOH vehicle, 100 mg/kg or 200 mg/kg 
Echinacea angustifolia.
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E. angustifolia 
200 mg/kg     
E. angustifolia 
DSS 
100 mg/kg     
E. angustifolia 
+ DSS 
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E. angustifolia 
+ DSS 
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Supplementary Figure 2. Neither 100 mg/kg or 200 mg/kg Echinacea angustifolia 
extract has negative impact on non-colitic mice. 
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Supplementary Figure 3. Photographs of colons and ceca from low and high dose 
DSS induced colitic or non-colitic mice treated with 5% EtOH vehicle or 200 mg/kg 
Echinacea angustifolia. 
Vehicle 
200 mg/kg     
E. angustifolia  
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Supplementary Figure 4. 200 mg/kg Echinacea angustifolia extract has no 
negative impact on non-colitic mice when dosed for 21 consecutive days. 
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Supplementary Figure 5. Photographs of colons and ceca from DSS induced colitic 
(2.5% DSS for 2 days followed by 1.5% for 5 days) or non-colitic mice treated with 
5% EtOH vehicle or 100 mg/kg Prunella vulgaris. 
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100 mg/kg     
P. vulgaris 
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P. vulgaris      
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Supplementary Fig 6. 100 mg/kg Prunella vulgaris extract has no negative impact 
on non-colitic mice. 
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Supplementary Figure 7. 100 mg/kg Prunella vulgaris extract is not therapeutically 
efficacious in a DSS chemically induced model of colitis.  
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Figure Legends 
 
Figure 1. Efficacy of 200 or 100 mg/kg Echinacea angustifolia extract in a DSS 
chemically induced model of colitis. Mice were prophylactically dosed E. angustifolia 
daily for 7 days prior to and 7 days during the administration of 2.5% DSS in drinking 
water. a) Body weights were recorded daily for the duration of the study, beginning 
on the first day of extract administration. Data is represented as a percent change 
from baseline. b) The additive macroscopic disease score was evaluated and 
recorded at necropsy based on 9 parameters as noted in the materials and methods. 
The maximally severe score is 9 while the minimal score for a completely healthy 
animal is 0. c) Colon lengths were measured at necropsy. Weight and colon length 
data were evaluated by non-parametric t-test, while macroscopic score was subject 
to non-parametric t-test. No significance (P < 0.05) in extract treatment groups was 
noted when compared to DSS treatment alone. 5% EtOH vehicle treatment n = 12, 
DSS only n = 14, 100 mg/kg E. angustifolia with DSS n = 6, 200 mg/kg E. 
angustifolia with DSS n = 6. 
 
Figure 2. Effect of 200 mg/kg Echinacea angustifolia extract on restitution following 
low or high dose DSS induced colitis. Mice were prophylactically dosed E. 
angustifolia daily for 7 days prior to DSS, 7 days during the administration of 2.5% or 
1.75% DSS in drinking water, and 7 days following discontinuation of DSS during 
restitution. a) Body weights, b) additive macroscopic disease scores and c) colon 
lengths were observed and statistically analyzed as noted in figure 1 and the 
materials and methods. No significance (P < 0.05) in extract treatment groups was 
noted when compared to appropriate DSS treatment alone. 5% EtOH vehicle 
treatment n = 18, 1.75% DSS only n = 7, 2.5% DSS only n = 18, 200 mg/kg E. 
angustifolia with 1.75% DSS n = 6, 200 mg/kg E. angustifolia with 2.5% DSS n = 11. 
 
Figure 3. Efficacy of 100 mg/kg Prunella vulgaris extract in a DSS chemically 
induced model of colitis. Mice were prophylactically dosed P. vulgaris daily for 7 
days prior to and 7 days during the administration of DSS (2.5% DSS for 2 days 
followed by 1.5% DSS for 5 days) in drinking water. a) Body weights, b) additive 
macroscopic disease scores and c) colon lengths were observed and statistically 
analyzed as noted in figure 1 and the materials and methods.  Statistical significance 
(*P < 0.05, **P < 0.01) is noted for comparisons to DSS treatment alone. 5% EtOH 
vehicle treatment n = 21, DSS only n = 21, 100 mg/kg P. vulgaris with DSS n = 19. 
 
Supplementary Figure 1. Photographs of colons and ceca from 2.5% DSS induced 
colitic or non-colitic mice treated with 5% EtOH vehicle, 100 mg/kg or 200 mg/kg 
Echinacea angustifolia. Photographs represent the average observed macroscopic 
score and colon lengths displayed in figure 1. 
 
Supplementary Figure 2. Neither 100 mg/kg or 200 mg/kg Echinacea angustifolia 
extract has negative impact on non-colitic mice. Mice were prophylactically dosed E. 
angustifolia daily for 14 days. a) Body weights, b) additive macroscopic disease 
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scores and c) colon lengths were observed and as noted in figure 1 and the 
materials and methods. 5% EtOH vehicle treatment n = 12, 100 mg/kg E. 
angustifolia n = 6, 200 mg/kg E. angustifolia n = 6. 
 
Supplementary Figure 3. Photographs of colons and ceca from low (1.75%) or high 
(2.5%) dose DSS induced colitic or non-colitic mice treated with 5% EtOH vehicle or 
200 mg/kg Echinacea angustifolia following restitution from DSS. Photographs 
represent the average observed macroscopic score and colon lengths displayed in 
figure 2. 
 
Supplementary Figure 4. 200 mg/kg Echinacea angustifolia extract has no 
negative impact on non-colitic mice when dosed for 21 consecutive days. Mice were 
prophylactically dosed E. angustifolia daily for 21 days. a) Body weights, b) additive 
macroscopic disease scores and c) colon lengths were observed and as noted in 
figure 1 and the materials and methods. 5% EtOH vehicle treatment n = 18, 200 
mg/kg E. angustifolia n = 18. 
 
Supplementary Figure 5. Photographs of colons and ceca from DSS induced (2.5% 
DSS for 2 days followed by 1.5% for 5 days) colitic or non-colitic mice treated with 
5% EtOH vehicle or 100 mg/kg Prunella vulgaris. Photographs represent the 
average observed macroscopic score and colon lengths displayed in figure 3. 
 
Supplementary Figure 6. 100 mg/kg Prunella vulgaris extract has no negative 
impact on non-colitic mice. Mice were prophylactically dosed P. vulgaris daily for 14 
days. a) Body weights, b) additive macroscopic disease scores and c) colon lengths 
were observed and as noted in figure 1 and the materials and methods. 5% EtOH 
vehicle treatment n = 9, 200 mg/kg P. vulgaris n = 21. 
 
Supplementary Figure 7. 100 mg/kg Prunella vulgaris extract is not therapeutically 
efficacious in a DSS chemically induced model of colitis. Mice were therapeutically 
dosed P. vulgaris daily beginning on the first day of DSS treatment and continuing 
for 7 days. DSS was dosed at 2.5% for 2 days followed by 1.5% for 5 days in 
drinking water. a) Body weights, b) additive macroscopic disease scores and c) 
colon lengths and d) cecal/colonic photographs were observed and as noted in 
previous figures and the materials and methods. Weight and colon length data were 
evaluated by non-parametric t-test, while macroscopic score was subject to non-
parametric t-test. No significance (P < 0.05) in extract treatment groups was noted 
when compared to DSS treatment alone. 5% EtOH vehicle treatment n = 5, DSS 
only n = 5, 100 mg/kg P. vulgaris n = 5, 100 mg/kg P. vulgaris with DSS n = 8. 
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Abstract 
The onset and extent of enteric injury associated with inflammatory bowel 
disease (IBD) is strongly influenced by epithelial barrier dysfunction and innate 
upregulation of inflammatory gene products, which enhance an aberrant, chronic 
adaptive inflammatory response. Previous studies have demonstrated the anti-
inflammatory capabilities of Prunella vulgaris, but never in an in vivo model of colitis. 
We hypothesized that P. vulgaris extract prophylaxis would attenuate intestinal 
lesion severity and onset of disease associated with spontaneous typhlocolitis in 
mdr1a-/- mice. Vehicle (5% ethanol), P. vulgaris (2.4 mg/day) or metronidazole (0.75 
mg/mL drinking water, an antibiotic and anti-colitic control) were administered orally 
to separate groups of 6-7 week old mdr1a-/- or FVBWT mice and continued daily until 
mice developed severe wasting or reached 20 weeks of age. Administration of P. 
vulgaris extract to mdr1a-/- mice significantly (p<0.05) delayed onset of colitis, 
reduced macroscopic and microscopic cecal histologic scores when compared to 
vehicle-treated mdr1a-/- mice. P. vulgaris extract prophylaxis resulted in significantly 
reduced (p<0.05) serum levels of G-CSF, GM-CSF, IL-9, IL-10, IP-10, KC, MIG, and 
TNFα as well as reduced gene expression of Ccl2, Ccl20, Cxcl1, Cxcl9, IL-1α, 
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Mmp10, VCAM-1, ICAM, IL-2, and TNFα in mdr1a-/- mice when compared to vehicle 
treated mdr1a-/- mice at necropsy. Histologically, cecal neutrophilic infiltrate was 
reduced in P. vulgaris-treated mdr1a-/- mice, as was myeloperoxidase (MPO) activity 
in the colon. CD4+ T cells, CD8+ T cells and germinal center B cells observed in the 
cecal tonsils of P. vulgaris-treated mdr1a-/- were significantly reduced (p < 0.5) from 
vehicle treated mdr1a-/- mice. Vehicle-treated mdr1a-/- mice were found to produce 
serum antibodies to antigens derived from their resident microbiota, indicative of 
severe colitis and a loss of adaptive tolerance to the members of the microbiota. 
These serum antibodies were greatly reduced or absent in P. vulgaris and 
metronidazole treated mdr1a-/- and FVBWT mice. The anti-inflammatory activity of 
Prunella vulgaris ethanolic extract was shown to attenuate innate inflammatory 
responses and spontaneous colitis in mdr1a-/-. 
 
Introduction 
The intestinal epithelium and innate immune system cooperate to protect the 
host from damage induced nutrient and water loss to the lumen as well as 
colonization and invasion by pathogens. The constant low level of inflammation 
present in the gut is generally important for mucosal homeostatic balance. In the 
context of inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and 
ulcerative colitis (UC), regulation of mucosal inflammation and homeostasis fail and 
contribute to intestinal mucosal damage and chronic inflammation (61). While 
idiopathic in nature, current hypotheses regarding the etiology of IBD point to 
complex multifactoral causalities which could include a disrupted intestinal epithelial 
barrier, dysbiosis of the microbiota, genetic susceptibilities, chronically activated 
inflammatory immune cells, and failed immune regulatory responses (16, 44).  
Much IBD research has focused on aberrant adaptive immune responses to 
antigens derived from the microbiota. More emphasis is now being placed on 
elucidating  the role innate immune cells (i.e. neutrophils), cytokines, chemokines, 
and their related transcription factors play in the initiation and/or maintenance of a 
compromised epithelium as the initial step in the onset of IBD (3). Without a tight, 
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intact, mucin covered epithelial barrier, compartmentalization that is meant to 
separate immune cells in the lamina propria from the numerous bacterial and food 
antigens normally sequestered in the lumen is lost (70). A loss of epithelial barrier 
integrity is characteristic of UC and CD, and the consequential loss of immunologic 
tolerance to the microbiota initiates a cascade of immune signals and functions 
which lead to chronic, unproductive innate immune responses. These signals, in 
turn, exacerbate an aberrant and ineffectively regulated adaptive response (9). A 
key factor in the initial cascade of inflammatory signals is NF-κB. 
  Over a decade ago, the transcription factor NF-κB was characterized as a key 
regulator of inflammation in the intestine (48). NF-κB is known to regulate a host of 
genes participating in innate immune function and inflammation, including but not 
limited to G-CSF, GM-CSF, IFNγ, IL-6, IP-10, KC, MIP-1α/β, TNFα, VEGF, IL-1α, 
VCAM-1 and ICAM (51). In UC, CD, and experimental colitis, recruitment of 
neutrophils, exacerbated by NF-κB activation, is chronic and their production of 
myeloperoxidase (MPO), elastase, and nitric oxide damage the host tissues while 
their production of IL-1, IL-6, and TNFα contribute to activation of adaptive immune 
responses (17, 31, 37). 
The most common therapies on the market for IBD are antibiotics or immune 
suppressive/anti-inflammatory agents (76, 77). Metronidazole and ciprofloxacin have 
been utilized in several clinical trials related to the treatment of UC, CD and pouchitis 
with underwhelming results, as evidenced by the fact that metronidazole is 
somewhat efficacious in the treatment of CD and pouchitis, but not UC (21). 
Immunosuppressive therapies include monoclonal antibodies against TNFα, 5-
aminosalicylates (5-ASA), and steroids (59, 60, 65). In addition to the risks these 
therapies present with regard to secondary bacterial or viral infection, in the case of 
some therapies, the long term efficacy and safety is unknown for some therapies. 
Surgical intervention is still common for severe forms of IBD. A recent study showed 
that IBD related hospitalizations at high volume IBD treatment centers around the 
United States increased 6-fold from 1998 to 2004 (49). This data illustrates that 
despite advances in IBD research, current therapies are not decreasing the 
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frequency of IBD related hospitalizations. These notions and the burdens of difficult 
and expensive therapeutic regimens have lead patients to explore more 
unconventional means of coping with IBD. 
A 1998 study showed that up to 51% of surveyed IBD patients had used 
alternative or complementary therapies, 16% of patients used the alternative 
therapies specifically for their IBD (18). For most nutraceuticals, many anecdotal 
claims of health benefits exist with very little scientific data to support or negate 
those claims. Given that increasing amounts of money are being spent every year 
on alternative medicines and supplements in the United States, more nutraceutical 
research is needed to identify potential biologic activity and safety of these products. 
Prunella vulgaris is commonly used in traditional Chinese medicine for wound 
healing, indigestion, burns and anti-inflammatory therapy. P. vulgaris contains 
several bioactive phenolics, triterpenoids, and flavonoids (11). Dietary phenolics like 
rosmarinic acid, ursolic acid, and caffeic acid, which are all found in extracts of P. 
vulgaris, have antioxidant, anti-inflammatory and anti-cancer activities (19, 36, 45, 
54, 72, 82). Caffeic acid has also been shown to effectively attenuate chemically 
induced experimental colitis through upregulation of cychrome P450 (CYP4B1) (83). 
Flavonoids, like those found in P. vulgaris, have been implicated as potential 
therapeutics for IBD as well. The flavonoid luteolin was found to attenuate 
spontaneous colitis by downregulating NF-κB. Despite this promising evidence, 
Prunella vulgaris extracts have never been studied as a treatment for IBD. In this 
context, we have designed this study to test the hypothesis that an ethanolic extract 
of P. vulgaris will decrease inflammatory signals that are mediated by NF-κB in the 
gut and thereby ameliorate the severity of spontaneous colitis. 
 
Materials and Methods 
Reagents.  Prunella vulgaris dried plant materials were kindly provided by Dr. 
Mark Wiederlichner at the USDA-ARS North Central Regional Plant Introduction 
Station (NCRPIS, Ames, IA). Ten percent buffered formalin for fixation of histologic 
samples; hydrogen peroxide and sulfuric acid for myeloperoxidase (MPO) assay 
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development; and all western blot reagents (tris, glycine, sodium lauryl sulfate, 
methanol) were purchased from Fisher Scientific (Fair Lawn, NJ). RNAlater for 
tissue sample storage prior to RNA isolation was purchased from Ambion (Austin, 
TX). Phenylmethanesulfonyl fluoride (PMSF), a protease inhibitor utilized in the 
MPO assay; 3,3`,5,5`-tetramethylbenzidine dihydrochloride hydrate (TMB), used in 
the development of the MPO assay; as well as Dimethylsulphoxide (DMSO) were all 
purchased from Sigma (St. Louis, MO). Heparin at 5,000 USP heparin units/0.5 mL 
was used as an anticoagulant in preparation of peripheral blood monocytes 
(PBMCs) and was purchased from Hospira, Inc. (Lake Forest, IL). Fetal bovine 
serum for cell culture medium was purchased from Atlanta Biologicals 
(Lawrenceville, GA) and heat inactivated prior to use. Cell wash/culture medium 
reagents (Dulbecco’s modified eagle’s medium (DMEM) 1X supplemented with 4.5 
g/L glucose and sodium pyruvate, penicillin-streptomycin, glutamine and hepes were 
all purchased from Cellgro (Herndon, VA). All anti-mouse conjugated antibodies and 
anti-rat isotype controls used in flow cytometric cecal tonsil analysis were purchased 
from ebioscience (San Diego, CA):  FITC-conjugated peanut agglutinin (PNA)+, PE-
Cy7-conjugated anti-CD4+ monoclonal antibody (mAb), APC-conjugated anti-CD8β+ 
mAb, PE-conjugated anti-CD19+ mAb, Alexa 700-conjugated anti-B220+ mAb, PE-
Cy7-conjugated anti-rat IgG2aκ+isotype, APC-conjugated anti-rat IgG2bκ+isotype, 
PE-conjugated anti-rat IgG2aκ+isotype, Alexa 700-conjugated anti-rat 
IgG2aκ+isotype. BD stabilizing fixative (for use with PE-Cy7 conjugates) purchased 
from BD biosciences (San Jose, CA) was used for cecal tonsil cells labeled for flow 
cytometric analysis. All reagents utilized for the Luminex platform multiplex flow 
cytometric analysis of serum cytokines and chemokines were purchased as part of 
the Milliplex MAP 32-plex mouse cytokine/chemokine kits from Millipore (Billerica, 
MA). TRIzol utilized for RNA isolation was purchased from Invitrogen (Carlsbad, 
CA). Materials utilized for RT2 profiler signal transduction pathway finder PCR array 
system including:   RT2 profiler signal transduction pathway finder PCR array 96-well 
plates, RT2 qPCR-grade RNA isolation kit, RT2 first strand kit and RT2 SYBR green / 
ROX qPCR master mix were purchased from SABiosciences (Frederick, MD). 
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Forward and reverse primers (sequences provided upon request) for real-time PCR 
validation of Ccl2, Cxcl1, Cxcl9, IL-1α, Mmp10, VCAM-1, TNFα, ICAM and GAPDH 
were purchased from Integrated DNA Technologies (Coralville, IA). SYBR green / 
ROX master mix components for real-time PCR validation were purchased from 
Invitrogen (Carlsbad, CA). 
Prunella vulgaris extract preparation. Information about the specific 
provenance of P. vulgaris accession Ames 27664, obtained from the NCRPIS, is 
available on the Germplasm Resources Information Network database at 
http://www.ars-grin.gov/npgs/acc/acc_queries.html. Arboreal portions of plants from 
P. vulgaris (Ames 27664), harvested in 2008, were prepared for storage by drying 
for 8 days at 38°C in a forced-air dryer with constant humidity. The dried material 
was ground with a 40-mesh screen and stored at -20°C until extraction. Extractions 
were made in 95% ethanol (EtOH) solvent by the Soxhlet method (6 hours). Upon 
complete drying of the extract by evaporation, the weight of the extracted material 
was recorded; the residue was lyophilized and stored at -20°C until solubilized in a 
final working solution of 5% EtOH (the lowest concentration of EtOH that would allow 
solubilization) at a final plant extract concentration of 12 mg/mL. The working P. 
vulgaris extract was divided into 2 mL aliquots and stored at -20°C until use. 
Prunella vulgaris extracts from NCRPIS were screened for endotoxin by using the 
Limulus Amebocyte Lysate Test (BioWhittaker, Inc., Walkersville, MD) according to 
manufacturers’ specifications for a microplate assay, and there was no detectable 
endotoxin present in the extract (data not shown). 
Animals. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) at Iowa State University. Four to five week old 
male Mdr1a -/- FVB.129P2-Abcb1a tm1BorN7 and wild type (WT) FVB.129P2 mice 
were obtained from Taconic Farms, Inc. (Germantown, NY). Animals were housed 
and maintained in the Laboratory Animal Resource facility at the college of 
veterinary medicine, Iowa State University. Established specific pathogen-free 
husbandry practices were followed and twelve hour light/dark cycles were applied. 
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Upon arrival, mice were fed a defined Harlan Teklad AIN93 (M) rodent chow 
(Madison, WI) to control the amount of phytochemicals in their diet. 
Experimental Design.  A total of six treatment groups of mice where utilized: 
groups 1 and 2) mdr1a-/- and FVBWT mice were orally gavaged with 2.4 mg/day P. 
vulgaris extract in a 200 µl volume (prepared as described above); groups 3 and 4) 
mdr1a-/- and FVBWT mice were orally gavaged with 200 µL 5% EtOH vehicle and 
given drinking water (refreshed weekly) containing 0.75 mg/mL metronidazole 
(Sigma, St. Louis, MO); groups 5 and 6) mdr1a-/- and FVBWT mice were orally 
gavaged with 5% EtOH vehicle alone. N = 4 to 10 mice per group per experiment. 
Gavage was performed using a 20 gauge feeding needle once a day beginning at 6 
weeks of age until the mice reached twenty weeks of age or were removed from the 
study because of severe clinical wasting and/or weight loss exceeding 15 % of their 
peak body weight. At necropsy, mice were euthanized by CO2 asphyxiation. 
Following euthanasia, blood was collected by cardiac puncture and separate 
sections of ceca and proximal colon were excised, washed, and stored for further 
histological, MPO enzymatic, and real-time PCR analysis. Serum was analyzed by 
multiplex flow cytometric assay to measure cytokine and chemokine levels as well 
as western blot analysis for antibody reactivity to antigens derived from the 
microbiota. Cecal tonsils were also collected for flow cytometric analysis of T and B 
cell populations. All results are representative of two independent experiments. 
Macroscopic typhlocolitis assessment. Following euthanization, the colon 
and cecum were excised, photographed, measured and scored for severity of 
macroscopic lesions. Gross typhlocolitic lesions were scored using a 9 point additive 
scale; a score of zero being a healthy animal and a score of 9 being a maximally 
diseased animal. Score parameters evaluated included: 1)cecal atrophy, 2) enlarged 
cecal tonsil or other enlarged lymphoid aggregates, 3) emptying of cecal contents, 4) 
abnormally watery or mucoid intraluminal cecal and/or colonic contents 5) bloody 
cecal contents, 6) bloody colonic contents, 7) visible thickening and rigidity of the 
cecum, 8) presence of visible thickening and rigidity of the colon, and 9) absence of 
formed fecal pellets in the colon. 
   108 
Histopathological assessment. Sections of excised cecum and proximal 
colon were placed in 10% buffered formalin overnight, paraffin embedded, 
sectioned, and routinely stained with hematoxylin and eosin. Stained colonic and 
cecal sections were scored by a pathologist, Dr. Jesse Hostetter of Iowa State 
University (Ames, IA), blinded to the treatments as previously described (23, 24). 
Microscopic mucosal lesion scores were assessed by five parameters, with each 
parameter scored on a scale of 0-5 (5 = maximum severity). Score parameters 
include:  1) ulceration of the mucosa; extent of inflammatory cell infiltrate; 2) mucosal 
edema characterized by the extent of lymphatic and vascular distortion from the 
normal architecture; 3) stromal collapse and necrosis of the glands; 4) glandular 
hyperplasia characterized by the distribution of enterocytes along the base of the 
gland; and 5) cellular proliferation. In addition to score, mucosal heights were 
determined and recorded in micrometers (µm), and the specific inflammatory cell 
populations, if present, were recorded. Score parameters were considered 
individually and as an additive histopathological score with mucosal height included 
in the additive score. 
Myeloperoxidase assay. Myeloperoxidase (MPO) activity was assessed as 
a measure of neutrophil/granulocyte accumulation in proximal colonic tissues. The 
MPO assay was performed as previously described with several modifications (83). 
Proximal colon sections collected at necropsy were gently flushed with PBS to 
remove luminal contents and stored in 1 mL of freshly prepared PBS supplemented 
with the protease inhibitor phenylmethanesulfonyl fluoride (PMSF) at 0.1mM and 
15% dimethylsulphoxide (DMSO) at -20°C for no more than 7 days prior to assay. 
Samples used as positive controls for MPO activity were prepared fresh the day the 
assay from peripheral blood. One FVBWT mouse, not on study, was euthanized by 
CO2 asphyxiation, and 500 µl to 1 mL of blood was immediately collected by cardiac 
puncture with a heparinized needle (heparin at 5,000 USP heparin units/0.5 mL is 
drawn into the needle and syringe and then expelled to coat the inside of the needle 
with heparin). The heparinized blood was centrifuged at 250 x g for 10 minutes, the 
supernatant discarded and the red blood cells (RBC) lysed. In brief, 1 mL of ACK 
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lysis buffer (8042.0 mg/L ammonium chloride, 1001.0 mg/L potassium bicarbonate, 
3.722 mg/L ethylene diamine tetraacetic acid disodium, pH 7.2, Sigma chemicals, 
St. Louis, MO) is added to the pellet, vortexed gently for 1 minute, 1 mL of PBS is 
added, and the mixture is centrifuged for 10 minutes at 250 x g. The lysis was 
repeated until the pellet was white and the supernatant was clear. Following RBC 
lysis, the pellet was resuspended in 1 mL of PBS/PMSF (0.1mM), cell numbers were 
recorded (average yield of 3 x 106 cells/mL) (Z Series Coulter Counter, Beckman 
Coulter, Fullerton, CA) and the cells were sonicated at an amplitude of 5, pulse on 
for 4 seconds, pulse off for 1 second for 20 seconds total (Sonicator 3000, Misonix, 
Inc., Farmingdale, NY). The sonicate is then centrifuged at 250 x g for 15 minutes, 
the supernatant stored at 4°C until the tissue samples were prepared. Frozen 
proximal colonic sections were thawed, blotted to remove as much excess fluid as 
possible, trimmed to roughly 35 mg and their weights recorded. Tissues were then 
homogenized for 1 minute at maximum power in 1 mL PBS/PMSF (0.1 mM) and the 
homogenizer probe was washed 5 times with PBS between tissue samples. 
Homogenate cell counts were recorded, and each sample was then sonicated as 
described above. The tissue sonicates were then centrifuged at 250 x g for 15 
minutes, the supernatant collected and the pellet discarded. Each lysate prepared 
from tissue or PBMC was analyzed for  total protein  using aNanoDrop ND-1000 UV-
Vis Spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE). Individual 
lysates were pipetted into 96-well, flat bottom microtiter plates.  The PBMC lysates 
(150 µl per well) were serially diluted (10, two-fold dilutions) and analyzed in 
triplicate wells. For each tissue lysate, 150 µl was pipetted into separate wells and 
analyzed in triplicate. To each well, 50 µl of 3,3`,5,5`-tetramethylbenzidine 
dihydrochloride hydrate (TMB) was added, followed immediately by the addition of  
50 µl hydrogen peroxide (H2O2) (5 mM). The reaction was allowed to proceeded for 
roughly 2 minutes (wells turned bright blue), followed by the addition of 50 µl of 
sulfuric acid (1 M) to stop the reaction. The optical density (OD) was measured at 
405 nm spectrophotometerically (V-Max, Molecular Devices, USA) using SOFTmax 
PRO 4.0 software. The MPO content was determined by comparison to the standard 
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curve and MPO activity was expressed as the relative units of enzyme activity per 
gram of wet weight of tissue. 
Serum cytokine/chemokine quantification. Following euthanization of 
mdr1a-/- and FVBWT mice, blood was collected via cardiac puncture. The blood was 
allowed to clot for 24 hours at 40C after which samples were centrifuged at 10,000 x 
g for 10 minutes. Serum was then removed and stored at -200C until use. The day of 
assay, serum samples were thawed to room temperature. Concentrations of 
cytokines and chemokines of interest were measured using the Millipore (Billerica, 
MA) mouse cytokine-chemokine 32-plex multiplexed flow-cytometric assay kit. 
Analytes screened include:  Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-10, IL-12 (p40), IL-
12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, 
KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNF-α, 
VEGF. The assay was performed according to the manufacturer’s instructions. In 
brief, supplied analyte standards (range - 10,000 to 3.2 pg/mL), quality control 
standard, and buffer only control samples were analyzed in duplicate wells of the 
supplied 96 well plate. Mouse serum samples were diluted 1:1 in supplied assay 
buffer plated for each mouse. Supplied serum matrix and supplied assay buffer were 
added to all wells. Supplied pre-conjugated multiplex analyte beads were added to 
each well and the samples were incubated at 40C overnight on a plate shaker 
(Barnstead International Titer Plate Shaker, setting #5, Model #4625). Supplied 
detection antibody was added to all wells and allowed to incubate at room 
temperature while shaking for 2 hours. Supplied streptavidine-phycoerithrin was 
incubated for 30 minutes at room temperature while shaking. The mean 
fluorescence intensity (MFI) was measured using Luminex platform technology (The 
FlowMetric System, Luminex, Austin, TX). MFIs were subsequently converted to 
concentrations using a 5-parameter logistic or line curve-fitting method in MasterPlex 
QT Software (MiraiBio Group, San Francisco, CA). 
Flow cytometric analysis of cecal tonsil cell populations. Cecal tonsils 
from mdr1a-/- and FVBWT mice were excised, placed in complete cell medium (10 mL 
heat-inactivated FBS, 1 mL penicillin/streptomycin, 1 mL glutamine, 0.1 mL 50 mM 
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β-mercaptoethanol, 2.5 mL 1M hepes in 85.4 mL DMEM with 4.5 g/L glucose and 
sodium pyruvate), and homogenized mechanically on ice. Stainless steel wire 
strainers (60 mesh) were used to prepare a single cell suspensions and remove 
particulate matter. Cells (5 x 105 cells/tube) were washed in FACs buffer, centrifuged 
at 250 x g and incubated in FACS buffer containing 1:100 rat IgG and fluorochrome 
labeled reagents for 15 minutes on ice. Following labeling, cells were washed with 
FACs buffer, centrifuged and fixed in 200 µl of BD stabilizing fixative. Cellular 
preparations from individual mice were labeled with the following fluorochrome-
labeled reagents:  germinal center B cells (PNA+B220+) were identified using FITC-
conjugated PNA and Alexa 700-conjugated anti-B220+ mAb, CD4+ T cells were 
identified using PE-Cy7-conjugated anti-CD4+ mAb, CD8+ T cells were identified 
using APC-conjugated anti-CD8β+ mAb, B cells that have yet to mature to plasma 
cells (CD-19+) were identified by PE-conjugated anti-CD19+ mAb. The following 
isotype controls were utilized:  Alexa 700-conjugated anti-rat IgG2aκ+, PE-Cy7-
conjugated anti-rat IgG2aκ+, APC-conjugated anti-rat IgG2bκ+ and PE-conjugated 
anti-rat IgG2aκ+. PNA has no isotype control. Working dilutions of PNA, anti-B220 
mAb, anti-CD4 mAb, anti-CD8β mAb, and anti-CD-19 mAb and their isotypes were 
1:50, 1:100, 1:80, 1:80 and 1:50, respectively. Analysis was performed using a BD 
FACSCanto flow cytometer (BD, San Jose, CA) made available through the Flow 
Cytometry Core Facility at Iowa State University (Ames, IA). Data analysis was 
performed using FlowJo software (TreeStar Inc., Ashland, OR). 
Western blot analysis. Anti-sera from mdr1a-/- and FVBWT mice was used to 
evaluate the presence of serum antibody against members of the resident 
microflora. Whole cell sonicates (WCS) of three members of the clostridial cluster 
group XIVa (ASF356, ASF500, and ASF502) were cultivated anaerobicly, cells were 
harvested by centrifugation, washed in PBS, lyophilized, and stored at -200C until 
use. Cells were then weighed and suspended in PBS to 2 mg/mL. The resulting 
suspension was sonicated on ice for 3 minutes at the following settings:  amplitude 
of 50 for 2, 30 second pulses with 5 seconds between each pulse; amplitude 75 for 
2, 30 second pulses with 5 seconds between each pulse; amplitude 100 for 2, 30 
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second pulses with 5 seconds between each pulse. The sonicate was sterilized by 
UV light  (six minute exposure)  and sterility was confirmed bacteriologically. For 
each preparation, protein content was determined by bicinchoninic acid (BCA) 
analysis (Pierce Laboratories, New Haven, Connecticut, USA),  aliquoted and stored 
at -200C. Whole cell sonicates of ASF356, ASF500, and ASF502 (8 µg of each by 
protein content) were subjected to SDS-PAGE using 12% tris-glycine gels (BioRad, 
Hercules, CA) and transferred to PVDF membranes. Each individual antigen 
(ASF356, ASF500, and ASF502) was  analyzed using pooled anti-sera (1:250) from 
separate treatment groups as described above  The membranes were then reacted 
with alkaline phosphatase (AP) conjugated anti-mouse IgG(H+L) ( 1:1000, Southern 
Biotech, Birmingham, AL) in a solution containing tris buffered saline (pH 7.6), 1% 
Tween 20 (TBST) and 2.5% non-fat, skim milk. Immunoreactive proteins were 
visualized using Sigma fast red tablets (Sigma, St. Louis, MO) according to 
manufacturers’ instructions.     
Pathway finder R2 profiler PCR array analysis and real-time RT-PCR 
validation. To uncover signal transduction pathway gene targets modulated by P. 
vulgaris, cecal RNA was analyzed using the RT2 profiler signal transduction pathway 
finder PCR array from SABiosciences (Frederick, MD) as per the Manufacturers’ 
instructions. In brief, RNA was isolated from cecal tissue collected at necropsy that 
had been stored at -200C in RNAlater using the TRIzol method (26). RNA was 
further purified using the RT2 qPCR-grade RNA isolation kit from SABiosciences 
(Frederick, MD) according to manufacturers’ instructions. RNA integrity was 
assessed using an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA) 
made available by the GeneChip Core Facility at Iowa State University (Ames, IA). 
RNA integrity values ranged from 8.2 – 9.4 (data not shown). Prior to preparation of 
cDNA, RNA samples were tested by PCR using oligonucleotide primers for GAPDH 
to confirm the absence of genomic DNA contamination. Invitrogen SYBR Green / 
ROX, primers and 1 µg of isolated RNA from each mouse were subjected to the 
following PCR conditions and were run on an ABI 5700 (Applied Biosystems Inc., 
Carlsbad, CA):  950C for 10 minutes, followed by 40 cycles of amplification (950C for 
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10 seconds, 600C for 15 seconds). All cycle threshold (CT) values were greater than 
30, and were acceptable for further use (data not shown). GAPDH oligonucleotide 
primers used were:  5'-TGTGTCCGTCGTGGAT CTGA-3' and 5'-
CCTGCTTCACCACCTTCTTGA-3'. RNA (1 µg) from each mouse was then 
converted to cDNA using SABiosciences RT2 First Strand kit according to 
manufacturers’ instructions. Resulting cDNA from individual mice was pooled into 
diseased and healthy groups of mice for each treatment group and each experiment, 
mixed with the kit’s array master mix experimental cocktail preparation and 
subjected to the same PCR conditions and equipment noted above. PCR array data 
was analyzed using SABiosciences’ RT2 PCR array analysis software and fold 
changes were calculated relative to house keeping genes by the software. Only 2-
fold changes or greater were considered. 
Statistical analysis. Statistical significance of parametric data was evaluated 
by student’s t-test. Non-parametric data (e.g., scores) were evaluated by the Mann-
Whitney test. All survival curves were evaluated by the Log Rand (Mantel-Cox) test 
and the Gehan-Breslow-Wilcoxon test. A p-value of < 0.05 was considered 
statistically significant. Prism 5 software was used for all statistical calculations. 
 
Results 
The ethanolic extract of P. vulgaris decreases severity of macroscopic 
disease parameters and delays onset of severe colitis in mdr1a-/- mice. To 
determine the efficacy of P. vulgaris extract in the treatment of spontaneous colitis, 
mdr1a-/- and FVBWT mice were gavaged daily with vehicle (5% EtOH) or 2.4 mg P. 
vulgaris extract. Previously published data shows that mdr1a-/- mice develop disease 
between 8 and 36 weeks of age, with the average age of disease onset occurring at 
20 weeks (52). As expected, FVBWT mice treated with P. vulgaris were not adversely 
affected by the administration of the extract despite the long course of prophylaxis. 
Photographs (Fig. 1) show the extent of inflammation and damage caused in vehicle 
treated mdr1a-/- mice. In these mice, ceca are atrophied with visible, prominent cecal 
tonsils suggesting immune activation. The ceca are almost empty of contents and 
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both cecal and colonic tissues are notably thickened and rigid to the point they 
cannot be straightened. Occasional blood was noted in cecal and colonic contents, 
while no formed fecal pellets are noted. Conversely, the cecum and colon of the P. 
vulgaris treated mdr1a-/- mouse is markedly improved and more closely resembles 
the tissue appearance of healthy FVBWT mice with regard to improvements in all of 
the parameters noted above. Enlargement of the ceca from  both mdr1a-/- and 
FVBWT mice treated with metronidazole was noted and would be a characteristic 
consequence of the metronidazole treatment by partially depleting the microbiota of 
the mice.  
Grossly, mild to severe typhlocolitis (a score of 2 to 9 respectively) was 
observed in 100% of vehicle treated mdr1a-/- mice compared to only 53% of P. 
vulgaris treated mice which experienced only mild to moderate colitis (Fig. 2A).  P. 
vulgaris prophylaxis significantly (p < 0.01) improved macroscopic parameters of 
disease when compared to vehicle treatment in mdr1a-/- mice. Despite these 
observations, P. vulgaris associated colon lengths displayed an improved trend 
when compared to vehicle treatment in mdr1a-/- mice, but not a significantly longer 
colon (Fig. 2B). As expected, no FVBWT mice, and only one metronidazole treated 
mdr1a-/- mouse, exhibited any parameters of disease (Fig. 2, A and B).  
As anticipated, many mdr1a-/- mice developed severe colitic wasting and were 
removed from study prior to aging 20 weeks. The majority of vehicle treated mdr1a-/- 
mice which developed severe colitic disease prior to 20 weeks of age had to be 
removed from study (lost ≥ 15% of their maximal body weight) within 3 to 5 days of 
visible clinical signs (bloody stools, diarrhea, ruffled fur, hunched gate) (data not 
shown). Out of 16 mdr1a-/- mice treated with vehicle, 7 required removal from study 
prior to 20 weeks of age, compared to only 4 out of 13 P. vulgaris treated mdr1a-/- 
mice. While P. vulgaris extract was able to delay onset of severe colitis and reduce 
the number of mdr1a-/- mice which had to be removed from study, the difference was 
not significant when compared to vehicle treated mdr1a-/- mice (Fig. 3). When P. 
vulgaris treatment was delayed until clinical signs of colitis were visible in mdr1a-/- 
mice, only the macroscopic typhlocolitic scores were improved significantly, while 
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other gross indicators of disease were not significantly improved (Supplementary 
Fig. 1). These results indicate that P. vulgaris extract prophylaxis is able to 
significantly improve macroscopic disease and delay the onset of spontaneous 
colitis in mdr1a-/- mice. 
Impact of P. vulgaris treatment on  the severity of histopathological 
lesions. Histological inflammation of the cecum and colon was evaluated in the 
context of mucosal height, ulceration, extent and character of inflammatory cell 
infiltrate, edema, stromal collapse and glandular necrosis, and glandular hyperplasia 
(Table 1). The ceca of vehicle treated mdr1a-/- mice were typified by crypt 
hyperplasia, extensive transmural ulceration and inflammatory infiltrate, as well as 
submucosal edema and occasional stromal collapse (Table 1 and Fig. 4). The P. 
vulgaris-treated mdr1a-/- mice exhibited statistically significant (p < 0.01 – p < 0.05) 
improvement in every cecal microscopic parameter except edema (Table 1). In 
addition, there was no significant inflammation (p < 0.05 – p < 0.001 compared to 
vehicle mdr1a-/-) noted in the metronidazole-treated mdr1a-/- mice. While the FVBWT 
mice presented with no evidence of inflammation or adverse effects of the 
treatments, both P. vulgaris and metronidazole treated FVBWT mice did present with 
increased mucosal edema, which could indicate an effect on the vasculature. While 
100% of vehicle treated mdr1a-/- mice exhibited extensive neutrophilic infiltration into 
the cecum, this population of inflammatory cells was absent in 62% of P. vulgaris-
treated mdr1a-/- mice (Table 1 and Fig. 4). As a measure of the infiltration of 
granulocytes into the mucosal tissue, MPO activity was measured in tissue 
homogenates.  In comparison to tissue samples from the vehicle-treated mdr1a-/- 
mice, the associated MPO enzymatic activity was significantly diminished in P. 
vulgaris- and metronidazole treated mdr1a-/- mice (p < 0.01) (Fig. 5). While colonic 
sections from the vehicle-treated mdr1a-/- mice were also histologically evaluated, 
the colons of these mice were not significantly improved in P. vulgaris-treated mice 
(data not shown) suggesting that the bioactive benefit of P. vulgaris localized in the 
cecum. When P. vulgaris treatment was delayed until clinical signs of colitis were 
visible in mdr1a-/- mice (i.e., therapeutically evaluated), there was no improvement in 
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microscopic typhlocolitic parameters relative to the vehicle-treated mdr1a-/- mice 
(Supplementary Fig. 1 and Supplementary Table 1). Together, these data indicate 
that the protection P. vulgaris prophylaxis provides the cecal mucosa from severe 
inflammation and injury is associated with a reduced presence of inflammatory 
neutrophils and their enzymatic activity 
Impact of the ethanolic extract of P. vulgaris on the induction of innate 
chemotactic and pro-inflammatory cytokines. To further investigate the 
mechanism related to improved cecal health and the associated reduction in 
neutrophil presence and enzymatic activity in the ceca of P. vulgaris-treated mdr1a-/- 
mice, serum samples collected at necropsy were examined for the presence of 
chemokines and cytokines including:  Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-10, IL-12 
(p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
9, IP-10, KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, 
TNF-α, VEGF. Several cytokines/chemokines (Eotaxin, IL-13, IL-15, IL-1α, IL-1β, IL-
2, IL-3, IL-4, IL-5, LIF, LIX, M-CSF, MCP-1, MIP-1α, MIP-2, and RANTES) were not 
detectable in any treatment group (data not shown). Several analytes were 
significantly elevated in mdr1a-/- mice compared to FVBWT mice:  G-CSF, IP-10, and 
MIG (p < 0.001); IL-10 and TNFα (p < 0.01); GM-CSF, IL-7, IL-17, and KC (p < 0.05) 
(Table 2). Significantly reduced serum analytes detected in metronidazole treated 
verses vehicle treated mdr1a-/- mice included:  TNFα and IL-17 (p < 0.001); G-CSF, 
IL-10, IP-10, KC and MIG (p < 0.05) (Table 2). Numerous serum analyte 
concentrations were also lower in the P. vulgaris-treated mdr1a-/- mice:  IL-10 (p < 
0.01), G-CSF, GM-CSF, IL-9, IP-10, KC, MIG, TNFα (p < 0.05) (Table 2). While not 
significant, there was a trend (p < 0.08) for reduced amounts of IFNγ, IL-6, IL-
12(p70), MIP-1β, and VEGF in the serum of P. vulgaris-treated mdr1a-/- mice when 
compared to vehicle-treated mdr1a-/- mice (Table 2). When P. vulgaris treatment was 
delayed until clinical signs of colitis were visible in mdr1a-/- mice, only IL-9 was 
significantly (p < 0.05) reduced (Supplementary Table 2). It is clear from these data 
that P. vulgaris is able to modulate production of many innate chemokines and 
inflammatory cytokines induced by the inflammatory response in mdr1a-/- mice.   
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Differential regulation of gene expression pathways by in vivo treatment 
with the ethanolic extract of P. vulgaris. To further evaluate the mechanism(s) 
associated with the attenuation of mucosal inflammation, microarray analysis was 
performed in order to identify differential gene regulation between disease 
phenotypes (healthy mice and colitic mice) and treatment groups (mdr1a-/- and 
FVBWT mice treated with vehicle, metronidazole, and P. vulgaris). Disease 
phenotype was determined “healthy” if microscopic and macroscopic scores were 
within the standard deviation of vehicle-treated FVBWT mice ( < 2). At the extremes, 
it was observed that no vehicle treated mdr1a-/- mice were characterized as “healthy” 
and no metronidazole treated mdr1a-/- or FVBWT mice were characterized as “colitic” 
(data not shown). Genes modulating the production of Ccl2, Cxcl1, Cxcl9, IL-1α, 
Mmp10, TNFα , VCAM-1, Ccl20 and IL-2 were all downregulated more than 2-fold 
by P. vulgaris prophylaxis in  mdr1a-/- mice that did not develop colitis (Table 3). In 
mdr1a-/- mice that remained healthy, the ethanolic extract of P. vulgaris 
downregulated the expression of  TNFα-specific mRNA  better than metronidazole. 
Out of 84 genes queried, 44 genes were differentially expressed in at least one 
comparison (Supplementary Table 3). P. vulgaris, but not metronidazole, effectively 
downregulates expression of several adaptive gene targets from NF-κB, nuclear 
factor of activated T cells (NFAT) and protein kinase C (PKC) pathways in mdr1a-/- 
mice. 
Influence of P. vulgaris on local T cell and B cell populations. Innate 
signaling, inflammatory cytokines and chemokines as well as innate inflammatory 
cells can impact development of adaptive immune responses. Local mucosal T cell 
and B cell populations in the cecal tonsils of mdr1a-/- and FVBWT mice were 
recovered in order to evaluate the effects of P. vulgaris prophylaxis on local 
lymphocyte populations (Fig 6 and 7). Severe colitis in vehicle-treated mdr1a-/- mice 
resulted in a 3-fold increase in CD4+ T cells (Fig. 6A) and a 6-fold increase in CD8ß+ 
T cells (Fig. 6B) in the cecal tonsil as compared to vehicle gavaged FVBWT mice. P. 
vulgaris prophylaxis significantly (p < 0.05) reduced numbers of  CD4+ and CD8+ T 
cells in the cecal tonsils of mdr1a-/- mice, while metronidazole treated mdr1a-/- mice 
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displayed baseline cecal tonsil T cell numbers (Fig. 6, A and B). Interestingly, both 
P. vulgaris and metronidazole reduced the percentage of CD4+ and CD8+ T cells in 
FVBWT mice by 47% and 64% (CD4+) and 63% and 59% (CD8+), respectively (Fig. 
6C).  
Vehicle-treated mdr1a-/- mice exhibited a 2-fold increase in CD19+ B cells 
(Fig. 7A) and a 2.5-fold increase in PNA+B220+ germinal center B cells (Fig. 7B) in 
the cecal tonsil as compared to vehicle gavaged FVBWT mice. Remarkably, P. 
vulgaris treatment increased CD19+ B cells in the cecal tonsils of mdr1a-/- and 
FVBWT mice (Fig. 7, A and C), but significantly (p < 0.05) decreased PNA+B220+ 
germinal center B cells in mdr1a-/- mice (Fig. 7B). Metronidazole significantly 
reduced CD19+ and PNA+B220+ germinal center B cells in both mdr1a-/- (p < 0.05 
and p < 0.01, respectively) and FVBWT (p < 0.001) mice (Fig 7). Therapeutically 
administered P. vulgaris did not affect the numbers of T cells or B cells in the cecal 
tonsil in comparison to those of vehicle-treated mdr1a-/- mice (Supplementary Fig. 2). 
P. vulgaris prophylaxis reduces CD4+ T cell, CD8+ T cell and PNA+B220+ germinal 
center B cell populations in the cecal tonsils of mdr1a-/- mice.  
P. vulgaris prevents antigenic responses to some members of the 
resident microbiota. Antigenic responses to the resident microbiota have been 
noted in IBD patients and in murine models of IBD (50, 79). These Ab responses are 
indicative of a loss of mucosal integrity and immune tolerance to the microbiota that 
do not occur in healthy humans or mice. Pooled serum samples from mdr1a-/- mice 
treated with P. vulgaris were evaluated by immunoblot analysis against WCS 
antigens from members of the microbiota (Fig. 8). As anticipated, sera from FVBWT 
mice did not display antibody reactivity against  bacterial antigens suggesting that 
these mice maintained tolerance to the microbiota. PCR did previously confirm the 
presence of these members of the microbiota in FVBWT mice (data not shown). 
Conversely, sera from mdr1a-/- mice did contain reactive antibodies to each of the 
bacterial WCS, indicating a loss of immunologic tolerance to the microbiota. Sera 
from both P. vulgaris and metronidazole treated mdr1a-/- mice displayed little to no 
detectible antigenic response to the WCS.  
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Discussion 
As the long term safety and efficacy of current parenteral therapeutics for IBD 
are in question and antibiotics are deemed more and more unreliable for consistent 
use in IBD patients, the need for new therapies and complementary treatments are 
ever growing (21, 76). Nutraceutical remedies hold realistic potential in treating or 
supplementing treatment of inflammatory disorders, as the anti-inflammatory and 
antioxidant benefits of plant-derived components like flavonoids, polyphenols, and 
triterpenoids are evidenced more extensively (30, 39, 67, 75, 88). Prunella vulgaris, 
already popular in Asian medicine, is a viable candidate for study as a therapeutic 
agent in the treatment of IBD as it contains several anti-inflammatory, 
immunomodulatory, and antioxidant flavonoids, polyphenols, and triterpenoids and 
has no documented toxic side-effects (8, 57, 67, 84-86). Recently rosmarinic acid, 
the most plentiful phenolic compound found in P. vulgaris, was found to protect mice 
against the deleterious effects associated with sepsis by downregulating 
inflammatory genes in the NF-κB pathway and the related inflammatory cytokines 
TNFα and IL-6 (25).  
The mdr1a-/- model of spontaneous colitis is ideal for study of potential IBD 
therapeutics relevant to human medicine as mdr1a-/- mice are immunocompetent, 
develop spontaneous colitis in the context of a leaky intestinal epithelium exhibit 
cytokine profiles and immune responses similar to those documented in clinical IBD 
cases (4, 6, 43, 52, 58, 64, 80). In current studies,  prophylactic treatment of mdr1a-/- 
mice with an ethanolic extract of P. vulgaris was found to attenuate macroscopic 
lesions associated with the characteristic severe typhlocolitis  observed in this model 
(Fig. 1 and 2). Ceca of mdr1a-/- mice treated with a P. vulgaris extract retained 
normal mucosal architecture, lacked enlarged lymphoid aggregates, and retained 
luminal contents without the presence of blood or mucus, unlike vehicle-treated 
mdr1a-/- mice. Colons of botanical-treated mdr1a-/- mice were similarly improved in 
comparison to sham treatment with regard to presence of formed feces, and lack of 
gross tissue edema and rigidity (Fig. 1). P. vulgaris did not markedly improve colon 
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lengths in mdr1a-/- mice nor did the extract attenuate the microscopic lesions scored 
in the colon (Table 1). There was significantly less evidence of microscopic lesion 
formation observed in the cecum of mice treated with the extract compared to the 
vehicle-treated mdr1a-/- mice.  This highlights the difference between colonic and 
cecal compartments. Perhaps this is due to the overwhelming concentration of 
microflora in this organ, which could more efficiently metabolize the extract, 
revealing active metabolic byproducts that might be more bioavailable to the host. 
Similar to previously published studies, onset of disease in vehicle-treated mdr1a-/- 
mice was observed, at roughly 10 weeks of age (Fig. 3) (52). Onset of colitis was 
delayed by treatment with the P. vulgaris extract as evidenced by the fact that 30% 
fewer mice developed severe colitis by 20 weeks of age. Limitations of the P. 
vulgaris extract could be due to the focused cecal benefit of extract therapy, or 
perhaps further dose titration or treatment schedule is required for more inclusive 
typhlocolitic benefit. 
While the etiology of IBD is still ill-defined, it is recognized that the inductive 
phase of colitis involves a compromised intestinal epithelium and activation of innate 
immune responses that include neutrophil activation, transmigration, and enzymatic 
damage to host tissues (12, 16, 17, 34, 37). Flavonoids from licorice have been 
shown to inhibit neutrophil infiltration into lung tissue after lippopolysaccharide-
induced inflammation, and reduce the severity of associated inflammatory damage 
to host airway tissues (81). Similarly, the P. vulgaris ethanolic extract greatly 
attenuated neutrophil infiltration into the cecal mucosa in 62% of extract treated 
mdr1a-/- mice (Table 1). Reduction of the neutrophil infiltrate in these mice was 
associated with significantly improved microscopic scores and a corresponding and 
significant decrease in MPO activity (Table 1, Fig. 4 and 5 ). MPO enzymatic activity 
is a known correlate to intestinal damage and is used as a marker of IBD severity in 
many models of colitis (2, 7, 15, 38, 41).  
Since neutrophils are not resident in the tissues, cytokine and chemokine 
signals produced by epithelial cells and local macrophages are responsible for 
transmigration of neutrophils to the sight of tissue distress (20, 31). Homeostatic 
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production of these innate chemokines are central to mucosal health while over 
production contributes to the development of severe inflammation in colitis (12, 34, 
53).  Debate regarding the role of NF-κB and innate immune cells in acute intestinal 
inflammatory models continues, with some research pointing to a protective effect by 
these components and others revealing a deleterious effect (28, 32, 46, 55). Many, 
however, agree that dysregulation of NF-κB and its related innate cellular responses 
are causative factors in the inductive phase and maintenance of chronic models of 
colitis and in human CD and UC (29, 47, 63). Pro-inflammatory targets of NF-κB 
have been found to be abnormally upregulated in CD and UC patients (35). Nuclear 
translocation of NF-κB in epithelial cells and local monocytes upregulates production 
of pro-inflammatory cytokines and chemokines like TNFα, IL-1β, KC and MIG. These 
cytokines increase expression of adhesion molecules (i.e. VCAM and ICAM) on 
endothelial cells while chemokines create the chemical gradients to attract 
neutrophils and other innate inflammatory cells to the sight of injury (12, 20, 40, 53). 
Regulation of cytokines (TNFα, IL-1α, IL-1β) which increase expression of adhesion 
molecules on endothelial cells, reduced production of cytokines (IFNγ) which 
upregulate chemokine production and downregulation of inflammatory monocyte-
derived or neutrophil chemotactic factors (IL-8/KC and VEGF) have been shown to 
reduce inflammatory tissue damage in several disease models, including colitis (25, 
46, 61, 74). Cytokine and chemokine production observed in aged-matched and 
sham-treated mdr1a-/- mice in the current study (Table 2) was consistent with that 
previously reported (43). Serum samples from mdr1-/- mice treated with the ethanolic 
extract of P. vulgaris had significantly lower levels of cytokines that would contribute 
to the production of granulocytes and monocytes (G-CSF and GM-CSF) as well as 
the neutrophil chemotactic factor KC (Table 2). Importantly, prophylaxis with the P. 
vulgaris extract reduced serum levels of TNFα (Table 2), a cytokine known to be a 
key regulator of inflammatory responses in colitis (78). This data implies that P. 
vulgaris extract reduced the chronic production of cytokines and chemokines which 
are critical in maintaining the chronicity of inflammatory cell infiltration. Maintenance 
of the delicate balance  between effective and deleterious inflammation in the gut is 
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imperative, and current IBD therapies, like monoclonal antibodies to TNFα,  have 
been shown to interfere with the beneficial functions of TNF, leaving patients 
vulnerable to secondary infections or inducing hypersensitivity (68).   
Many studies have linked the activation of the transcription factor NF-κB and 
the regulation of gene expression to the chronicity of inflammation associated with  
IBD (26, 29, 47, 63). Recent studies have shown that flavonoids are capable of 
downregulating NF-κB, which is responsible for the gene regulation leading to 
production of innate chemotactic factors and pro-inflammatory cytokines (71, 73). 
One such study showed that the flavonoid luteolin decreased NF-κB expression in 
the ceca of IL-10-/- mice, and effectively ameliorated spontaneous cecitis (28). 
Similarly, the ethanolic extract of P. vulgaris, which is known to contain several 
flavonoids (data not shown), downregulated expression of chemokine genes (Ccl2, 
Cxcl1/KC, Cxcl9/MIG, and Ccl20) and genes involved in increased expression of 
adhesion molecules (VCAM-1, ICAM, TNFα and IL-1α) and tissue remodeling to 
allow for inflammatory cell transmigration (MMP-10) (Table. 3. All of these genes 
participate in activation of or are regulated by NF-κB (1, 27, 62, 69, 87, 89). Clearly, 
the ethanolic extract of P. vulgaris attenuates neutrophil recruitment in the cecal 
tissues of mdr1a-/- mice by downregulating gene expression of targets regulated by 
NF-κB signaling. The importance of regulating inflammation in mdr1a-/- mice, and in 
other colitic models, is underscored by recent data showing that regulation of 
inflammatory gene expression is altered in mdr1a-/- mice and in mice treated with 
dextran sodium sulfate (DSS) prior to any histologic signs of inflammation (13, 56). 
Since defects in gene expression precede inflammation, perhaps this suggests an 
advantage of prophylactic approaches to control IBD rather than therapy at flare 
onset. In the current study, it was demonstrated that initiation of the treatment with 
the ethanolic extract of P. vulgaris after the appearance of clinical signs of colitis was 
ineffective at reducing the severity of inflammation (Supplementary Tables 1 and 2, 
Supplementary Fig.1 and 2 ). This observation supports the current mechanistic 
hypothesis that the ethanolic extract of P. vulgaris is modulating innate inflammatory 
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gene expression in mdr1a-/- mice, as treatment must begin at a time prior to onset of 
inflammation.  
Adaptive immune responses play a part in the chronicity and severity of colitic 
disease in experimental models and in humans with IBD. Aberrant CD4+ T cell 
responses to antigens derived from the resident microbiota have been implicated in 
the pathogenesis of IBD (14, 50). It should, however, not be forgotten that innate cell 
signaling during the inductive phase of IBD has an impact on the chronicity of IBD 
and on the development and activity of adaptive immune responses  The ethanolic 
extract of P. vulgaris prevented neutrophil transmigration into the cecal tissues of 
mdr1a-/- mice, and serum cytokine and chemokine data indicates decreased 
production of IP-10, MIG, MIP-1β, IL-6, IL-9, IFNγ, and TNFα (Table 2). IP-10, MIG 
and MIP-1β are interferon-inducible proteins (27, 33). IP-10 and MIG are 
chemotactic for T cells, while MIP-1β stimulates neutrophil and macrophage 
production of IL-6, TNFα, and IL-1ß. These cytokines and chemokines participate in 
inflammatory feedback loops that may be interrupted by treatment with the ethanolic 
extract of P. vulgaris. The observation that there are reduced numbers of CD4+ and 
CD8+ T cells in the cecal tonsils of mdr1a-/- mice (Fig. 6) are consistent with the 
reduction in the serum levels of IP-10 and MIG. Treatment with the ethanolic extract 
of P. vulgaris reduced serum IL-6 in mdr1a-/- mice (Table 2). IL-9 has been shown to 
enhance proliferation of CD4+ T cells (42) and the production of this cytokine is 
decreased by the  P. vulgaris extract in the current study (Table 2). Additional 
evidence for the secondary effect of treatment with the P. vulgaris extract on T cell 
chemotaxis would be consistent with the  decreased expression of genes regulating 
MIG, Ccl2, IL-1α, TNFα, and Ccl20 in extract treated mdr1a-/- mice (Table 3 and 4). 
Ccl20 is strongly chemotactic for immature dendritic cells, which would mature upon 
collecting antigen in the tissues, present that antigen to T cells, and stimulate an 
adaptive immune response (22). Moreover, mice treated with the P. vulgaris extract 
had decreased gene expression of IL-2 (Table 4), a cytokine responsible for CD8+ T 
cell differentiation and survival as well as memory T cells (66). The reduction of IL-2 
gene expression is possibly due to a reduction in local CD4+ T cells and, therefore, 
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less IL-2 production. Perhaps this is the causative factor in the reduced presence of 
both CD4+ and CD8+ T cells in the cecal tonsils of mdr1a-/- mice treated with extract. 
This observation could contribute to the reduced serum antibody response to 
microfloral antigens in P. vulgaris treated mdr1a-/- mice (Fig. 8). While T regulatory 
cell populations were not assessed in this study, it is possible that P. vulgaris 
extracts could affect T effector cell function through modulation of T regulatory cell 
activity. 
Dendritic cell antigen presentation and T cell help is responsible for B cell 
proliferation, maturation, and antibody production. Germinal centers in lymphoid 
tissues, an important component of the B cell humoral response, develop upon B 
cell activation by T dependant antigen (5). Germinal center B cells bind peanut 
agglutinin (PNA) and are B220/CD45R+ (10). This study illustrates that while CD19+ 
B cells are slightly increased in number in the cecal tonsils of mdr1a-/- mice treated 
with the P. vulgaris extract, the number of PNA+B220+ B cells were significantly less 
than that detected in the vehicle-treated mdr1a-/- mice (Fig. 7). The impact of this 
arrest in B cell maturation is functionally relevant, as evidenced by the lack of 
antibody production to bacterial antigens in P. vulgaris treated mdr1a-/- mice (Fig. 8). 
Collectively, these data present evidence that the ethanolic extract of P. vulgaris 
acts to maintain immunologic tolerance to the host microbiota and preserve mucosal 
homeostasis in mdr1a-/- mice by regulating gene expression associated with innate 
immunity and subsequently attenuating the activation of the adaptive immune 
response. This work highlights the need for further study and consideration of P. 
vulgaris as a legitimate prophylactic or supplementary option for the treatment of IBD 
and other chronic inflammatory disorders. 
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Figure 1. Photographs of the cecum from mice treated prophylactically with 
Prunella vulgaris. Male mdr1a-/- mice were treated with oral 5% EtOH vehicle (n = 
16), 0.075 mg/mL metronidazole (n = 10) or 2.4mg P. vulgaris extract (n = 13) daily 
as described in methods. FVBWT mice were also represented in each treatment 
group (n = 6 per group). Images are representative of two independent experiments. 
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Figure 2. Macroscopic assessment of colitis in mdr1a-/- mice treated with 
Prunella vulgaris. A) Macroscopic typhlocolitic scores of mdr1a-/- and FVBWT mice 
treated with vehicle, metronidazole or P. vulgaris extract as described in Materials 
and Methods (Max/Severe = 9, Min/Healthy = 0.) B) Colon lengths of mdr1a-/- and 
FVBWT mice treated with vehicle, metronidazole or P. vulgaris extract were 
measured at necropsy and the group range is represented. Whiskers indicate 
minimum and maximum values, while the horizontal line represents the group 
median. *p < 0.05, **p < 0.01, ***p < 0.001 compared to mdr1a-/- vehicle. The n for 
each group is the same as noted in Figure 1 and data is representative of two 
independent experiments.  
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Figure 3.  The percent of mdr1a-/- mice remaining on study. The mdr1a-/- mice 
were removed from the study as they developed severe colitis or at the termination 
of the experiment as described in Materials and Methods.*p < 0.05, **p < 0.01, ***p 
< 0.001 compared to mdr1a-/- vehicle. This adapted survival curve is representative 
of two separate experiments. 
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Microscopic 
Parameter 
VWT 
(n = 6) 
MWT 
(n = 6) 
PVWT 
(n = 6) 
V-/- 
(n = 16) 
M-/- 
(n = 10) 
PV-/- 
(n = 13) 
Mucosal Height 
(µM) 3.5 ± 0.2** 3.0 ± 0.0*** 3.3 ± 0.2** 4.6 ± 0.2 3.5 ± 0.2** 3.9 ± 0.2* 
Ulceration 0.2 ± 0.2** 0.0 ± 0.0*** 0.0 ± 0.0*** 1.9 ± 0.3 0.0 ± 0.0*** 1.2 ± 0.4 
Inflammation 1.3 ± 0.2** 1.0 ± 0.0** 1.0 ± 0.0** 3.6 ± 0.2 1.7 ± 0.3*** 2.5 ± 0.4* 
Edema 0.7 ± 0.5* 1.8 ± 0.2 3.0 ± 0.4 2.4 ± 0.3 0.8 ± 0.3** 0.9 ± 0.3** 
Stromal Collapse 
(Necrosis) 0.0 ± 0.0* 0.0 ± 0.0* 0.0 ± 0.0* 1.7 ± 0.4 0.0 ± 0.0** 0.5 ± 0.4* 
Gland Hyperplasia 1.2 ± 0.2** 1.7 ± 0.2** 1.0 ± 0.0** 2.8 ± 0.2 1.9 ± 0.3* 2.1 ± 0.3* 
Additive Cecal 
Score 6.9 ± 0.9** 7.5 ± 0.3** 8.3 ± 0.5** 17.0 ± 1.2 7.9 ± 0.9*** 11.1 ±1.5** 
% Mice Exhibiting 
Cecal 
Neutrophil 
Infiltrate 
0% 0% 0% 100% 10% 38% 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, PVWT = Prunella 
vulgaris  treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated mdr1a-
/-
 mice, PV-/- = Prunella vulgaris treated mdr1a-/- mice. Data are expressed as the mean ± SEM. Statistical 
significance is noted in three levels:  * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
 
Table 1. Prunella vulgaris prophylaxis significantly decreases cecal 
histologic/microscopic damage associated with severe typhlocolitis in mdr1a-/- 
mice, and decreases the occurrence of neutrophil influx associated with 
histologic inflammation. Cecal sections collected from mdr1a-/- and FVBWT mice 
treated with vehicle, metronidazole or Prunella vulgaris extract at the time of 
necropsy were formalin fixed, paraffin embedded and subject to routine hematoxylin 
and eosin staining. Stained histologic sections were scored for inflammation by a 
pathologist blinded to the treatments. The additive cecal score is based on the 
addition of mucosal height (µm) to the collective scores for ulceration, inflammation, 
edema, necrosis and gland hyperplasia. Scores for ulceration, Inflammation, edema, 
necrosis and gland hyperplasia were scored on a 0 (normal) to 5 (severe) scale. 
Average values are shown here ± standard error of the mean (SEM) except where 
noted. *p < 0.05, **p < 0.01, ***p < 0.001 compared to mdr1a-/- vehicle. Mucosal 
heights were subject to parametric unpaired t-test, while microscopic scores were 
subject to non-parametric, Mann-Whitney t-test. Statistical analysis was performed 
using GraphPad Prism 5. Data are representative of two separate experiments. 
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Figure 4. Prunella vulgaris protects cecal microscopic architecture in mdr1a-/- 
mice and decreases inflammatory cell infiltrate. Representative 
photomicrographs (200x) of cecal sections collected from mdr1a-/- and FVBWT mice 
treated with vehicle, metronidazole or Prunella vulgaris extract at the time of 
necropsy were formalin fixed, paraffin embedded and subject to routine hematoxylin 
and eosin staining. FVBWT ceca of all treatments are characterized by normal 
mucosal architecture and height, intact glands, little to no mucosal or submucosal 
edema, and normal resident populations of mononuclear cells. In contrast, diseased 
mdr1a-/- ceca exhibit mucosal and glandular hyperplasia, transmural ulceration and 
inflammation, as well as stromal necrosis and an inflammatory population of 
neutrophils. P. vulgaris and metronidazole treated mdr1a-/- ceca are significantly 
improved toward the normal wild type condition. 
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Figure 5. Metronidazole and P. vulgaris reduce local myeloperoxidase (MPO) 
activity in the colon of mdr1a-/- mice. Homogenates of colonic tissue were used to 
assay for MPO activity. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared to 
mdr1a-/- vehicle. 
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Cytokine/ 
Chemokine 
VWT 
(n = 6) 
MWT 
(n = 6) 
PVWT 
(n = 6) 
V-/- 
(n = 16) 
M-/- 
(n = 10) 
PV-/- 
(n = 13) 
G-CSF 140 ± 15*** 132 ± 14*** 99 ± 9*** 9694 ± 2563 622 ± 199* 4597 ± 1931* 
GM-CSF 0 ± 0* 0 ± 0* 0 ± 0* 21 ± 11 4 ± 3 2 ± 2* 
IFNγ 0 ± 0 0 ± 0 0 ± 0 8 ± 4 6 ± 3 4 ± 2 
IL-6 0 ± 0 0 ± 0 0 ± 0 59 ± 28 9 ± 3 49 ± 40 
IL-7 1 ± 1* 1 ± 1* 1 ± 1* 28 ± 11 3 ± 2 47 ± 21 
IL-9 78 ± 27* 118 ± 21 129 ± 34 200 ± 38 130 ± 23 118 ± 14* 
IL-10 0 ± 0** 0 ± 0** 0 ± 0** 19 ± 4 6 ± 2* 5 ± 2** 
IL-12(p40) 0 ± 0 0 ± 0 0 ± 0 70 ± 37 167 ± 59 164 ± 56 
IL-12(p70) 0 ± 0 0 ± 0 0 ± 0 21 ± 8 13 ± 6 14 ± 7 
IL-17 4 ± 2* 3 ± 2* 0 ± 0*** 16 ± 4 1 ± 1*** 18 ± 13 
IP-10 8 ± 6*** 84 ± 43*** 14 ± 10*** 724 ± 136 280 ± 74* 397 ± 85* 
KC 70 ± 24** 85 ± 10** 140 ± 61* 527 ± 119 232 ± 67* 253 ± 58* 
MIG 109 ± 37*** 403 ± 136*** 113 ± 35*** 3901 ± 858 1499 ± 564* 1319 ± 277* 
MIP-1β 48 ± 8 70 ± 5 72 ± 10 57 ± 8 57 ± 8 46 ± 9 
TNFα 9 ± 0** 9 ± 0** 9 ± 0** 15 ± 2 7 ± 2*** 10 ± 3* 
VEGF 1 ± 1 0 ± 0 0 ± 0 13 ± 6 11 ± 4 3 ± 1 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, PVWT = Prunella 
vulgaris treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated mdr1a-/- 
mice, PV-/- = Prunella vulgaris treated mdr1a-/- mice. Data are expressed as the mean serum 
cytokine/chemokines content (pg/mL) ± SEM. Statistical significance is noted in three levels:  * = P < 0.05, ** = P 
< 0.01, *** = P < 0.001. 
 
Table 2. Prunella vulgaris prophylaxis reduces serum content of several 
chemotactic and inflammatory cytokines associated with severe typhlocolitis 
in mdr1a-/- mice. Serum collected at necropsy from mdr1a-/- and FVBWT mice 
treated with vehicle, metronidazole or P. vulgaris subjected multiplex flow cytometric 
bead analysis for chemokine and cytokine concentrations using a 32-plex mouse 
chemokine/cytokine kit. Only cytokines and chemokines which were detectible in at 
least one treatment group are represented above. Average serum concentrations 
(pg/mL) are shown here ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, 
***p < 0.001 compared to mdr1a-/- vehicle. Concentrations were subject to non-
parametric, Mann-Whitney t-test. Statistical analysis was performed using GraphPad 
Prism 5. Data are representative of two separate experiments. 
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Fold change compared to diseased 
 vehicle treated mdr1a-/- mice (n = 12) 
Gene 
Target 
Pathway 
Affiliation 
VWT 
Healthy 
(n = 6) 
M-/- 
Healthy 
(n = 9) 
PV-/- 
Healthy 
(n = 10) 
PV-/- 
Colitic 
(n = 3) 
Ccl2 NF-κB, LDL -7.3 -2.6 -3.4 -1.1 
Cxcl1 NF-κB -11.3 -3.8 -7.2 -1.0 
Cxcl9 NF-κB, Jak/Stat -23.9 -2.3 -4.2 -1.1 
ICAM-1 NF-κB, Phospholipase C -3.2 -1.6 -1.2 1.8 
IL-1α NF-κB -13.4 -5.5 -8.0 1.3 
Mmp10 NF-κB, Jak/Stat -6.6 -3.4 -8.5 1.2 
TNFα NF-κB -10.2 -1.8 -2.6 1.2 
VCAM-1 NF-κB, Phospholipase C, LDL -3.8 -2.4 -2.0 1.2 
Ccl20 NF-κB -3.6 -1.9 -2.0 1.4 
IL-2 NF-κB, NFAT, Calcium, PKC -3.7 -1.9 -2.2 -1.5 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, M-/- = Metronidazole treated mdr1a-/- mice, PV-/- = Prunella 
vulgaris treated mdr1a-/- mice. Healthy denotes mice with a macroscopic score of < 2. Colitic denotes mice with a 
macroscopic disease score of 2 or >. Data are expressed as Fold changes compared to colitic vehicle treated 
mdr1a-/- mice.  
 
Table 3. Fold change in gene expression of gene targets in healthy and colitic 
mice compared to colitic vehicle treated mdr1a-/- mice. 
Cecal tissue total RNA from mdr1a-/- (healthy and colitic) and FVBWT mice (healthy) 
treated with vehicle, metronidazole or Prunella vulgaris was converted to cDNA and 
subjected to gene expression analysis using the Signal Transduction Pathway 
Finder RT2 PCR array system. Gene target names, signaling pathway involvement 
and fold change compared to mdr1a-/- vehicle are noted above. Fold changes were 
calculated relative to house keeping genes in SAbiosciences’ RT2 PCR array 
analysis software for the Signal Transduction Pathway Finder 96-well format array. (-
) indicates downregulation from control. Data are representative of two separate 
experiments. 
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Figure 6. Evaluation of CD4+ and CD8+ T cell subsets in the cecal tonsil 
lymphoid tissues of mdr1a-/- mice treated with P. vulgaris. Cecal tonsils were 
excised at necropsy, single cell suspensions prepared and stained for flow 
cytometric analysis as described in materials and methods. A) Numbers of CD4+ T 
cells in the cecal tonsil, B) Numbers of CD8ß+ T cells in the cecal tonsil, C) Dot plots 
of percentages of CD4+ and CD8ß+ T cells in the cecal tonsil. *p < 0.05, **p < 0.01, 
***p < 0.001 compared to mdr1a-/- vehicle. Flow cytometric data was analyzed using 
FlowJo software and statistical analysis was performed using GraphPad 5. The n for 
each group is equal to that noted in fig. 1 and data is representative of two 
independent experiments.   
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Figure 7. Modulated populations of CD19+ B cells and PNA+B220+ germinal 
center B cells in the cecal tonsil lymphoid tissues of mdr1a-/- mice treated with 
P. vulgaris extract compared to vehicle treated mdr1a-/- controls. Cecal tonsils 
were removed at necropsy, homogenized and stained for flow cytometric analysis as 
described in materials and methods with anti-CD19, peanut agglutinin (PNA) and 
anti-B220. A) Relative numbers of CD19+ B cells in the cecal tonsil. B) Relative 
numbers of PNA+B220+ germinal center B cells in the cecal tonsil C) Percentages of 
CD19+ B cells in the cecal tonsil. *p < 0.05, **p < 0.01, ***p < 0.001 compared to 
mdr1a-/- vehicle. Flow cytometric data was analyzed using FlowJo software and 
statistical analysis was performed using GraphPad 5. The n for each group is equal 
to that noted in fig. 1 and data is representative of two independent experiments. 
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Figure 8. Vehicle treated mdr1a-/- mice with severe colitic inflammation 
developed serum antibody responses to antigens derived from microflora 
members of the clostridial cluster XIVa, while those treated with metronidazole 
and P. vulgaris extract did not. Whole cell sonicates of each of three clostridial 
species found as part of the enteric microflora were subjected to SDS-PAGE. 
Western blot analysis was performed using anti-sera collected at necropsy. Antigens 
in lanes represented in each blot are as follows from left to right:  ASF502, ASF500, 
ASF356. 
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Supplementary Figure 1. Mdr1a-/- mice treated therapeutically with the 
ethanolic extract of P. vulgaris, beginning at visible colitic onset, improves 
typhlocolitic score, but does not improve colon lengths or MPO activity 
associated with severe spontaneous colitis in mdr1a-/- mice.  
A) Gross/macroscopic additive typhlocolitic score. Additive score parameters 
included cecal atrophy, enlarged lymphoid aggregate/s, cecal emptying, presence of 
watery/mucoid cecal or colon contents, cecal blood, colonic blood, cecal thickening, 
colonic thickening and lack of formed fecal pellets. Max/Severe = 9, Min/Healthy = 0. 
B) Colon lengths of mdr1a-/- and FVBWT mice treated with vehicle, metronidazole or 
P. vulgaris extract were measured at necropsy and the group range is represented. 
Whiskers indicate minimum and maximum values, while the center bar represents 
the group median. C) Colonic tissues collected at necropsy were subjected to 
colorimetric assay for MPO activity. *p < 0.05, **p < 0.01, ***p < 0.001 compared to 
mdr1a-/- vehicle. Colon lengths and MPO were subject to parametric unpaired t-test, 
while typhlocolitic scores were subject to non-parametric, Mann-Whitney t-test. 
Statistical analysis was performed using GraphPad Prism 5. Data is representative 
of two separate experiments. 
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Microscopic 
Parameter 
VWT 
(n = 6) 
V-/- 
(n = 16) 
Prophylactic 
PV-/- 
(n = 13) 
Therapeutic 
PV-/- 
(n = 7) 
Mucosal Height 
(µM) 3.5 ± 0.2** 4.6 ± 0.2 3.9 ± 0.2* 4.3 ± 0.2 
Ulceration 0.2 ± 0.2** 1.9 ± 0.3 1.2 ± 0.4 1.5 ± 0.4 
Inflammation 1.3 ± 0.2** 3.6 ± 0.2 2.5 ± 0.4* 3.5 ± 0.4 
Edema 0.7 ± 0.5* 2.4 ± 0.3 0.9 ± 0.3** 2.3 ± 0.3 
Stromal Collapse 
(Necrosis) 0.0 ± 0.0* 1.7 ± 0.4 0.5 ± 0.4* 1.4 ± 0.4 
Gland Hyperplasia 1.2 ± 0.2** 2.8 ± 0.2 2.1 ± 0.3* 2.8 ± 0.3 
Additive Cecal 
Score 6.9 ± 0.9** 17.0 ± 1.2 11.1 ±1.5** 15.6 ±0.5 
% Mice Exhibiting 
Cecal 
Neutrophil 
Infiltrate 
0% 100% 38% 88% 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, PVWT = Prunella 
vulgaris treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated mdr1a-/- 
mice, PV-/- = Prunella vulgaris treated mdr1a-/- mice. Data are expressed as the mean serum 
cytokine/chemokines content (pg/mL) ± SEM. Statistical significance is noted in three levels:  * = P < 0.05, ** = P 
< 0.01, *** = P < 0.001 
 
Supplementary Table 1. P. vulgaris dosed therapeutically does not improve 
cecal histologic/microscopic damage or neutrophil infiltrate associated with 
severe typhlocolitis in mdr1a-/- mice.  
Cecal sections collected from mdr1a-/- and FVBWT mice treated with vehicle, 
metronidazole or Prunella vulgaris extract at the time of necropsy were formalin 
fixed, paraffin embedded and subject to routine hematoxylin and eosin staining. 
Stained histologic sections were scored for inflammation by a pathologist blinded to 
the treatments. The additive cecal score is based on the addition of mucosal height 
(µm) to the collective scores for ulceration, inflammation, edema, necrosis and gland 
hyperplasia. Scores for ulceration, Inflammation, edema, necrosis and gland 
hyperplasia were scored on a 0 (normal) to 5 (severe) scale. Average values are 
shown here ± standard error of the mean (SEM) except where noted. *p < 0.05, **p 
< 0.01, ***p < 0.001 compared to mdr1a-/- vehicle. Mucosal heights were subject to 
parametric unpaired t-test, while microscopic scores were subject to non-parametric, 
Mann-Whitney t-test. Statistical analysis was performed using GraphPad Prism 5. 
Data are representative of two separate experiments.  
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Cytokine/ 
Chemokine 
VWT 
(n = 6) 
V-/- 
(n = 16) 
Prophylactic 
PV-/- 
(n = 10) 
Therapeutic 
PV-/- 
(n = 7) 
G-CSF 140 ± 15*** 9694 ± 2563 622 ± 199* 5512 ± 1707 
GM-CSF 0 ± 0* 21 ± 11 4 ± 3 8 ± 6 
IFNγ 0 ± 0 8 ± 4 6 ± 3 19 ± 2 
IL-6 0 ± 0 59 ± 28 9 ± 3 197 ± 144 
IL-7 1 ± 1* 28 ± 11 3 ± 2 56 ± 30 
IL-9 78 ± 27* 200 ± 38 130 ± 23 115 ± 26* 
IL-10 0 ± 0** 19 ± 4 6 ± 2* 10 ± 4 
IL-12(p40) 0 ± 0 70 ± 37 167 ± 59 74 ± 36 
IL-12(p70) 0 ± 0 21 ± 8 13 ± 6 24 ± 7 
IL-17 4 ± 2* 16 ± 4 1 ± 1*** 14 ± 5 
IP-10 8 ± 6*** 724 ± 136 280 ± 74* 497 ± 72 
KC 70 ± 24** 527 ± 119 232 ± 67* 326 ± 155 
MIG 109 ± 37*** 3901 ± 858 1499 ± 564* 1999 ± 146 
MIP-1β 48 ± 8 57 ± 8 57 ± 8 59 ± 9 
TNFα 9 ± 0** 15 ± 2 7 ± 2*** 11 ± 3 
VEGF 1 ± 1 13 ± 6 11 ± 4 3 ± 3 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, PVWT = Prunella 
vulgaris treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated mdr1a-/- 
mice, PV-/- = Prunella vulgaris treated mdr1a-/- mice. Data are expressed as the mean serum 
cytokine/chemokines content (pg/mL) ± SEM. Statistical significance is noted in three levels:  * = P < 0.05, ** = P 
< 0.01, *** = P < 0.001. 
 
Supplementary Table 2. P. vulgaris dosed therapeutically does not reduce 
serum content of chemotactic and inflammatory cytokines associated with 
severe typhlocolitis in mdr1a-/- mice, with the exception of IL-9. Serum collected 
at necropsy from mdr1a-/- and FVBWT mice treated with vehicle, metronidazole or 
Prunella vulgaris subjected multiplex flow cytometric bead analysis for chemokine 
and cytokine concentrations using a 32-plex mouse chemokine/cytokine kit. Only 
cytokines and chemokines which were detectible in at least one treatment group are 
represented above. Average serum concentrations (pg/mL) are shown here ± 
standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001 compared to 
mdr1a-/- vehicle. Concentrations were subject to non-parametric, Mann-Whitney t-
test. Statistical analysis was performed using GraphPad Prism 5. Data are 
representative of two separate experiments.  
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Supplementary Figure 2. P. vulgaris dosed therapeutically does not decrease 
expression of CD4+ and CD8+ T cell markers or CD19+ and PNA+B220+ B cell 
numbers in the cecal tonsil lymphoid tissues of mdr1a-/- mice compared to 
vehicle treated mdr1a-/- controls. Cecal tonsils were removed at necropsy, 
homogenized and stained for flow cytometric analysis as described in materials and 
methods with anti-CD4 and anti-CD8. A) Relative numbers of CD4+ T cells in the 
cecal tonsil. B) Relative numbers of CD8+ T cells in the cecal tonsil. C) Relative 
numbers of CD19+ B cells in the cecal tonsil. D) Relative numbers of PNA+B220+ 
germinal center B cells in the cecal tonsil *p < 0.05, **p < 0.01, ***p < 0.001 
compared to mdr1a-/- vehicle. Flow cytometric data was analyzed using FlowJo 
software and statistical analysis was performed using GraphPad 5. Data is 
representative of two independent experiments. 
0
2×100 3
4×100 3
6×100 3
8×100 3
**
*
# 
CD
4 
Po
si
tiv
e 
Ce
lls
0
1×100 3
2×100 3
3×100 3
Co
n
tro
l
(V
eh
ic
le
)
Th
er
ap
eu
tic
Pr
u
n
el
la
vu
lg
ar
is
Co
n
tro
l
(V
eh
ic
le
)
FVBWT mdr1a-/-
**
*
Pr
o
ph
yla
ct
ic
Pr
u
n
el
la
vu
lg
ar
is
# 
CD
8 ββ ββ
 
Po
si
tiv
e 
Ce
lls
0
2×100 3
4×100 3
6×100 3
8×100 3
*
# 
CD
19
 P
o
s
iti
ve
 C
e
lls
0
2×100 3
4×100 3
6×100 3
8×100 3
C
o
n
tr
o
l
(V
e
hi
c
le
)
Th
e
ra
pe
u
tic
Pr
u
n
e
lla
v
u
lg
ar
is
C
o
n
tr
o
l
(V
e
hi
c
le
)
FVBWT mdr1a-/-
**
# 
B
22
0+
PN
A
+
 
C
e
lls
Pr
o
ph
yl
a
c
tic
Pr
u
n
el
la
v
u
lg
ar
is
A C 
B D 
   140 
References 
 
1. Amiri KI and Richmond A. Fine tuning the transcriptional regulation of the 
CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol 74: 1-36, 2003. 
2. Anezaki K, Asakura H, Honma T, Ishizuka K, Funakoshi K, Tsukada Y, and 
Narisawa R. Correlations between interleukin-8, and myeloperoxidase or luminol-
dependent chemiluminescence in inflamed mucosa of ulcerative colitis. Intern Med 
37: 253-258, 1998. 
3. Arseneau KO, Tamagawa H, Pizarro TT, and Cominelli F. Innate and 
adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep 9: 
508-512, 2007. 
4. Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, and Gale JD. 
Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in 
a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J 
Pharmacol 143: 590-598, 2004. 
5. Bhattacharya D, Cheah MT, Franco CB, Hosen N, Pin CL, Sha WC, and 
Weissman IL. Transcriptional profiling of antigen-dependent murine B cell 
differentiation and memory formation. J Immunol 179: 6808-6819, 2007. 
6. Bilsborough J and Viney JL. Out, out darn toxin: the role of MDR in intestinal 
homeostasis. Gastroenterology 127: 339-340, 2004. 
7. Boussetta T, Raad H, Letteron P, Gougerot-Pocidalo MA, Marie JC, Driss F, 
and El-Benna J. Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced 
neutrophil hyperactivation and protects from experimental colon inflammation in rats. 
PLoS One 4: e6458, 2009. 
8. Brindley MA, Widrlechner MP, McCoy JA, Murphy P, Hauck C, Rizshsky L, 
Nikolau B, and Maury W. Inhibition of lentivirus replication by aqueous extracts of 
Prunella vulgaris. Virol J 6: 8, 2009. 
9. Brown SJ and Mayer L. The immune response in inflammatory bowel 
disease. Am J Gastroenterol 102: 2058-2069, 2007. 
10. Butcher EC, Rouse RV, Coffman RL, Nottenburg CN, Hardy RR, and 
Weissman IL. Surface phenotype of Peyer's patch germinal center cells: implications 
for the role of germinal centers in B cell differentiation. J Immunol 129: 2698-2707, 
1982. 
11. Cheung HY and Zhang QF. Enhanced analysis of triterpenes, flavonoids and 
phenolic compounds in Prunella vulgaris L. by capillary zone electrophoresis with 
the addition of running buffer modifiers. J Chromatogr A 1213: 231-238, 2008. 
12. Cole AT, Pilkington BJ, McLaughlan J, Smith C, Balsitis M, and Hawkey CJ. 
Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of 
interleukin 8 and leukotriene B4. Gut 39: 248-254, 1996. 
13. Collett A, Higgs NB, Gironella M, Zeef LA, Hayes A, Salmo E, Haboubi N, 
Iovanna JL, Carlson GL, and Warhurst G. Early molecular and functional changes in 
colonic epithelium that precede increased gut permeability during colitis 
development in mdr1a(-/-) mice. Inflamm Bowel Dis 14: 620-631, 2008. 
   141 
14. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, and Barry S. Foxp3+ 
regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory 
bowel disease. J Clin Immunol 30: 80-89, 2010. 
15. Edwards SW and Swan TF. Regulation of superoxide generation by 
myeloperoxidase during the respiratory burst of human neutrophils. Biochem J 237: 
601-604, 1986. 
16. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, and Weaver CT. 
Experimental models of inflammatory bowel disease reveal innate, adaptive, and 
regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206: 260-
276, 2005. 
17. Gouni-Berthold I, Baumeister B, Wegel E, Berthold HK, Vetter H, and Schmidt 
C. Neutrophil-elastase in chronic inflammatory bowel disease: a marker of disease 
activity? Hepatogastroenterology 46: 2315-2320, 1999. 
18. Hilsden RJ, Scott CM, and Verhoef MJ. Complementary medicine use by 
patients with inflammatory bowel disease. Am J Gastroenterol 93: 697-701, 1998. 
19. Hsu CL, Hong BH, Yu YS, and Yen GC. Antioxidant and anti-inflammatory 
effects of Orthosiphon aristatus and its bioactive compounds. J Agric Food Chem 
58: 2150-2156, 2010. 
20. Imhof BA and Dunon D. Basic mechanism of leukocyte migration. Horm 
Metab Res 29: 614-621, 1997. 
21. Isaacs KL and Sartor RB. Treatment of inflammatory bowel disease with 
antibiotics. Gastroenterol Clin North Am 33: 335-345, x, 2004. 
22. Izadpanah A, Dwinell MB, Eckmann L, Varki NM, and Kagnoff MF. Regulated 
MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for 
modulating mucosal immunity. Am J Physiol Gastrointest Liver Physiol 280: G710-
719, 2001. 
23. Jergens AE, Dorn A, Wilson J, Dingbaum K, Henderson A, Liu Z, Hostetter J, 
Evans RB, and Wannemuehler MJ. Induction of differential immune reactivity to 
members of the flora of gnotobiotic mice following colonization with Helicobacter bilis 
or Brachyspira hyodysenteriae. Microbes Infect 8: 1602-1610, 2006. 
24. Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, 
Hostetter J, and Wannemuehler MJ. Helicobacter bilis triggers persistent immune 
reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN 
mice. Gut 56: 934-940, 2007. 
25. Jiang WL, Chen XG, Qu GW, Yue XD, Zhu HB, Tian JW, and Fu FH. 
Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory 
factor release and ameliorating hemodynamics. Shock 32: 608-613, 2009. 
26. Jobin C, Haskill S, Mayer L, Panja A, and Sartor RB. Evidence for altered 
regulation of I kappa B alpha degradation in human colonic epithelial cells. J 
Immunol 158: 226-234, 1997. 
27. Kanda N, Shimizu T, Tada Y, and Watanabe S. IL-18 enhances IFN-gamma-
induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J 
Immunol 37: 338-350, 2007. 
   142 
28. Karrasch T, Kim JS, Jang BI, and Jobin C. The flavonoid luteolin worsens 
chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of 
NF-kappaB-dependent protective molecules. PLoS One 2: e596, 2007. 
29. Karrasch T, Kim JS, Muhlbauer M, Magness ST, and Jobin C. Gnotobiotic IL-
10-/-;NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in 
commensal bacteria-induced colitis. J Immunol 178: 6522-6532, 2007. 
30. Kim JE, Son JE, Jung SK, Kang NJ, Lee CY, Lee KW, and Lee HJ. Cocoa 
polyphenols suppress TNF-alpha-induced vascular endothelial growth factor 
expression by inhibiting phosphoinositide 3-kinase (PI3K) and mitogen-activated 
protein kinase kinase-1 (MEK1) activities in mouse epidermal cells. Br J Nutr: 1-8, 
2010. 
31. Kucharzik T and Williams IR. Neutrophil migration across the intestinal 
epithelial barrier--summary of in vitro data and description of a new transgenic 
mouse model with doxycycline-inducible interleukin-8 expression in intestinal 
epithelial cells. Pathobiology 70: 143-149, 2002. 
32. Kuhl AA, Kakirman H, Janotta M, Dreher S, Cremer P, Pawlowski NN, 
Loddenkemper C, Heimesaat MM, Grollich K, Zeitz M, Farkas S, and Hoffmann JC. 
Aggravation of different types of experimental colitis by depletion or adhesion 
blockade of neutrophils. Gastroenterology 133: 1882-1892, 2007. 
33. Laine PS, Schwartz EA, Wang Y, Zhang WY, Karnik SK, Musi N, and Reaven 
PD. Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB 
activation. Biochem Biophys Res Commun 358: 150-155, 2007. 
34. Lampinen M, Sangfelt P, Taha Y, and Carlson M. Accumulation, activation, 
and survival of neutrophils in ulcerative colitis: regulation by locally produced factors 
in the colon and impact of steroid treatment. Int J Colorectal Dis 23: 939-946, 2008. 
35. Latinne D and Fiasse R. New insights into the cellular immunology of the 
intestine in relation to the pathophysiology of inflammatory bowel diseases. Acta 
Gastroenterol Belg 69: 393-405, 2006. 
36. Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak MK, and Jung Y. 
Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition 
are involved in NFkappaB inhibitory effect: Structural analysis for NFkappaB 
inhibition. Eur J Pharmacol, 2010. 
37. Lloyd AR and Oppenheim JJ. Poly's lament: the neglected role of the 
polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol 
Today 13: 169-172, 1992. 
38. Lu F, Fernandes SM, and Davis AE, 3rd. The role of the complement and 
contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 
inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 298: 
G878-883, 2010. 
39. Magrone T and Jirillo E. Polyphenols from red wine are potent modulators of 
innate and adaptive immune responsiveness. Proc Nutr Soc 69: 279-285, 2010. 
40. Malave I, Perdomo Y, Escalona E, Rodriguez E, Anchustegui M, Malave H, 
and Arends T. Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera 
from patients with sickle cell disease. Acta Haematol 90: 172-176, 1993. 
   143 
41. Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, Kaur S, 
and Singh K. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective 
biomarkers in the assessment of disease activity and severity in patients with 
idiopathic ulcerative colitis. J Gastroenterol Hepatol 24: 1768-1774, 2009. 
42. Masse GX, Corcuff E, Decaluwe H, Bommhardt U, Lantz O, Buer J, and Di 
Santo JP. gamma(c) cytokines provide multiple homeostatic signals to naive CD4(+) 
T cells. Eur J Immunol 37: 2606-2616, 2007. 
43. Masunaga Y, Noto T, Suzuki K, Takahashi K, Shimizu Y, and Morokata T. 
Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis. Inflamm 
Res 56: 439-446, 2007. 
44. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, Neale 
BM, Ong RT, Lagace C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, 
Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lordal M, Padyukov L, Andriulli A, 
Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de 
Jong DJ, Stokkers PC, Weersma RK, Consortium NIG, Sharma Y, Silverberg MS, 
Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer 
NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan 
SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, 
and Seielstad M. Genome-wide association identifies multiple ulcerative colitis 
susceptibility loci. Nat Genet 42: 332-337, 2010. 
45. Moon MK, Lee YJ, Kim JS, Kang DG, and Lee HS. Effect of caffeic acid on 
tumor necrosis factor-alpha-induced vascular inflammation in human umbilical vein 
endothelial cells. Biol Pharm Bull 32: 1371-1377, 2009. 
46. Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, 
Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y, and Hibi T. Inhibition of 
neutrophil elastase prevents the development of murine dextran sulfate sodium-
induced colitis. J Gastroenterol 41: 318-324, 2006. 
47. Neurath MF, Fuss I, Schurmann G, Pettersson S, Arnold K, Muller-Lobeck H, 
Strober W, Herfarth C, and Buschenfelde KH. Cytokine gene transcription by NF-
kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad 
Sci 859: 149-159, 1998. 
48. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, and Strober W. 
Local administration of antisense phosphorothioate oligonucleotides to the p65 
subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 
2: 998-1004, 1996. 
49. Nguyen GC and Steinhart AH. Nationwide patterns of hospitalizations to 
centers with high volume of admissions for inflammatory bowel disease and their 
impact on mortality. Inflamm Bowel Dis 14: 1688-1694, 2008. 
50. Packey CD and Sartor RB. Interplay of commensal and pathogenic bacteria, 
genetic mutations, and immunoregulatory defects in the pathogenesis of 
inflammatory bowel diseases. J Intern Med 263: 597-606, 2008. 
51. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. 
Oncogene 18: 6853-6866, 1999. 
   144 
52. Panwala CM, Jones JC, and Viney JL. A novel model of inflammatory bowel 
disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously 
develop colitis. J Immunol 161: 5733-5744, 1998. 
53. Parkos CA, Delp C, Arnaout MA, and Madara JL. Neutrophil migration across 
a cultured intestinal epithelium. Dependence on a CD11b/CD18-mediated event and 
enhanced efficiency in physiological direction. J Clin Invest 88: 1605-1612, 1991. 
54. Petersen M and Simmonds MS. Rosmarinic acid. Phytochemistry 62: 121-
125, 2003. 
55. Qualls JE, Kaplan AM, van Rooijen N, and Cohen DA. Suppression of 
experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol 80: 802-
815, 2006. 
56. Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, Andry CD, O'Brien 
M, and Becker JM. NF-kappaB activation precedes increases in mRNA encoding 
neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in 
dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 50: 2366-2378, 2005. 
57. Reichling J, Nolkemper S, Stintzing FC, and Schnitzler P. Impact of ethanolic 
lamiaceae extracts on herpesvirus infectivity in cell culture. Forsch Komplementmed 
15: 313-320, 2008. 
58. Resta-Lenert S, Smitham J, and Barrett KE. Epithelial dysfunction associated 
with the development of colitis in conventionally housed mdr1a-/- mice. Am J Physiol 
Gastrointest Liver Physiol 289: G153-162, 2005. 
59. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, 
Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, 
Sands BE, and Colombel JF. Infliximab for induction and maintenance therapy for 
ulcerative colitis. N Engl J Med 353: 2462-2476, 2005. 
60. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione 
R, D'Haens G, Li J, Rosenfeld MR, Kent JD, and Pollack PF. Adalimumab induction 
therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann 
Intern Med 146: 829-838, 2007. 
61. Sartor RB. Innate immunity in the pathogenesis and therapy of IBD. J 
Gastroenterol 38 Suppl 15: 43-47, 2003. 
62. Saunders WB, Bayless KJ, and Davis GE. MMP-1 activation by serine 
proteases and MMP-10 induces human capillary tubular network collapse and 
regression in 3D collagen matrices. J Cell Sci 118: 2325-2340, 2005. 
63. Schreiber S, Nikolaus S, and Hampe J. Activation of nuclear factor kappa B 
inflammatory bowel disease. Gut 42: 477-484, 1998. 
64. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange 
E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann 
U, Zanger UM, and Eichelbaum M. Association between the C3435T MDR1 gene 
polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33, 
2003. 
65. Shah SB and Hanauer SB. Risks and benefits of the use of concomitant 
immunosuppressives and biologics in inflammatory bowel disease. Rev 
Gastroenterol Disord 8: 159-168, 2008. 
   145 
66. Shi M, Hao S, Chan T, and Xiang J. CD4(+) T cells stimulate memory CD8(+) 
T cell expansion via acquired pMHC I complexes and costimulatory molecules, and 
IL-2 secretion. J Leukoc Biol 80: 1354-1363, 2006. 
67. Shin TY, Kim YK, and Kim HM. Inhibition of immediate-type allergic reactions 
by Prunella vulgaris in a murine model. Immunopharmacol Immunotoxicol 23: 423-
435, 2001. 
68. Stallmach A, Hagel S, and Bruns T. Adverse effects of biologics used for 
treating IBD. Best Pract Res Clin Gastroenterol 24: 167-182, 2010. 
69. Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, and Ethier SP. 
Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by 
amphiregulin in human breast cancer cells. Mol Cancer Res 5: 847-861, 2007. 
70. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB, Abraham 
C, and Turner JR. Targeted epithelial tight junction dysfunction causes immune 
activation and contributes to development of experimental colitis. Gastroenterology 
136: 551-563, 2009. 
71. Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q, and Zhao YF. 
Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the 
apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by 
quercetin. Apoptosis 15: 850-863, 2010. 
72. Takada K, Nakane T, Masuda K, and Ishii H. Ursolic acid and oleanolic acid, 
members of pentacyclic triterpenoid acids, suppress TNF-alpha-induced E-selectin 
expression by cultured umbilical vein endothelial cells. Phytomedicine, 2010. 
73. Terra X, Valls J, Vitrac X, Merrillon JM, Arola L, Ardevol A, Blade C, 
Fernandez-Larrea J, Pujadas G, Salvado J, and Blay M. Grape-seed procyanidins 
act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by 
inhibiting NFkB signaling pathway. J Agric Food Chem 55: 4357-4365, 2007. 
74. Tillinger W, McCole DF, Keely SJ, Bertelsen LS, Wolf PL, Junger WG, and 
Barrett KE. Hypertonic saline reduces neutrophil-epithelial interactions in vitro and 
gut tissue damage in a mouse model of colitis. Am J Physiol Regul Integr Comp 
Physiol 295: R1839-1845, 2008. 
75. Tran TA, McCoy MK, Sporn MB, and Tansey MG. The synthetic triterpenoid 
CDDO-methyl ester modulates microglial activities, inhibits TNF production, and 
provides dopaminergic neuroprotection. J Neuroinflammation 5: 14, 2008. 
76. Triantafillidis JK, Merikas E, and Georgopoulos F. Current and emerging 
drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 5: 185-
210, 2010. 
77. Van Assche G, Vermeire S, and Rutgeerts P. Medical treatment of 
inflammatory bowel diseases. Curr Opin Gastroenterol 21: 443-447, 2005. 
78. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 40: 443-
448, 1997. 
79. Vermeire S, Vermeulen N, Van Assche G, Bossuyt X, and Rutgeerts P. 
(Auto)antibodies in inflammatory bowel diseases. Gastroenterol Clin North Am 37: 
429-438, vii, 2008. 
   146 
80. Wilk JN, Bilsborough J, and Viney JL. The mdr1a-/- mouse model of 
spontaneous colitis: a relevant and appropriate animal model to study inflammatory 
bowel disease. Immunol Res 31: 151-159, 2005. 
81. Xie YC, Dong XW, Wu XM, Yan XF, and Xie QM. Inhibitory effects of 
flavonoids extracted from licorice on lipopolysaccharide-induced acute pulmonary 
inflammation in mice. Int Immunopharmacol 9: 194-200, 2009. 
82. Ye L, Luo Y, Peng X, Zhou Y, and Ou X. Synthesis and biological activity of 
3-(2, 8, 9-trioxa-aza-1-germatricyclo [3. 3. 3. 0] undecane-1-yl)-caffeic acid. Med 
Chem 5: 382-384, 2009. 
83. Ye Z, Liu Z, Henderson A, Lee K, Hostetter J, Wannemuehler M, and 
Hendrich S. Increased CYP4B1 mRNA is associated with the inhibition of dextran 
sulfate sodium-induced colitis by caffeic acid in mice. Exp Biol Med (Maywood) 234: 
605-616, 2009. 
84. Zdarilova A, Svobodova A, Simanek V, and Ulrichova J. Prunella vulgaris 
extract and rosmarinic acid suppress lipopolysaccharide-induced alteration in human 
gingival fibroblasts. Toxicol In Vitro 23: 386-392, 2009. 
85. Zhang Y, But PP, Ooi VE, Xu HX, Delaney GD, Lee SH, and Lee SF. 
Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin-
carbohydrate complex from Prunella vulgaris. Antiviral Res 75: 242-249, 2007. 
86. Zheng J, He J, Ji B, Li Y, and Zhang X. Antihyperglycemic activity of Prunella 
vulgaris L. in streptozotocin-induced diabetic mice. Asia Pac J Clin Nutr 16 Suppl 1: 
427-431, 2007. 
87. Zhou Z, Connell MC, and MacEwan DJ. TNFR1-induced NF-kappaB, but not 
ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 
expression on endothelial cells. Cell Signal 19: 1238-1248, 2007. 
88. Ziyan L, Yongmei Z, Nan Z, Ning T, and Baolin L. Evaluation of the anti-
inflammatory activity of luteolin in experimental animal models. Planta Med 73: 221-
226, 2007. 
89. Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, Imberti B, 
te Loo M, Monnens L, Remuzzi G, and Morigi M. Shiga toxin-2 triggers endothelial 
leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of 
IL-8 and MCP-1. Kidney Int 62: 846-856, 2002. 
 
 
 147 
CHAPTER 4.  Hypericum gentianoides extract prophylaxis delays 
onset and severity of spontaneous colitis in mdr1a deficient mice 
 
A paper to be submitted to the Journal of Gastroenterology 
 
Kelley Haarberg 1, Amanda Ramer-Tait 1, Cathy Hauck 2, Pat Murphy 2, Jesse 
Hostetter 3 and Michael J. Wannemuehler 1 
 
1Department of Veterinary Microbiology and Preventive Medicine, College of 
Veterinary Medicine, 2178 Vet Med, Iowa State University, Ames, IA 50011-1250 
2Department of Food Science and Human Nutrition, 2312 Food Science, Iowa State 
University, Ames, IA 50011-1061 
3Department of Veterinary Pathology, College of Veterinary Medicine, 2764 Vet 
Med, Iowa State University, Ames, IA 50011-1250 
 
Abstract 
Background. Nutraceuticals are gaining ground as therapeutic modalities for 
inflammatory and autoimmune disorders due to their low toxicity and high patient 
compliance. Several species of Hypericum possess immunomodulatory capabilities 
in many disease models; however the therapeutic potential of the chemically unique 
Hypericum gentianoides (HG) is largely untested. We investigated the efficacy of HG 
prophylaxis in the mdr1a deficient (mdr1a-/-) murine model of spontaneous colitis. 
Methods. Vehicle (5% ethanol), HG (4.8 mg/day) or metronidazole (0.75 mg/mL) 
were orally administered daily to mdr1a-/- or FVBWT mice (6-7 weeks old) until vehicle 
treated mdr1a-/- mice developed severe wasting or reached 20 weeks of age. 
Macroscopic disease assessment included measurement of weight loss, colon 
shortening and combined colonic/cecal scores. Colonic/cecal inflammation was also 
scored histologically. Immune responses were assessed using myeloperoxidase 
(MPO) assay, analysis of serum cytokines/chemokines, and flow cytometry. 
Results. HG prophylaxis significantly (p < 0.05) delayed colitic onset, reduced 
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mortality, macroscopic and microscopic disease/inflammatory scores, and 
maintained colonic health. Histological evaluation of colonic tissue revealed a 
decrease in neutrophil infiltrate in HG treated mice, substantiated by a significant 
decrease in colonic MPO. HG prophylaxis inhibited induction of G-CSF, IL-7, KC, 
LIX, MIP-1β, and TNFα while significantly increasing IL-6. Histologic and flow 
cytometric analysis revealed B cell increases in gut tissues of HG treated mice. 
Conclusions. HG exerts suppression of chemotactic signals which dampens colitic 
damage. These observations provide novel evidence that HG has 
immunomodulatory potential which can delay the onset and lessen the severity of 
spontaneous IBD. 
Key Words:  Hypericum gentianoides, colitis, IBD, mdr1a deficient mice 
 
Introduction 
Inflammatory bowel disease (IBD) is complex and multifactoral, with a poorly 
defined etiology and high variability in symptomatic presentation from patient to 
patient.1 The two predominant forms of IBD, ulcerative colitis (UC) and Crohn’s 
disease (CD), are characterized by relapsing inflammatory lesions.2 A 2007 study 
found the instance of adult CD and UC in the United States to be 238/105 and 
201/105, respectively, while the pediatric instance of these diseases was 43/105 and 
28/105, respectively.3 The prevalence of IBD is increasing in developing countries 
where funding and access to new biologic therapies, such as anti-tumor necrosis 
factor alpha (anti-TNFα), are very scarce.4, 5 Because the underlying etiology of IBD 
is unknown, clinicians continue to focus on and treat the symptoms of IBD. The most 
popular and effective therapeutics consist of mesalazines, corticosteroids and anti-
TNFα antibodies.6 More traditional treatments like corticosteroids, mesalazines and 
the immunosupressants azathioprine and methotrexate, are plagued by difficulties in 
titration, toxicity, low tolerance, low patient compliance, delayed activity and the 
need for additional medications to combat secondary infections.7 Additionally, the 
long term effects of newer biologic therapies are still in question and patients can 
become refractory to these treatments. In the case of anti-TNFα antibody therapies, 
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20 to 30 percent of patients with CD and 30 to 40 percent of patients with UC 
eventually fail to respond to treatment and fail to respond to a switch in anti-TNF 
agent.8-12 
 In increasing numbers, physicians and their patients are adding natural 
products to therapeutic regimens to directly treat disease or to alleviate the side 
effects of primary therapies. It has been estimated that up to 50 percent of patients 
suffering with IBD in North America utilize some form of complementary or 
alternative medicine (CAM).13, 14 Herbal supplementation is one of the most popular 
complementary and alternative medications utilized by IBD patients worldwide.14 
While the use of CAM is increasing worldwide, CAM is underrepresented in high-
impact studies, clinical trials, and medical education programs.15 At the same time, 
over half of all pharmaceuticals developed in the last two decades arose from 
naturally occurring compounds.16 Complex plant extracts have the advantages of 
containing various combinations of anti-inflammatory, anti-bacterial, anti-viral and 
antioxidant compounds while being less costly and inducing fewer toxic side effects 
due to synergy between chemical compounds.17, 18 It has been recognized that 
consumption of selected species of Hypericum or their extracts could be 
therapeutically or supplementally (i.e., prophylactically) efficacious in the treatment 
of IBD due to their use in treating gastrointestinal upset as well as reported anti-
inflammatory, analgesic, wound healing and free radical inhibitory effects.19-23 The 
chemical constituents of the most commonly known species of this genus, 
Hypericum perforatum (common name, St. John’s Wort), are well defined and 
include several flavonoids:  quercetin, hyperoside, isoquercitrin, quercitrin, rutin, and 
amentoflavone.24, 25 Of these compounds, rutin has been shown to ameliorate 
experimental colitis.26 H. perforatum also consists of the phenols caffeic acid and 
chlorogenic acid, as well as tannins. Caffeic acid has been shown to modulate the 
IL-12/IL-23 pathway, while proanthocyanidins inhibit nuclear-factor kappa B (NFκB) 
activity.27, 28 The bioactive compounds that have received the most attention in H. 
perforatum are the photoactive compounds hypericin and pseudohypericin, as well 
as hyperphorin.29 While these three chemicals are reported to have a great deal of 
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biologic activity, they can also cause photosensitivity and toxicity in animals and 
humans.30-32 
 While the species H. gentianoides is dispersed throughout the eastern United 
States, their biochemical and medicinal properties are not well documented. 
However, it is known that HG has been used by Native Americans to reduce 
gastrointestinal upset and fever and to speed wound healing.33 Compared to other 
species of Hypericum, the chemical composition of HG is unique in that it contains 
the anti-bacterial compounds uliginosin A and B but lacks hypericin, pseudohypericin 
and hyperforin.34, 35 This suggests that HG extracts would have fewer potential toxic 
side effects when compared to other Hypericum species. Recently, it was shown 
that an extract of HG reduced inflammatory prostaglandin E2 (PGE2) production in 
RAW 264.7 macrophage cells with no significant cytotoxicity.35 Neither HG nor any 
extracts of HG have been evaluated for biologic activity in vivo. In this study, we 
evaluate the anti-inflammatory and immunomodulatory activities of HG in the mdr1a-
/-
 mouse model of spontaneous colitis. Due to the recently reported chemical 
composition of HG, its ability to reduce inflammatory prostaglandin synthesis and its 
potential for anti-inflammatory biologic activity, we postulate that HG will reduce the 
severity of inflammatory complications associated with the onset of spontaneous 
colitis.  
 
Materials and Methods 
Reagents.  HG dried plant materials were kindly provided by Dr. Mark 
Wiederlichner at the USDA-ARS North Central Regional Plant Introduction Station 
(NCRPIS, Ames, IA). 10% buffered formalin; 30 % hydrogen peroxide and 
concentrated sulfuric acid, were purchased from Fisher Scientific (Fair Lawn, NJ). 
Phenylmethanesulfonyl fluoride (PMSF), a protease inhibitor, 3,3`,5,5`-
tetramethylbenzidine dihydrochloride hydrate (TMB), and dimethylsulphoxide 
(DMSO) were purchased from Sigma (St. Louis, MO). Heparin (5,000 USP units/0.5 
mL) was purchased from Hospira, Inc. (Lake Forest, IL). Fetal bovine serum was 
purchased from Atlanta Biologicals (Lawrenceville, GA). Cell wash/culture medium 
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reagents (Dulbecco’s modified eagle’s medium (DMEM) supplemented with 4.5 g/L 
glucose and sodium pyruvate, penicillin-streptomycin, glutamine and hepes buffer) 
were all purchased from Cellgro (Herndon, VA). All anti-mouse conjugated 
antibodies and rat isotype control antibodies were purchased from eBioscience (San 
Diego, CA):  PE-Cy7-conjugated anti-CD4+ monoclonal antibody (mAb), APC-
conjugated anti-CD8β+ mAb, PE-conjugated anti-IgM+ mAb, Alexa 700-conjugated 
anti-B220+ mAb, PE-Cy7-conjugated rat IgG2aκ+isotype, APC-conjugated rat 
IgG2bκ+isotype, PE-conjugated rat IgG2aκ+isotype, Alexa 700-conjugated rat 
IgG2aκ+isotype. Stabilizing fixative (for use with PE-Cy7 conjugates) was purchased 
from BD biosciences (San Jose, CA). All reagents utilized for the cytokine and 
chemokine multiplex analysis were purchased as part of the Milliplex MAP 32-plex 
mouse cytokine/chemokine kit from Millipore (Billerica, MA).  
Hypericum gentianoides extract preparation. Information about the 
specific provenance of HG accession Ames 28015, obtained from the NCRPIS, is 
available on the Germplasm Resources Information Network database at 
http://www.ars-grin.gov/npgs/acc/acc_queries.html. Arboreal portions of plants from 
HG (Ames 28015), harvested in 2009, were prepared for storage by drying for 8 
days at 38°C in a forced-air dryer with constant humidity. The dried material was 
ground with a 40-mesh screen and stored at -20°C until extraction. Extractions were 
made in 95% ethanol (EtOH) solvent by the Soxhlet method.25 Upon complete drying 
of the extract by evaporation, the weight of the extracted material was recorded; the 
residue was lyophilized and stored at -20°C until solubilized in a final working 
solution of 5% EtOH (the lowest concentration of EtOH that would allow 
solubilization) at a final plant extract concentration of 24 mg/mL. The working HG 
extract was divided into 2 mL aliquots and stored at -20°C until use. HG extracts 
from NCRPIS were screened for endotoxin by using the Limulus Amebocyte Lysate 
Test (BioWhittaker, Inc., Walkersville, MD) according to manufacturers’ 
specifications, and there was no detectable endotoxin present in the extract (data 
not shown). 
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Animals. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) at Iowa State University. Four to five week old 
male mdr1a-/- FVB.129P2-Abcb1a tm1BorN7 and wild type (WT) FVB.129P2 mice 
were obtained from Taconic Farms, Inc. (Germantown, NY). Animals were housed 
and maintained in the Laboratory Animal Resource facility at the College of 
Veterinary Medicine, Iowa State University. Established specific pathogen-free 
husbandry practices were followed and twelve-hour light/dark cycles were applied. 
Upon arrival, mice were fed a defined Harlan Teklad AIN93 (M) rodent chow 
(Madison, WI) to control the amount of phytochemicals in their diet. Food and water 
was provided ad libitum. 
Experimental Design.  A total of six treatment groups of mice where utilized: 
groups 1 and 2) mdr1a-/- and FVBWT mice were orally gavaged with 4.8 mg/day HG 
extract in a 200 µL volume (prepared as described above); groups 3 and 4) mdr1a-/- 
and FVBWT mice were orally gavaged with 200 µL 5% EtOH vehicle and given 
drinking water (refreshed weekly) containing 0.75 mg/mL metronidazole (Sigma, St. 
Louis, MO); groups 5 and 6) mdr1a-/- and FVBWT mice were orally gavaged with 5% 
EtOH vehicle alone. N = 4 to 10 mice per group per experiment. Gavage was 
performed using a 20 gauge feeding needle once a day beginning at 6 weeks of age 
until the mice reached twenty weeks of age or were removed from the study 
because of weight loss exceeding 15 % of their peak body weight. At necropsy, mice 
were euthanized by CO2 asphyxiation. Following euthanasia, blood was collected by 
cardiac puncture and sections of ceca and proximal colon were excised, washed, 
and stored for further histological and MPO enzymatic analysis. Serum was 
analyzed by multiplex flow cytometric assay to measure cytokine and chemokine 
levels. Cecal tonsils and mesenteric lymph nodes were also collected single cell 
suspensions prepared for flow cytometric analysis of T and B cell populations.  
Macroscopic typhlocolitis assessment. Following euthanization, the colon 
and cecum were excised, photographed, measured for length, and scored for 
severity of macroscopic lesions. Gross typhlocolitic lesions were scored using a nine 
point additive scale; a score of zero being a healthy animal and a score of 9 being a 
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maximally diseased animal. Score parameters evaluated included: 1) cecal atrophy, 
2) enlarged cecal tonsil or other enlarged lymphoid aggregates, 3) cecal emptying, 
4) abnormally watery or mucoid intraluminal cecal and/or colonic contents, 5) bloody 
cecal contents, 6) bloody colonic contents, 7) visible thickening and rigidity of the 
cecum, 8) presence of visible thickening and rigidity of the colon, and 9) absence of 
formed fecal pellets in the colon. 
Histopathological assessment. Sections of excised cecum and proximal 
colon were placed in 10% buffered formalin overnight, paraffin embedded, 
sectioned, and routinely stained with hematoxylin and eosin. Stained colonic and 
cecal sections were scored by a pathologist, Dr. Jesse Hostetter of Iowa State 
University (Ames, IA), blinded to the treatments as previously described 36, 37. 
Microscopic mucosal lesion scores were assessed by five parameters, with each 
parameter scored on a scale of 0 to 5 (5 = maximum severity). Score parameters 
include:  1) ulceration of the mucosa; extent of inflammatory cell infiltrate; 2) mucosal 
edema characterized by the extent of lymphatic and vascular distortion from the 
normal architecture; 3) stromal collapse and necrosis of the glands; 4) glandular 
hyperplasia characterized by the distribution of enterocytes along the base of the 
gland; and 5) cellular proliferation. In addition to score, mucosal heights were 
determined using an ocular micrometer and recorded in micrometers (µm), and the 
presence of inflammatory cells was recorded.  
Myeloperoxidase assay. Myeloperoxidase (MPO) activity was assessed as 
a measure of neutrophil/granulocyte accumulation in proximal colonic and cecal 
tissues. The MPO assay was performed as previously described with several 
modifications 38. Proximal colon and cecal sections collected at necropsy were 
gently flushed with PBS to remove luminal contents and stored in 1 mL of freshly 
prepared PBS supplemented with the protease inhibitor phenylmethanesulfonyl 
fluoride (PMSF) at 0.1 mM and 15% dimethylsulphoxide (DMSO) at -20°C for no 
more than 7 days prior to assay. Samples used as positive controls for MPO activity 
were prepared fresh the day the assay from peripheral blood. One FVBWT mouse, 
not on study, was euthanized by CO2 asphyxiation, and 500 µl to 1 mL of blood was 
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immediately collected by cardiac puncture with a heparinized needle (heparin at 
5,000 USP heparin units/0.5 mL is drawn into the needle and syringe and then 
expelled to coat the inside of the needle with heparin). The heparinized blood was 
centrifuged at 250 x g for 10 minutes, the supernatant discarded and the red blood 
cells (RBC) lysed. In brief, 1 mL of ACK lysis buffer (8042.0 mg/L ammonium 
chloride, 1001.0 mg/L potassium bicarbonate, 3.722 mg/L ethylene diamine 
tetraacetic acid disodium, pH 7.2, Sigma chemicals, St. Louis, MO) is added to the 
pellet, vortexed gently for 1 minute, 1 mL of PBS is added, and the mixture is 
centrifuged for 10 minutes at 250 x g. The lysis was repeated until the pellet was 
white and the supernatant was clear. Following RBC lysis, the pellet was 
resuspended in 1 mL of PBS/PMSF (0.1mM), cell numbers were recorded (average 
yield of 3 x 106 cells/mL) (Z Series Coulter Counter, Beckman Coulter, Fullerton, CA) 
and the cells were sonicated at an amplitude of 5, pulse on for 4 seconds, pulse off 
for 1 second for 20 seconds total (Sonicator 3000, Misonix, Inc., Farmingdale, NY). 
The sonicate is then centrifuged at 250 x g for 15 minutes, the supernatant stored at 
4°C until the tissue samples were prepared. Frozen proximal colonic sections were 
thawed, blotted to remove as much excess fluid as possible, trimmed to roughly 35 
mg and their weights recorded. Tissues were then homogenized for 1 minute at 
maximum power in 1 mL PBS/PMSF (0.1 mM) and the homogenizer probe was 
washed 5 times with PBS between tissue samples. Homogenate cell counts were 
recorded, and each sample was then sonicated as described above. The tissue 
sonicates were then centrifuged at 250 x g for 15 minutes, the supernatant collected 
and the pellet discarded. Each lysate prepared from tissue or PBMC was analyzed 
for total protein using a NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE). Individual lysates were pipetted into 96-well, flat 
bottom microtiter plates.  The PBMC lysates (150 µl per well) were serially diluted 
(10, two-fold dilutions) and analyzed in triplicate wells. For each tissue lysate, 150 µL 
was pipetted into separate wells and analyzed in triplicate. To each well, 50 µL of 
3,3`,5,5`-tetramethylbenzidine dihydrochloride hydrate (TMB) was added, followed 
immediately by the addition of  50 µL hydrogen peroxide (H2O2) (5 mM). The 
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reaction was allowed to proceeded for roughly two minutes (wells turned bright 
blue), followed by the addition of 50 µL of sulfuric acid (1 M) to stop the reaction. The 
optical density (OD) was measured spectrophotometerically at 405 nm (V-Max, 
Molecular Devices, USA) using SOFTmax PRO 4.0. The MPO content was 
determined by comparison to the standard curve and MPO activity was expressed 
as the relative units of enzyme activity per gram of wet weight of tissue. 
Serum cytokine/chemokine quantification. Following euthanization of 
mdr1a-/- and FVBWT mice, blood was collected via cardiac puncture. The blood was 
allowed to clot for 24 hours at 40C after which samples were centrifuged at 10,000 x 
g for 10 minutes. Serum was then removed and stored at -20 0C until use. The day 
of assay, serum samples were thawed to room temperature. Concentrations of 
cytokines and chemokines of interest were measured using the Millipore (Billerica, 
MA) mouse cytokine-chemokine 32-plex multiplexed flow-cytometric assay kit. 
Analytes screened include:  Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-10, IL-12 (p40), IL-
12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, 
KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNF-α, 
VEGF. The assay was performed according to the manufacturer’s instructions. In 
brief, supplied analyte standards (range - 10,000 to 3.2 pg/mL), quality control 
standard, and buffer only control samples were analyzed in duplicate wells of the 
supplied 96 well plate. Individual serum samples were diluted 1:1 in supplied assay 
buffer. The manufacturer’s supplied serum matrix and supplied assay buffer were 
added to all wells. Supplied pre-conjugated multiplex analyte beads were added to 
each well and the samples were incubated at 4 0C overnight on a plate shaker 
(Barnstead International Titer Plate Shaker, setting #5, Model #4625). Following 
vacuum filtration and washing, supplied detection antibody was added to all wells 
and allowed to incubate at room temperature while shaking for two hours. Supplied 
streptavidine-phycoerithrin was then added to each well and incubated for 30 
minutes at room temperature while shaking. After a final vacuum filtration and rinse, 
the beads/samples were resuspended in supplied sheath fluid and the mean 
fluorescence intensity (MFI) was measured using Luminex platform technology (The 
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FlowMetric System, Luminex, Austin, TX). MFI values were subsequently converted 
to concentrations using a 5-parameter logistic or line curve-fitting method in 
MasterPlex QT Software (MiraiBio Group, San Francisco, CA). 
Flow cytometric analysis of cecal tonsil cell populations. Mesenteric 
lymph nodes and cecal tonsils from mdr1a-/- and FVBWT mice were excised, placed 
in complete cell medium (10 mL heat-inactivated FBS, 1 mL penicillin/streptomycin, 
1 mL glutamine, 0.1 mL 50 mM β-mercaptoethanol, 2.5 mL 1M hepes in 86 mL 
DMEM with 4.5 g/L glucose and sodium pyruvate), and homogenized mechanically 
on ice. Stainless steel wire strainers (60 mesh) were used to prepare a single cell 
suspensions and remove particulate matter. Cells (5 x 105 cells/tube) were washed 
in FACs buffer, centrifuged at 250 x g and incubated in FACS buffer containing 
1:100 rat IgG and fluorochrome labeled reagents for 15 minutes on ice. Following 
labeling, cells were washed with FACs buffer, centrifuged and fixed in 200 µL of BD 
stabilizing fixative. Cellular preparations from individual mice were labeled with the 
following fluorochrome-labeled reagents:  B cells (B220+) were identified using Alexa 
700-conjugated anti-B220 mAb, CD4+ T cells were identified using PE-Cy7-
conjugated anti-CD4 mAb, CD8+ T cells were identified using APC-conjugated anti-
CD8β mAb, Plasma cells (IgM+) were identified by PE-conjugated anti-IgM mAb. The 
following isotype controls were utilized:  Alexa 700-conjugated anti-rat IgG2aκ, PE-
Cy7-conjugated anti-rat IgG2aκ, APC-conjugated anti-rat IgG2bκ and PE-
conjugated anti-rat IgG2aκ. Working dilutions of anti-B220 mAb, anti-CD4 mAb, anti-
CD8β mAb, and anti-IgM mAb and their isotypes were 1:50, 1:100, 1:80 and 1:50, 
respectively. Analysis was performed using a BD FACSCanto flow cytometer (BD, 
San Jose, CA) made available through the Flow Cytometry Core Facility at Iowa 
State University (Ames, IA). Data analysis was performed using FlowJo software 
(TreeStar Inc., Ashland, OR).  
Statistical analysis. Statistical significance of parametric data was evaluated 
by student’s t-test. Non-parametric data (e.g., scores) were evaluated by the Mann-
Whitney test. All survival curves were evaluated by the Log Rank (Mantel-Cox) test 
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and the Gehan-Breslow-Wilcoxon test. A P-value of < 0.05 was considered 
statistically significant. Prism 5 software was used for all statistical calculations. 
 
Results 
The ethanolic extract of HG delays the onset of severe colitis and 
decreases the severity of macroscopic disease parameters in mdr1a-/- mice. To 
determine the efficacy of HG extract in the treatment of spontaneous colitis, mdr1a-/-  
and FVBWT mice were gavaged daily with vehicle (5% EtOH) or 4.8 mg HG extract. 
Previously published data shows that mdr1a-/- mice spontaneously develop colitis 
between 8 and 36 weeks of age, with the average age of disease onset being 20 
weeks 39. As anticipated, the majority of vehicle treated mdr1a-/- mice (11 out of 16) 
developed severe colitic disease prior to 20 weeks of age. Only 6 of the 16 HG 
treated mice developed severe colitis prior to reaching 20 weeks of age (Fig. 1). The 
delay in colitic onset in HG treated mdr1a-/- was significant (P < 0.05) when 
compared to vehicle treated mdr1a-/- mice.  
 Representative photographs of ceca and colons (Fig. 2) show the extent of 
macroscopic tissue changes that developed in vehicle treated mdr1a-/- mice. In these 
mice, ceca are atrophied with visible, prominent cecal tonsils suggestive of local 
immune activity. Decreased presence of cecal and colonic contents was common 
while both cecal and colonic tissues were notably thickened. Blood was observed in 
some cecal and colonic contents and formed fecal pellets were absent. Conversely, 
the ceca and colons of HG treated mdr1a-/- mice were markedly improved and more 
similar to those from healthy FVBWT mice. The cecal and colonic tissues of mdr1a-/- 
mice treated with metronidazole were also markedly improved and healthy and all of 
these mice survived to the end of the experiment (Fig. 1).  
Grossly, severe typhlocolitis (a score of 5 or greater) was observed in 75% of 
vehicle treated mdr1a-/- mice compared to only 25% of HG treated mdr1a-/- mice and 
none of the metronidazole treated mdr1a-/- mice. (Fig. 3A).  All vehicle treated 
mdr1a-/- mice displayed at least mild macroscopic disease, while all of the 
macroscopic scores for HG treated mdr1a-/- mice are below the median score of the 
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vehicle treated mdr1a-/- mice (Fig. 3A). HG prophylaxis significantly (P < 0.01) 
prevented macroscopic parameters of disease when compared to vehicle treatment 
in mdr1a-/- mice. Similar to metronidazole treated mdr1a-/- mice, colon lengths in HG 
treated mdr1a-/- mice displayed significant (P < 0.001) improvement compared to 
vehicle treatment (Fig. 3B). As expected, no FVBWT mice exhibited any signs of 
disease (Fig. 3, A and B). 
Impact of HG treatment on the severity of histopathological lesions. 
Histological inflammation of cecal and colonic tissues was scored based on changes 
in mucosal height, ulceration, extent and character of inflammatory cell infiltrate, 
edema, stromal collapse and glandular necrosis, and glandular hyperplasia (Tables 
1 and 2). Both the colons and ceca of vehicle treated   mdr1a-/- mice were typified by 
crypt hyperplasia, extensive transmural ulceration and inflammatory infiltrate, as well 
as occasional submucosal edema and stromal collapse (Table 1 and Fig. 4). HG-
treated mdr1a-/- mice exhibited statistically significant (p < 0.05) improvement in 
colonic edema (Table 1), cecal ulceration, edema, and stromal collapse or necrosis 
(Table 2). As expected, tissues from metronidazole-treated mdr1a-/- mice did not 
exhibit significant inflammation (p < 0.05 – p < 0.001 compared to vehicle mdr1a-/-), 
nor did  FVBWT mice. Importantly, HG prophylaxis in WT mice did not induce any 
adverse toxic or inflammatory responses. While 100 % of vehicle treated mdr1a-/- 
mice exhibited extensive neutrophil infiltration into colonic and cecal tissues, 
inflammatory cells were absent in 31% and 44% colons and ceca of HG-treated 
mdr1a-/- mice, respectively (Tables 1, 2 and Fig. 4).  
As a measure of inflammation and infiltration of granulocytes into the mucosal 
tissue, MPO activity was measured in colonic and cecal homogenates (Fig. 5). In 
comparison to tissue samples from the vehicle-treated mdr1a-/- mice, the associated 
MPO enzymatic activity was significantly diminished in colons of HG and 
metronidazole treated mdr1a-/- mice (P < 0.05 and P < 0.01, respectively) (Fig. 5a). 
Cecal tissue of HG-treated mdr1a-/- mice exhibited a decreasing trend (P < 0.08) in 
MPO activity that was not statistically significant (Fig. 5b) 
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Unexpectedly, HG prophylaxis corresponded with a notable increase in 
plasma cell infiltrate into both colonic and cecal tissues of mdr1a-/- mice (Tables 1, 2 
and Fig. 4). Together, these data indicate that reduced neutrophil and increased 
plasma cell populations present in the ceca and colons of HG-treated mdr1a-/- mice 
provide some protection from severe inflammation and injury associated with 
spontaneous colitis.  
Impact of the ethanolic extract of HG on the induction of chemotactic 
and pro-inflammatory cytokines. To further investigate inflammatory modulation 
related to improved macroscopic and microscopic cecal and colonic health, serum 
samples collected at necropsy were examined for the presence of cytokines and 
chemokines. Many analytes (G-CSF, IL-6, IL-7, IL-17, IP-10, KC, MIG, TNFα and 
VEGF) were significantly (P < 0.5) elevated in vehicle-treated mdr1a-/- mice 
compared to FVBWT controls (Table 3). Significantly reduced (P < 0.5) serum 
cytokines/chemokines (G-CSF, IL-6, IL-7, IL-17, KC and TNFα) were detected in 
metronidazole treated verses vehicle treated mdr1a-/- mice included: (Table 3). Other 
serum analytes (G-CSF, IL-7, KC, LIX, MIP-1β, TNFα) were significantly (P < 0.5) 
lower in HG-treated mdr1a-/- mice (Table 2). Of note, IL-6 serum concentrations were 
significantly (P < 0.5) increased in HG-treated mdr1a-/- mice when compared to 
vehicle-treated mdr1a-/- mice. It is clear from these data that HG is able to modulate 
production of many chemokines and inflammatory cytokines involved in the immune 
response in mdr1a-/- mice. 
Influence of H. gentianoides on local T cell and B cell populations. The 
extent of inflammation and magnitude of the accompanying cytokine and chemokine 
responses can impact the course of adaptive immune responses. T cell and B cell 
populations in the mesenteric lymph nodes and cecal tonsils of mdr1a-/- and FVBWT 
mice were examined in order to evaluate the effects of HG prophylaxis on 
lymphocyte populations in these tissues (Fig. 6 and 7). Even in the presence of 
severe colitis, there was no significant difference in CD4+, CD8+, B220+, or IgM+ cell 
populations present in the mesenteric lymph nodes of vehicle treated mdr1a-/- mice 
(Fig. 6a-d). Even though no cell population was elevated above the FVBWT baseline 
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in vehicle-treated mdr1a-/- mice, HG and metronidazole prophylaxis reduced the 
percentage of IgM+ cells below baseline (Fig. 6d).  
In contrast to the mesenteric lymph node, vehicle- treated mdr1a-/- mice did 
display an approximate 2-fold (P < 0.5) elevation in CD4+ T cells and B220+ B cells 
in cecal tonsils when compared to FVBWT mice (Fig. 7a and c). CD8+ and IgM+ cell 
percentages were not significantly altered in the ceca of these mice (Fig. 7b and d). 
Though not statistically significant, HG-treatment did cause an increase in the 
percentage of CD4+ T cells detected in the cecal tonsils of FVBWT and mdr1a-/- mice 
when compared to vehicle controls (Fig. 7a). In comparison to metronidazole 
therapy, HG prophylaxis in mdr1a-/- mice significantly (P < 0.5) increased the 
percentage of detectable B220+ B cells in cecal tonsil tissues when compared to 
FVBWT and mdr1a-/- vehicle-treated mice (Fig. 7c).  
HG prophylaxis consistently reduced the percent of IgM+ B cells in both cecal 
tonsil and mesenteric lymphoid tissues, while simultaneously increasing cecal tonsil 
percentages of B220+ B cells. Additionally, HG increases CD4+ T cell presence in 
cecal tonsils regardless of health status.  
 
Discussion 
Mice deficient in mdr1a are genetically susceptible to barrier disruption and 
increased antigen presentation to the lamina propria.39, 40 This model is 
characterized by an increase in colonic inflammation which is grossly observable by 
8 weeks of age.39 This colitis becomes transmural, multifocal, and is characterized 
by the production of multiple inflammatory cytokines and chemokines.41, 42 The 
mechanism of colitic onset associated with this model as well as the genetic basis 
for the onset are consistent with some forms of human IBD, adding to the relevance 
of this model in screening for potential therapeutic or prophylactic modalities for 
IBD.43, 44  
This study is novel in evaluation of the therapeutic potential and biologic 
activity of Hypericum gentianoides in vivo in a spontaneous model of murine colitis. 
Using the mdr1a-/- model of spontaneous murine colitis, we evaluated the anti-colitic 
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efficacy of oral HG in comparison to vehicle (5% EtOH) alone and metronidazole.  
The timeframe and severity of colitic onset in vehicle-treated mdr1a-/- mice was 
consistent with that reported in previous studies.39, 40 As expected, FVBWT mice 
remained free of colitis. Only two metronidazole-treated mdr1a-/- mice developed 
mild clinical signs, which underscores the importance of the role of the resident 
microflora in the process of colitic onset. HG prophylaxis significantly delayed 
mortality by 33 days when compared to vehicle treated mdr1a-/- controls. Despite this 
delay by HG treatment of mdr1a-/- mice, the majority of these mice did develop 
clinical signs of colitis as evidenced by weight loss around 20 weeks of age. The HG 
treatment regimen used in these studies was unable to completely prevent the onset 
of disease in the mdr1a-/- mice.  
 Despite the inability to prevent the onset of colitis, HG significantly reduced 
macroscopic disease parameters in mdr1a-/- mice when compared to controls. While 
longer studies would be required, this could indicate that HG could further reduce 
long-term mortality, while allowing mice to survive with only mild to moderate clinical 
disease. 
 The improvements in macroscopic data in HG-treated mdr1a-/- mice 
correlated with significantly decreased microscopic colonic edema and significantly 
reduced cecal ulceration, edema and stromal necrosis in these mice. The 
improvements in microscopic and subsequent macroscopic disease morphology in 
HG treated mdr1a-/- mice could be attributed to the significant reduction in cecal and 
colonic neutrophil infiltrate in these mice (a 25% and 31% improvement, 
respectively). MPO activity, a known contributor to and marker of inflammation, was 
similarly reduced in the colons and ceca of HG treated mdr1a-/- mice.45-47 Neutrophil 
damage is known to contribute to disease severity in IBD.48-52 A greater number of 
microscopic parameters were improved in the ceca of HG-treated mdr1a-/- mice, yet 
the reduction in neutrophil infiltrate and subsequent MPO activity was less dramatic 
in the cecal tissues of these mice than in the colon. This would indicate that 
neutrophils are not the only inflammatory cell population affected by HG or 
contributing to colitic pathogenesis in these tissues. 
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  The increase in the presentation of plasma cells seen histologically in the 
colons and ceca of HG-treated mdr1a-/- mice was unexpected. It has been previously 
documented that increasing numbers of plasma cells are found in the tissues of 
diseased mdr1a-/- mice.53  Given that HG treated mdr1a-/- mice exhibited significantly 
reduced colitic disease in most parameters in this study, it is unclear what the cause 
and function of the increased plasma cell migration into the cecal and colonic tissues 
of these mice is. HG prophylaxis did not cause any plasma cell infiltrate in FVBWT 
mice, perhaps indicative of the fact that there is no direct cause or effect related to 
the HG treatment and the increase in plasma cells. 
 Serum cytokine data from HG-treated mdr1a-/- mice illustrates another aspect 
of the anti-inflammatory potential of the extract in this model. HG prophylaxis in 
mdr1a-/- mice resulted in a significant reduction in the production of cytokines and 
chemokines G-CSF, KC, LIX, MIP-1β, IL-7 and TNFα. G-CSF and KC are both 
stimulatory and chemoattractant for neutrophils.54, 55 Their downregulation by HG 
prophylaxis is consistent with the decrease in colonic and cecal neutrophil infiltrate 
seen in HG-treated mdr1a-/- mice. LIX is also a chemoattractant for neutrophils and 
is the murine homologue of human epithelial neutrophil-activating peptide-78 (ENA-
78). The decrease in LIX production associated with HG treatment further supports 
histologic reductions in neutrophil infiltrate. This could be a significant interaction as 
the inhibition of LIX by anti-sense oligonucleotides has been shown to ameliorate 
experimental colitis.56 MIP-1β, or CCL4, is a macrophage inflammatory protein which 
has been shown to have high activity during the acute phase of experimental colitis 
while sharply decreasing in concentration during the recovery phase of colitis.57 
There is an association between increased levels of macrophage inflammatory 
proteins, such as  MIP-1β, and the severity of colitis.58  IL-7 is known to be an 
important growth and maturation factor for colitogenic memory T cells and B cells, 
but also contributes to non-T or B cell colitic related inflammatory processes.59, 60. 
HG reduction of TNFα serum concentrations is a significant finding, as TNFα has 
been directly implicated in the pathogenesis and chronicity of IBD.61 TNFα is also 
known to be elevated in the mdr1a-/- spontaneous mouse model of colitis.42 HG 
 163 
prophylaxis in mdr1a-/- mice did result in the increase of IL-6 in the serum. IL-6 can 
be pro-inflammatory or anti-inflammatory by enhancing Th17 cell development or 
Treg cell development dependant on the cytokine milieu of the microenvironment.62 
HG prophylaxis results in a reduction in macroscopic and microscopic disease 
parameters and an increase in serum concentrations of IL-6. This can perhaps be 
explained by a recent study which has shown that IL-6 levels are elevated in the 
tissues of human patients with active IBD in the absence of microscopic and 
macroscopic inflammation.63 The authors concluded this to be evidence of immune 
activity even in the absence of histological inflammation. Much of the 
cytokine/chemokine data presented here could relate to the reduction in microscopic 
and macroscopic disease associated with reduced granulocyte and neutrophil 
activity in HG-treated mdr1a-/- mice. The increase in IL-6 serum concentrations in 
these mice could be one facet of the limitation of long-term anticolitic maintenance of 
HG. The increase in IL-6 could also explain the unusual increase in plasma cell and 
CD4+ T cell concentrations in the tissues of these mice noted histologically and by 
flow cytometry. It has been shown that IL-6 can enhance or facilitate B cell 
differentiation and production of IgG in a ‘feed-forward’ mechanism.64 Perhaps the 
increased production of IL-6 and increase in B cell presence in the tissues of HG 
treated mdr1a-/- are functionally linked. 
 In summary, the ethanolic extract of Hypericum gentianoides has anti-
inflammatory and immunomodulatory potential based on its ability to attenuate 
inflammation in the mdr1a-/- mouse model of spontaneous colitis. This activity could 
be related to the flavonoid and polyphenolic compounds in the extract. This work 
highlights the need for further study of HG, the potential synergy of its components, 
and its efficacy in other disease models. 
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Figure 1. The percent of mdr1a-/- mice remaining on study. 
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Figure 2. Photographs of colons and ceca from WT or mdr1a-/- mice treated with 
vehicle, metronidazole or Hypericum gentianoides.  
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Figure 3. Macroscopic assessment of colitis in WT or mdr1a-/- mice treated with 
vehicle, metronidazole or Hypericum gentianoides. 
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Table 1. Hypericum gentianoides prophylaxis significantly decreases colonic edema 
associated with severe typhlocolitis in mdr1a-/- mice, decreases the occurrence of 
neutrophil influx associated with histologic inflammation and increases colonic 
plasma cell infiltrate. 
Microscopic 
Parameter 
VWT 
(n = 6) 
MWT 
(n = 4) 
HGWT 
(n = 6) 
V-/- 
(n = 16) 
M-/- 
(n = 10) 
HG-/- 
(n = 16) 
Mucosal Height 
(µM) 3.2 ± 0.2*** 3.0 ± 0.0*** 3.7 ± 0.7** 5.2 ± 0.2 4.4 ± 0.3* 4.9 ± 0.2 
Ulceration 0.0 ± 0.0*** 0.0 ± 0.0*** 0.5 ± 0.5** 1.9 ± 0.3 0.4 ± 0.3** 1.3 ± 0.3 
Inflammation 1.0 ± 0.0*** 1.0 ± 0.0*** 1.3 ± 0.3*** 3.5 ± 0.2 2.1 ± 0.2*** 3.2 ± 0.3 
Edema 0.2 ± 0.2* 0.3 ± 0.3* 0.3 ± 0.2* 1.2 ± 0.3 0.4 ± 0.2* 0.4 ± 0.2* 
Stromal Collapse 
(Necrosis) 0.0 ± 0.0** 0.0 ± 0.0* 0.0 ± 0.0** 1.1 ± 0.3 0.1 ± 0.1* 1.0 ± 0.2 
Gland Hyperplasia 0.3 ± 0.2*** 0.0 ± 0.0*** 0.8 ± 0.5** 3.0 ± 0.2 1.4 ± 0.3*** 3.0 ± 0.2 
% Mice Exhibiting 
Colonic 
Neutrophil 
Infiltrate 
0% 0% 0% 100% 20% 69% 
% Mice Exhibiting 
Colonic Plasma 
Cell Infiltrate 
0% 0% 0% 12% 0% 31% 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, HGWT = Hypericum 
gentianoides treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated 
mdr1a-/- mice, HG-/- = Hypericum gentianoides treated mdr1a-/- mice. Data are expressed as the mean ± SEM. 
Statistical significance is noted in three levels:  * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
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Table 2. Hypericum gentianoides prophylaxis significantly decreases cecal edema 
associated with severe typhlocolitis in mdr1a-/- mice, decreases the occurrence of 
neutrophil influx associated with histologic inflammation and increases colonic 
plasma cell infiltrate. 
Microscopic 
Parameter 
VWT 
(n = 6) 
MWT 
(n = 4) 
HGWT 
(n = 6) 
V-/- 
(n = 16) 
M-/- 
(n = 10) 
HG-/- 
(n = 16) 
Mucosal Height 
(µM) 3.7 ± 0.2*** 3.0 ± 0.6*** 3.5 ± 0.2** 4.5 ± 0.2 3.8 ± 0.2* 4.6 ± 0.2 
Ulceration 0.0 ± 0.0*** 0.0 ± 0.0*** 0.0 ± 0.0*** 2.3 ± 0.3 0.1 ± 0.1*** 0.7 ± 0.3** 
Inflammation 1.5 ± 0.3*** 1.0 ± 0.0*** 1.5 ± 0.2*** 3.2 ± 0.2 2.1 ± 0.3** 3.1 ± 0.2 
Edema 1.3 ± 0.3* 0.8 ± 0.5 0.8 ± 0.3** 2.1 ± 0.2 0.9 ± 0.3** 1.6 ± 0.3* 
Stromal Collapse 
(Necrosis) 0.0 ± 0.0*** 0.0 ± 0.0** 0.0 ± 0.0*** 1.7 ± 0.3 0.1 ± 0.1** 0.6 ± 0.3* 
Gland 
Hyperplasia 0.7 ± 0.3*** 0.8 ± 0.5** 0.3 ± 0.2*** 2.8 ± 0.3 1.7 ± 0.3* 2.6 ± 0.2 
% Mice Exhibiting 
Cecal 
Neutrophil 
Infiltrate 
0% 0% 0% 81% 20% 56% 
% Mice Exhibiting 
Cecal Plasma 
Cell Infiltrate 
0% 0% 0% 12% 10% 31% 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, HGWT = Hypericum 
gentianoides treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated 
mdr1a-/- mice, HG-/- = Hypericum gentianoides treated mdr1a-/- mice. Data are expressed as the mean ± SEM. 
Statistical significance is noted in three levels:  * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
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Figure 4. Hypericum gentianoides protects microscopic architecture in mdr1a-/- 
mice, decreases inflammatory cell infiltrate, and increases plasma cell infiltrate.  
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Figure 5. Metronidazole and Hypericum gentianoides reduce local myeloperoxidase 
(MPO) activity in the colons and ceca of mdr1a-/- mice. 
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Table 3. Hypericum gentianoides prophylaxis reduces serum content of several 
chemotactic and inflammatory cytokines associated with severe typhlocolitis in 
mdr1a-/- mice. 
Cytokine/ 
Chemokine 
VWT 
(n = 6) 
MWT 
(n = 4) 
HGWT 
(n = 6) 
V-/- 
(n = 16) 
M-/- 
(n = 10) 
HG-/- 
(n = 16) 
Eotaxin 443 ± 42 468 ± 28 559 ± 102 742 ± 126 956 ± 160 901 ± 198 
G-CSF 156 ± 43*** 1223 ± 1073* 175 ± 41*** 7944 ± 2635 443 ± 124*** 2009 ± 625** 
GM-CSF 17 ± 2 20 ± 5 18 ± 2 18 ± 3 13 ± 4 15 ± 3 
IFNγ 2 ± 0 6 ± 2 4 ± 1 19 ± 4 9 ± 3 11 ± 3 
IL-1α 104 ± 17 140 ± 7 132 ± 20 133 ± 13 125 ± 13 105 ± 15 
IL-1β 10 ± 2 16 ± 4 9 ± 2 14 ± 3 12 ± 2 12 ± 2 
IL-6 9 ± 3* 339 ± 337 6 ± 2*** 149 ± 56 11 ± 2*** 230 ± 117* 
IL-7 3 ± 0** 3 ± 0** 2 ± 1** 22 ± 13 2 ± 1** 16 ± 12* 
IL-9 355 ± 57 336 ± 68 340 ± 54 265 ± 28 217 ± 41 269 ± 31 
IL-10 18 ± 4 6 ± 5* 18 ± 4 20 ± 2 17 ± 3 28 ± 9 
IL-12(p40) 29 ± 4 43 ± 7 33 ± 6 85 ± 35 176 ± 56 100 ± 36 
IL-12(p70) 49 ± 8 45 ± 6 28 ± 3 39 ± 7 30 ± 7 31 ± 6 
IL-13 518 ± 68 601 ± 31* 834 ± 214 475 ± 45 466 ± 45 383 ± 46 
IL-17 2 ± 0* 3 ± 1 3 ± 1 10 ± 2 1 ± 1* 10 ± 3 
IP-10 25 ± 5*** 56 ± 8** 25 ± 4*** 612 ± 151 300 ± 69 361 ± 80 
KC 125 ± 31*** 182 ± 546*** 92 ± 26*** 801 ± 122 251 ± 83*** 251 ± 30*** 
LIF 3 ± 0 3 ± 0 3 ± 0 4 ± 2 1 ± 0 2 ± 0 
LIX 14000 ± 1 14000 ± 1 130310 ± 617 137510 ± 1264 169750 ± 1922 8088 ± 1415** 
MIG 73 ± 19*** 230 ± 73* 90 ± 25** 2119 ± 469 1734 ± 561 1461 ± 248 
MIP-1β 40 ± 5 40 ± 4 43 ± 9 42 ± 5 40 ± 8 28 ± 6* 
TNFα 2 ± 0** 3 ± 0** 3 ± 1** 12 ± 2 5 ± 1** 7 ± 1* 
VEGF 2 ± 1* 1 ± 0* 2 ± 1* 13 ± 6 12 ± 4 9 ± 4 
 
VWT = Vehicle (5% EtOH) treated FVBWT mice, MWT = Metronidazole treated FVBWT mice, HGWT = Hypericum 
gentianoides treated FVBWT mice, V-/- = Vehicle (5% EtOH) treated mdr1a-/- mice, M-/- = Metronidazole treated 
mdr1a-/- mice, HG-/- = Hypericum gentianoides treated mdr1a-/- mice. Data are expressed as the mean serum 
cytokine/chemokines content (pg/mL) ± SEM. Statistical significance is noted in three levels:  * = P < 0.05, ** = P 
< 0.01, *** = P < 0.001. 
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Figure 6. Evaluation of CD4+, CD8+, B220+ and IgM+ cell subsets in the mesenteric 
lymph nodes of mice treated with vehicle, metronidazole or Hypericum gentianoides. 
 177 
0
20
40
60
80
** **
*
%
 
CD
4 
Po
si
tiv
e 
Ce
lls
0
20
40
60
80
**
**
**
***
%
 
B2
20
 
Po
si
tiv
e 
Ce
lls
0
2
4
6
8
10
Co
n
tr
o
l
(V
eh
ic
le
)
M
et
ro
n
id
az
o
le
H
yp
er
ic
u
m
ge
n
tia
n
o
id
es
Co
n
tr
o
l
(V
eh
ic
le
)
M
et
ro
n
id
az
o
le
Hy
pe
ric
u
m
ge
n
tia
n
o
id
es
FVBWT mdr1a-/-
* *
%
 
CD
8 ββ ββ
 
Po
si
tiv
e 
Ce
lls
0
20
40
60
80
Co
n
tr
o
l
(V
eh
ic
le
)
M
et
ro
n
id
az
o
le
Hy
pe
ric
u
m
ge
n
tia
n
o
id
es
Co
n
tr
o
l
(V
eh
ic
le
)
M
et
ro
n
id
az
o
le
Hy
pe
ric
u
m
ge
n
tia
n
o
id
es
FVBWT mdr1a-/-
**
*%
 
Ig
M
 
Po
si
tiv
e 
Ce
lls
a
b d
c
 
Figure 7. Evaluation of CD4+, CD8+, B220+ and IgM+ cell subsets in the cecal tonsils 
of mice treated with vehicle, metronidazole or Hypericum gentianoides. 
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Figure Legends 
 
Figure 1. The percent of mdr1a-/- mice remaining on study. Mdr1a-/- mice were 
removed from the study as they developed severe colitis or at the termination of the 
experiment as described in Materials and Methods.*P < 0.05, **P < 0.01, ***P < 
0.001 compared to mdr1a-/- vehicle. This adapted survival curve is representative of 
two separate experiments (vehicle n = 16, 0.075 mg/mL metronidazole n = 10, 4.8 
mg/kg Hypericum gentianoides n = 16).  
 
Figure 2. Photographs of colons and ceca from WT or mdr1a-/- mice treated with 
vehicle, metronidazole or Hypericum gentianoides. Mdr1a-/- mice were gavaged with 
5% EtOH vehicle (n = 16), 0.075 mg/mL metronidazole dosed in drinking water (n = 
10) or gavaged with 4.8 mg Hypericum gentianoides extract (n = 16) daily as 
described in Materials and Methods. FVBWT mice were also represented in each 
treatment group (n = 6, FVBWT mice per treatment). Images are representative of 
two independent experiments. 
 
Figure 3. Macroscopic assessment of colitic severity. a) Macroscopic typhlocolitic 
scores of mdr1a-/- and FVBWT mice treated with vehicle, metronidazole or Hypericum 
gentianoides extract as described in Materials and Methods (Max/Severe = 9, 
Min/Healthy = 0.) b) Colon lengths of mdr1a-/- and FVBWT mice treated with vehicle, 
metronidazole or Hypericum gentianoides extract were measured at necropsy and 
the group range is represented. Whiskers indicate minimum and maximum values, 
while the horizontal line represents the group median. *P < 0.05, ** P < 0.01, *** P < 
0.001 compared to mdr1a-/- vehicle. Data is representative of two independent 
experiments with n = those listed in Figure 1. 
 
Figure 4. Hypericum gentianoides protects microscopic architecture in mdr1a-/- 
mice, decreases inflammatory cell infiltrate, and increases plasma cell infiltrate. 
Representative photomicrographs (200x) of cecal and colonic sections collected 
from mdr1a-/- and FVBWT mice treated with vehicle, metronidazole or Hypericum 
gentianoides extract at the time of necropsy were formalin fixed, paraffin embedded 
and subject to routine hematoxylin and eosin staining. FVBWT ceca of all treatments 
are characterized by normal mucosal architecture and height, intact glands, little to 
no mucosal or submucosal edema, and normal resident populations of mononuclear 
cells and lack of plasma cells. In contrast, diseased mdr1a-/- ceca exhibit mucosal 
and glandular hyperplasia, transmural ulceration and inflammation, as well as 
stromal necrosis and an inflammatory population of neutrophils. Hypericum 
gentianoides and metronidazole treated mdr1a-/- ceca and colons are improved 
toward the normal wild type condition. A significant increase in the tissue presence 
of plasma cells was noted in mdr1a-/- mice treated with Hypericum gentianoides. 
Photographs were chosen based on the average macroscopic and microscopic 
score data for each group and are representative of two independent experiments 
with n = those listed in Figure 1.  
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Figure 5. Metronidazole and Hypericum gentianoides reduce local myeloperoxidase 
(MPO) activity in the colons and ceca of mdr1a-/- mice. Homogenates of colonic or 
cecal tissue were used to assay for MPO activity.* = p < 0.05, ** = p < 0.01, *** = p < 
0.001 compared to mdr1a-/- vehicle. Data is representative of: FVBWT vehicle n = 6, 
metronidazole n= 4, Hypericum gentianoides n = 6; mdr1a-/- vehicle n = 10, 
metronidazole n= 4, Hypericum gentianoides n = 10. 
 
Figure 6. Evaluation of CD4+, CD8+, B220+ and IgM+ cell subsets in the mesenteric 
lymph nodes of mice treated with vehicle, metronidazole or Hypericum gentianoides. 
Mesenteric lymph nodes were excised at necropsy, single cell suspensions prepared 
and stained for flow cytometric analysis as described in materials and methods. a) 
Percent of CD4+ T cells in the mesenteric lymph nodes, b) Percentof CD8ß+ T cells 
in the mesenteric lymph nodes, c) Percent of B220+ B cells in the mesenteric lymph 
nodes. d) Percent of IgM+ B cells in the mesenteric lymph nodes.*P < 0.05, ** P < 
0.01 compared to mdr1a-/- vehicle. Flow cytometric data was analyzed using FlowJo 
software and statistical analysis was performed using GraphPad 5. Data is 
representative of: FVBWT vehicle n = 6, metronidazole n= 4, Hypericum gentianoides 
n = 6; mdr1a-/- vehicle n = 10, metronidazole n= 4, Hypericum gentianoides n = 10. 
 
 
Figure 7. Evaluation of CD4+, CD8+, B220+ and IgM+ cell subsets in the cecal tonsils 
of mice treated with vehicle, metronidazole or Hypericum gentianoides. Cecal tonsils 
were excised at necropsy, single cell suspensions prepared and stained for flow 
cytometric analysis as described in materials and methods. a) Percent of CD4+ T 
cells in the cecal tonsils, b) Percent of CD8ß+ T cells in the cecal tonsils, c) Percent 
of B220+ B cells in the cecal tonsils. d) Percent of IgM+ B cells in the cecal tonsils.*P 
< 0.05, ** P < 0.01, *** P < 0.001 compared to mdr1a-/- vehicle. Flow cytometric data 
was analyzed using FlowJo software and statistical analysis was performed using 
GraphPad 5. Data is representative of: FVBWT vehicle n = 6, metronidazole n= 4, 
Hypericum gentianoides n = 6; mdr1a-/- vehicle n = 10, metronidazole n= 4, 
Hypericum gentianoides n = 10. 
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Table Legends 
 
Table 1. Hypericum gentianoides prophylaxis significantly decreases colonic edema 
associated with severe typhlocolitis in mdr1a-/- mice, decreases the occurrence of 
neutrophil influx associated with histologic inflammation and increases colonic 
plasma cell infiltrate. Colonic sections collected at the time of necropsy were 
formalin fixed; paraffin embedded and subject to routine hematoxylin and eosin 
staining. Stained histologic sections were scored for inflammation by a pathologist 
blinded to the treatments. Scores for ulceration, Inflammation, edema, necrosis and 
gland hyperplasia were scored on a 0 (normal) to 5 (severe) scale. Data is 
represented as mean ± SEM (except where noted). *P < 0.05, ** P < 0.01, *** P < 
0.001 compared to mdr1a-/- vehicle. Mucosal heights were subject to parametric 
unpaired t-test, while microscopic scores were subject to non-parametric, Mann-
Whitney t-test. Statistical analysis was performed using GraphPad Prism 5. Data are 
representative of two separate experiments with n = those listed in Figure 1. 
 
Table 2. Hypericum gentianoides prophylaxis significantly decreases cecal edema 
associated with severe typhlocolitis in mdr1a-/- mice, decreases the occurrence of 
neutrophil influx associated with histologic inflammation and increases colonic 
plasma cell infiltrate. Cecal sections were prepared and assessed as noted in Table 
1. Data is represented as mean ± SEM (except where noted). *P < 0.05, ** P < 0.01, 
*** P < 0.001 compared to mdr1a-/- vehicle. Mucosal heights were subject to 
parametric unpaired t-test, while microscopic scores were subject to non-parametric, 
Mann-Whitney t-test. Statistical analysis was performed using GraphPad Prism 5. 
Data are representative of two separate experiments with n = those listed in Figure 
1. 
 
Table 3. Hypericum gentianoides prophylaxis reduces serum content of several 
chemotactic and inflammatory cytokines associated with severe typhlocolitis in 
mdr1a-/- mice. Serum collected from individual mice at was subjected to multiplex 
flow cytometric bead analysis for chemokine and cytokine concentrations using a 32-
plex mouse chemokine/cytokine kit. Only cytokines and chemokines which were 
detectible in at least one treatment group are represented. Data is represented as 
average serum concentrations (pg/mL) ± SEM. *P < 0.05, ** P < 0.01, *** P < 0.001 
compared to mdr1a-/- vehicle. Concentrations were subject to non-parametric, Mann-
Whitney t-test. Statistical analysis was performed using GraphPad Prism 5. Data are 
representative of two separate experiments with n = those listed in Figure 1. 
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CHAPTER 5.  GENERAL CONCLUSIONS 
 
Summary 
 The experiments presented in this dissertation illustrate that mice exposed to 
2.5% DSS, an epithelial toxin and colitic instigator, develop worsening colitic lesions 
which do not respond to daily oral prophylaxis with 100 or 200 mg/kg of the ethanolic 
extract of Echinacea angustifolia (EA). Restitution from a mild (1.75%) or severe 
(2.5%) DSS colitic insult is likewise not significantly enhanced by 200 mg/kg EA 
prophylaxis. In a model of moderate, controlled DSS colitis (titration from 2.5% to 
1.5%) daily oral prophylaxis with an ethanolic extract of Prunella vulgaris (PV) (100 
mg/kg) significantly reduced weight loss and intestinal lesion formation. This effect 
was not maintained if PV ethanolic extract was dosed therapeutically in the same 
DSS model. 
 Additional analysis of the prophylactic anti-colitic and anti-inflammatory 
efficacy of PV was examined in the human relevant mdr1a-/- model of spontaneous 
colitis. PV ethanolic extract (2.4 mg/day = 100 mg/kg/day) significantly delayed onset 
of colitic clinical signs and mortality related to onset of severe spontaneous colitis. 
Colitic injury was macroscopically and microscopically improved in PV treated 
mdr1a-/- mice. Anti-colitic effects of PV in this model were associated with reduced 
innate neutrophil function and presence in the intestinal tissues. These observations 
in PV treated mdr1a-/- mice were accompanied by suppression of serum 
inflammatory chemokines and cytokines which function as growth factors and 
chemoattractants for inflammatory cells. PV prophylaxis in mdr1a-/- mice lead to 
reduced expression of genes related to NF-κB activity and subsequently reduced the 
presence of cecal CD4+ and CD8+ inflammatory T cells. As noted in the DSS 
induced model of colitis, all of these effects of PV ethanolic extracts were abolished 
when PV was dosed in a therapeutic fashion at the onset of colitic clinical signs in 
mdr1a-/- mice. These combined experiments underscore the immunosuppressive 
and related anti-colitic activities of PV ethanolic extracts in vivo. PV is a prophylactic 
medicinal option for further study in colitic therapy. 
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 Similar to PV, ethanolic extract of Hypericum gentianoides (HG) was 
examined as a prophylactic anti-colitic in the mdr1a-/- model of spontaneous colitis. A 
4.8 mg/kg dose of HG ethanolic extract dosed to mdr1a-/- mice significantly delayed 
colitic onset and significantly reduces colitic mortality and macroscopic as well as 
microscopic inflammatory intestinal injury. Microscopically and enzymatically, colonic 
and cecal neutrophil related inflammation was reduced by HG prophylaxis in mdr1a-/- 
mice. HG prophylaxis was also responsible for increased plasma cell infiltrate into 
the intestines of mdr1a-/- mice but had no effect on intestinal T cell populations in 
these mice. While several inflammatory cytokines and chemokines were reduced by 
HG prophylaxis, IL-6 levels in the serum were increased in mdr1a-/- mice. These 
novel in vivo studies of HG ethanolic extracts uncover the potential of a brand new 
treatment modality for IBD.  
 
Discussion 
 Inflammatory bowel disease (IBD) is a collection of idiopathic inflammatory 
enteric disorders which continue to take a heavy toll on the financial, economic and 
quality of life status of patients suffering from these diseases (1). It is effective and 
important to optimize old therapeutic strategies related to IBD treatment. However, 
the continued cost inflation and growing inaccessibility to evermore complex IBD 
remedies and the absence of confidence in long-term safety and efficacy of current 
anti-colitics underscore the need for concentration of scientific research to effectively 
and quickly screen new, safe, and broadly efficacious anti-IBD treatment modalities 
(2-8). Herbal or nutraceutical CAM is an attractive medicinal option for IBD primary 
or adjunct therapy due to its documented safety, low cost, public and commercial 
accessibility, and generally high patient compliance (9-15). In addition to these 
positive aspects of CAM, evidence supporting the bioavailability and anti-
inflammatory bioactivity of herbal compounds is growing (13, 16-28). 
Therapeutic and prophylactic medicinal targets must be studied in animal 
models of disease to assess safety and efficacy. The DSS induced model of colitis 
offers an inexpensive, highly flexible and disease relevant method of quickly titrating 
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and assessing the activity of potentially anti-colitic and anti-inflammatory compounds 
for further examination in even more accurate and complex models of disease (29). 
In this context, ethanolic extracts of EA, PV and HG were screened for anti-colitic 
and anti-inflammatory activities in the DSS induced mouse model of colitis. 
The mdr1a-/- mouse model of spontaneous colitis is a well described, 
repeatable and relevant model for the study of human and animal IBD (30). This 
model encompasses the vital contributions of the intestinal epithelial barrier 
dysfunction and the host microflora to colitic onset. Similar to human and animal 
IBD, colitic lesions in mdr1a-/- mice are transmural and generally continuous 
throughout the colon (31). Mucosal edema, thickening and lamina proprial 
inflammatory cell infiltrate are common to these lesions. Furthermore, enhanced 
expression of IFNγ, IL-6, IL-1β, TNFα, MCP-1, MIP-1α, RANTES and Eotaxin 
mRNA, along with increased expression of the chemokine receptors CCR2 and 
CCR5 in mdr1a deficient mice is comparable to changes seen in patients with UC 
and CD (32). Mdr1a has been directly implicated in human UC and CD (30, 33, 34). 
In this context, ethanolic extracts of PV and HG were screened for anti-colitic and 
anti-inflammatory activities in the mdr1a-/- mouse model of spontaneous colitis. 
Echinacea angustifolia 
Utilizing the DSS model of chemically induced colitis, the macroscopic anti-
colitic activity of oral EA in comparison to 5% EtOH vehicle alone as a sham 
treatment was assessed. With regard to experiments evaluating EA anti-colitic 
activity, extract prophylaxis was chosen due to the low concentration of individual 
bioactive compounds in whole extracts and the knowledge that the colonic mucosa 
turns over or replenishes every 4 to 7 days (35, 36). Pre-treatment would allow for 
accumulation of potentially bioactive compounds and would ensure thorough 
exposure of the gut epithelium to these compounds prior to inflammatory DSS insult, 
increasing the likelihood of immediate and effective constituent influence on the 
rapid onset of inflammation caused by the initial exposure to DSS. As penetrance of 
some compounds into the deeper layers of the lamina propria or submucosa could 
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be poor, there is a better chance that bioactive compounds could interact directly 
with the mucosal epithelium to exert effects (37).   
EA effectively inhibits inflammatory prostaglandin E2 (PGE2) production and 
modulates COX-2 signaling (23). Potential anti-inflammatory bioactivity combined 
with the inherent feature of increased colonic permeability and potential for 
increased chemical exposure in the colitic gut, make EA an interesting potential anti-
colitic therapy (38). The progression of weight loss, severity of macroscopic disease 
scores reduced colon lengths seen in DSS treated mice alone were unchanged in 
EA treated mice exposed to DSS. EA did not positively or negatively statistically 
effect the severity of colitis induced by 2.5% DSS. It is clear that EA is non-toxic 
macroscopically. Because colitic intestinal epithelia are more permeable or ‘leaky’, if 
EA were toxic, it could potentially have caused excess weight loss or additional 
adverse effects in mice treated with DSS. Additionally, EA was not toxic in healthy 
control mice. 
 It was considered that the potent inflammatory insult of 2.5% DSS might mask 
significant bioactivity of EA. For this reason, EA was tested in a DSS model which 
included an additional 7 days of DSS free restitution and a lower dose of DSS 
(1.75%) was also examined. While 1.75% DSS clearly caused lesser colitic damage 
than 2.5% DSS; as evidenced by weight loss, restitution weight recovery, disease 
score and colon lengths; EA was still ineffective in treating this milder colitic insult 
and was also inefficient at enhancing mucosal restitution. 
 While the totality of this data would indicate that EA is not an ideal option for 
anti-colitic therapy, it is possible that further extract or DSS dose adjustments could 
be required to uncover the bioactivity of EA in this model. Moreover, it is possible 
that the efficacy of EA might be directed more towards an aspect of colitis not 
addressed in this model, such as a colitic model driven more by dysbiosis or a 
different inflammatory insult than an epithelial toxin like DSS. These experiments did 
not address metabolic end products or their concentrations in feces or serum. While 
these studies are ongoing, the serum concentrations, penetrance and metabolic 
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byproducts related to EA extract treatment in this model could underscore the lack of 
activity seen here or point to need for adjustments to treatment or the model. 
Prunella vulgaris 
Dosing strategies for PV in the DSS induced model of colitis were influenced 
by the same considerations as those previously mentioned for EA. The macroscopic 
anti-colitic activity of oral PV ethanolic extract in comparison to 5% EtOH vehicle 
alone was assessed in this model. PV anti-colitic activity was identified in DSS 
studies presented in this dissertation. Previous studies show that PV is capable of 
anti-inflammatory effects in several models and contains several bioactive phenolics, 
triterpenoids, and flavonoids (27, 39-42). These studies supported the hypothesis 
that PV could reduce colitic inflammation. PV prophylaxis was examined in the 
context of a ‘controlled lesion’ DSS dosing model in which a moderate to sever 
colitic insult was initiated with 2.5% DSS followed by an extended period of mild 
DSS dosing (1.5%) to maintain a constant, non-progressive lesion (43). Daily mouse 
weight maintenance, decreased macroscopic score, and increased colon lengths all 
indicate that prophylactic PV significantly reduces the severity of DSS colitis. 
Prophylaxis is required for this activity as therapeutic dosing in this model abolished 
anti-colitic efficacy of PV ethanolic extract. This would indicate that prior exposure of 
gut tissues to PV is required in the absence inflammatory insult. This might not be 
true at a lower dose of DSS not investigated here. 
The anti-DSS colitic efficacy of ethanolic PV extracts required further testing 
in a more complex, human relevant model of IBD. The mdr1a-/- model of 
spontaneous colitis is ideal for study of potential IBD therapeutics relevant to human 
and animal medicine (30). PV extract prophylaxis was found to improve the 
macroscopic damage associated with severe typhlocolitic lesion as ceca of mdr1a-/- 
mice gavaged with PV retained normal architecture, lacked grossly developed 
lymphoid aggregates, and retained luminal contents without the presence of blood or 
mucus, unlike vehicle treated mdr1a-/- mice. Presence of formed feces and lack of 
gross tissue edema and rigidity in colons of PV treated mdr1a-/- mice underscored 
improved function and homeostasis in these mice. Significant microscopic benefit of 
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extract treatment was targeted to the cecum, perhaps not surprising as the 
concentration of microflora in this organ could more efficiently metabolize PV, 
revealing active metabolic byproducts (44). Colitic onset was slightly delayed by P. 
vulgaris and 30% fewer mice developed severe colitis by 20 weeks of age when 
gavaged with PV extract. Limitations of P. vulgaris could be due to the focused cecal 
benefit of extract therapy, or perhaps further dose titration is required for more 
inclusive typhlocolitic benefit. 
The inductive phase of colitis involves a compromised intestinal epithelium 
and innate neutrophil activation, transmigration and enzymatic damage to host 
tissues (45-49). Flavonoids from licorice have been shown to inhibit neutrophil 
infiltration into lung tissue after lippopolysaccharide-induced inflammation, and 
reduce the severity of associated inflammatory damage to host lungs (50). Similarly, 
PV prevented cecal neutrophil infiltrate in 62% of mdr1a-/- mice. Related to this 
affect, microscopic scores and MPO activity were improved by PV. 
Since neutrophils are not resident in the tissues, cytokine and chemokine 
signals produced by epithelial cells and local macrophage are responsible for 
transmigration of neutrophils to the sight of tissue distress (51, 52). Innate immune 
chemokines are central to the development of severe inflammation in colitis (45, 48, 
53). Downregulation of cytokines which increase expression of adhesions on 
endothelial cells (TNFα, IL-1α, IL-1β), reduced production of cytokines which 
upregulate neutrophil chemokine production (IFNγ) and downregulation of 
inflammatory monocyte derived or neutrophil chemotactic factors (IL-8/KC and 
VEGF) have been shown to reduce inflammatory tissue damage in several disease 
models, including colitis (54-57). PV treatment of mdr1a-/- mice lead to reductions in 
innate growth factors (G-CSF and GM-CSF), the neutrophil chemokine KC, and 
TNFα; a key potentiator of colitis (58). This data illustrates that PV reduces the 
chronic production of cytokines and chemokines critical in replenishing the supply of 
inflammatory immune cells and their damaging products in the intestine but does not 
completely block their production. In other words, PV is not completely shutting 
down cytokine and chemokine production, perhaps allowing for homeostatic or 
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maintenance levels of inflammatory signaling. Trying to maintain the delicate 
balance of minimal but constant homeostatic inflammation in the gut is imperative, 
and current IBD therapies like monoclonal antibodies to TNFα disrupt that balance 
by abolishing the necessary homeostatic functions of TNF, leaving patients 
vulnerable to secondary infections or inducing hypersensitivity (59).  
NF-κB and its gene targets are inflammatory targets in IBD (60-63). 
Flavonoids are capable of downregulating NF-κB and ameliorating spontaneous 
cecitis (26, 43, 64). Perhaps the flavonoids present in PV contributed to the 
downregulation of gene targets controlling neutrophil and monocyte chemotaxis 
(Ccl2, Cxcl1/KC and Cxcl9/MIG), adhesion expression (VCAM-1, ICAM, TNFα and 
IL-1α), tissue remodeling and inflammatory cell transmigration (MMP-10) mdr1a-/- 
mouse ceca. All of these genes participate in activation of, or are regulated by NF-
κB (65-70). Clearly, PV is decreasing neutrophil chemotaxis and activity 
downregulating gene expression of targets regulated by or participating in NF-κB 
signaling. Prophylaxis might be key in this point due to the observation activation of 
inflammatory gene regulation is altered in mdr1a-/- mice and DSS colitic mice prior to 
any histologic signs of inflammation (71, 72). Supporting this hypothesis is the 
evidence that therapeutic PV ethanolic extract gavage had no anti-colitic efficacy in 
mdr1a-/- mice. PV might be modulating early innate inflammatory gene expression in 
mdr1a-/- mice, as treatment must begin at a time prior to inflammatory protein 
activity. 
PV also inhibited serum presence of IP-10 and MIG (chemotactic for T cells), 
MIP-1β (enhances innate cell production of IL-6), TNFα and IL-1 in   mdr1a-/- mice. 
These cytokines and chemokines participate in inflammatory feedback loops and 
could support the evidence of reduced numbers of CD4+ and CD8+ T cells in the 
cecal tonsils of mdr1a-/- mice treated with PV. PV related reduction in serum IL-9 in 
mdr1a-/- mice, shown to enhance proliferation of CD4+ T cells, is additional evidence 
for the secondary decrease in T cell chemotaxis caused by PV (73). PV related 
reduction of IL-2 gene expression is possibly due to a reduction in local CD4+ T cell 
presence. Perhaps PV related reduction of gene expression and production of 
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inflammatory and chemotactic signals for dendritic cells and T cells is the causative 
factor in the reduced presence of both CD4+ and CD8+ T cells in the cecal tonsils of 
mdr1a-/- mice treated with extract. 
Changes in DC and T cell function and location would B cell proliferation, 
maturation and eventual antibody production. Germinal centers in lymphoid tissues, 
an important component of the B cell humoral response, develop upon B cell 
activation by T dependant antigen (74). Germinal center B cell populations in the 
cecal tonsils of PV treated mdr1a-/- mice are significantly reduced. The functional 
relevance of this data could be tied to the lack of antibody production to microflora 
WCS in PV treated mdr1a-/- mice. Collectively these data present evidence that PV 
acts to maintain immunologic tolerance to the host microflora and preserve cecal 
homeostasis in mdr1a-/- mice by arresting NF-κB regulated innate cell chemotaxis, 
and starving the adaptive immune response of inflammatory cytokine and 
chemokine signals necessary for complete activation and chronicity. This work 
highlights the need for further study and consideration of PV as a legitimate primary 
prophylactic or adjunct option for the treatment of IBD and other chronic 
inflammatory disorders.  
Hypericum gentianoides 
To date, work presented in this dissertation is a novel evaluation of the 
bioactive potential of Hypericum gentianoides in vivo. Mdr1a-/- mouse studies 
presented here are also the first evaluate the effects of any species of Hypericum in 
a spontaneous colitic model. Using the mdr1a-/- model of spontaneous murine colitis, 
we evaluated the anti-colitic efficacy of oral HG in comparison to 5% EtOH vehicle. 
HG prophylaxis significantly delayed colitic. Notably, roughly one third of HG-treated 
mdr1a-/- mice were removed from study during the final 20 days of the experiment, 
and another third of these mice expressed 2 or greater scorable macroscopic 
disease parameters by the time the study ended and the mice reached 20 weeks of 
age. These observations highlight a limitation in HG efficacy. While HG is capable of 
significantly staving off severe colitic onset, this potential diminishes overtime. HG is 
not therefore capable of totally preventing colitic onset.  
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 HG was potent in significantly reducing macroscopic disease parameters in 
mdr1a-/- mice and significantly increasing colon lengths in these. While longer 
studies would be required, this could indicate that HG could further reduce long-term 
mortality, while allowing mice to survive with only mild to moderate symptoms of 
colitis. 
 Macroscopic and microscopic improvements in HG-treated mdr1a-/- mice 
were correlative. HG prophylaxis resulted in significantly decreased microscopic 
colonic edema and reduced cecal ulceration, edema and stromal necrosis. These 
observations could be attributed to the significant reduction in cecal and colonic 
neutrophil infiltrate in these mice. As previously described, neutrophil damage is 
known to contribute to disease severity in IBD (48, 55, 75-77). A greater number of 
microscopic parameters were improved in the ceca of HG-treated mdr1a-/- mice, yet 
the reduction in neutrophil infiltrate and subsequent MPO activity was less dramatic 
in the cecal tissues of these mice than in the colonic tissues. This would indicate that 
neutrophils are not the only inflammatory cell population acted upon by HG and 
contributing to colitic pathogenesis in these tissues. An interaction between HG and 
another inflammatory moiety must be responsible for the excess microscopic 
improvement in the ceca of HG-treated mdr1a-/- mice compared to colonic 
improvements. 
  The unexpected increase in plasma cells seen histologically in the colons 
and ceca of HG-treated mdr1a-/- mice could involve the increase in IL-6 serum levels 
also noted in these mice. The function of these plasma cells was not investigated in 
these experiments, so the mechanism of their presence and activity is unknown. HG 
prophylaxis did not cause any plasma cell infiltrate in FVBWT mice, perhaps 
indicative of increased bioavailability of HG beyond the mucosa in the “leaky” gut 
tissues of the mdr1a-/- mice. This idea would be supported by the general lack of 
biologic effects observed in HG-treated FVBWT mice. 
 HG prophylaxis in mdr1a-/- mice resulted in a significant down regulation of 
the cytokines and chemokines G-CSF, KC, LIX, MIP-1β, IL-7 and TNFα. G-CSF and 
KC are both stimulatory and chemoattractant for neutrophils (78, 79). Their 
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downregulation by HG prophylaxis supports the decrease in colonic and cecal 
neutrophil infiltrate seen in HG-treated mdr1a-/- mice. LIX is also chemoattractant for 
neutrophils and is the murine homologue of human epithelial neutrophil-activating 
peptide-78 (ENA-78). The downregulation of LIX by HG further validates histologic 
reductions in neutrophil infiltrate, and inhibition of this chemokine by anti-sense 
oligonucleotides has been shown to ameliorate experimental colitis (80). MIP-1β, or 
CCL4, is a macrophage inflammatory protein which has been shown to have high 
activity during the acute phase of experimental colitis while sharply decreasing in 
concentration during the recovery phase of colitis (81). Increased levels of related 
isoforms of MIP-1β have also been shown to increase the severity of colitis (82).  IL-
7 is known to be an important growth and maturation factor for colitogenic memory T 
cells and B cells, but also contributes to non-T or B cell colitic related inflammatory 
processes.(83, 84). HG reduction of TNFα serum concentrations is a significant 
finding, as TNFα has been thoroughly implicated in the pathogenesis and chronicity 
of IBD (85). HG prophylaxis in mdr1a-/- mice did result in the upregulation of IL-6 
serum concentrations. This is an interesting observation as IL-6 is pro-inflammatory, 
and generally perpetuates adaptive T cell and B cell responses (86). IL-6 levels are 
elevated in the tissues of human patients with active IBD in the absence of 
microscopic and macroscopic inflammation (87). HG modulation of serum 
cytokines/chemokines explains the reduction in microscopic and macroscopic 
disease which could be associated with reduced granulocyte and neutrophil activity 
in HG-treated mdr1a-/- mice. The increase in IL-6 serum concentrations in these 
mice could be one facet of the limitation of long-term anticolitic maintenance of HG 
or could contribute to the unusual increase in plasma cell and CD4+ T cell 
concentrations in the tissues of these mice noted histologically and by flow 
cytometry. The mechanism behind this increase in IL-6 will require more 
investigation. 
 In summary, Hypericum gentianoides has immunomodulatory potency 
in the mdr1a-/- mouse model of spontaneous colitis. This activity could be related to 
the flavonoid and polyphenolic compounds in the extract. Additionally, this work 
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does not address the potential impacts of HG and its antibiotic compound, uliginosin, 
on the microflora or colitic associated dysbiosis in this model. This work highlights 
the need for further study of HG, the potential synergy of its components, and its 
efficacy in other disease models. 
Recommendations for Future Studies 
 Dosing of EA, PV and HG were primarily chosen due to previous studies and 
lack of host toxicity. In all models presented in this dissertation, it is possible that 
further extract or DSS dose adjustments could be required to uncover the true range 
of bioactivities of EA, PV or HG. With regard to DSS studies, it is possible that 
further efficacy of PV or EA might be directed more towards an aspect of colitis not 
addressed in this model, such as a colitic model driven more by dysbiosis or a 
different inflammatory insult than an epithelial toxin like DSS. EA should be 
evaluated in the mdr1a-/- mouse model of spontaneous colitis, as a different colitic 
mechanism addressed by this model could highlight bioactivity of EA not seen in the 
presence of DSS insult. While the microflora is a vital part of spontaneous colitic 
development in the mdr1a-/- mouse model of spontaneous colitis, the microflora and 
potential effects of EA, PV or HG were not specifically addressed to a great extent in 
these experiments. Additionally, these experiments did not address metabolic end 
products or their concentrations in feces or serum. While these studies are ongoing, 
the serum concentrations, penetrance and metabolic byproducts specifically related 
to EA extract treatment are worth consideration as they could underscore the lack of 
activity seen in DSS experiments or point to the need for adjustments to treatment or 
the model. 
The bioactivity of EA and PV in the DSS model of colitis is quite different. This 
could be explained in a number of ways. Previous studies highlight the importance of 
alkylamides and ketones in EA, while PV harbors many bioactive polyphenols and 
flavonoids making the totality of their chemical compositions are very different (23, 
27, 42). These differences in chemical constituents could lead to different compound 
stabilities or synergies impacting bioactivity. This furthers the need for studies to 
address the metabolic byproducts associated with these extracts, transport of extract 
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components and their bioavailability in healthy, homeostatic gut tissues compared to 
leaky colitic tissues. Studies of extract component synergy and related synergistic 
bioactivity of target compounds would clarify ways to alter the extracts to make them 
more efficacious for therapeutic use. 
Because of the lack of literature and study of HG, and the results summarized 
above, the specific cellular responses related to HG extract prophylaxis could be of 
great importance to study further. Specifically, the propensity of HG to encourage IL-
6 serum increases and plasma cell activity in gut tissues of mice with barrier 
dysfunction and genetic susceptibility to colitis. Additionally, this work presented 
here does not address the potential impacts of HG and its antibiotic compound, 
uliginosin, on the microflora or colitic associated dysbiosis in the mdr1a-/- mouse 
model of spontaneous colitis. 
The totality of this dissertation identifies PV and HG as nutraceutical 
modalities with legitimate evidence for continued scientific pursuit as primary or 
adjunct therapies for IBD. EA will require more in depth investigation for potential 
anti-colitic activity in IBD model systems. Clearly, herbal extracts are not simply 
“snake-oil” and warrant greater scientific exposure and investigation as reasonable 
medicinal therapies and supplements. 
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